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Methylmalonic acidemia (MMA), propionic acidemia (PA), and Barth syndrome (BTHS) 
are three inborn errors of intermediary mitochondrial metabolism where the primary 
metabolic defects are well defined, but there is limited knowledge of the downstream 
cellular effects thus limiting development of novel therapeutics. Using hypothesis-
generating untargeted proteomics and metabolomics in cellular models of these disorders, 
we identified and functionally confirmed novel areas of cellular pathogenicity. 
In patient and CRISPR/Cas9-edited cells modeling MMA and PA, we 
demonstrated increased abundance of proteins and metabolites involved in serine synthesis 
and thiol metabolism. We functionally confirmed these findings with flux metabolomics 
and identified an increase in de novo serine biosynthesis, serine transport, and abnormal 
downstream tricarboxylic acid (TCA) cycle utilization. Together, we identified serine 
metabolism as a novel target of cellular pathogenesis in MMA and PA, and a potential new 
target for therapeutic investigation.  
In patient and CRISPR/Cas9-edited cells that we validated as a new model of 
BTHS, we identified abnormal regulation of proteins associated with two distinct 
pathways: mitochondrial respiratory chain complex I (CI), mitochondrial quality control. 
We confirmed reduced expression, abundance, and activity of CI, as well as increased 
abundance and activity of PARL, a rhomboid protein involved in the regulation of 
mitophagy and apoptosis. By modulating cardiolipin (CL), the phospholipid affected in 
BTHS, via phospholipase inhibitor bromoenol lactone and the CL targeted SS-peptide, SS-
 iii 
31, we showed that each is able to remediate abnormalities in CI abundance as well as 
PARL activity. Together, we further delineated a previously described pathway, 
mitochondrial respiratory chain CI, and identified a novel pathway for further 
investigation, mitochondrial quality control.  
We conclude that untargeted studies harnessing the power of -omics has the ability 
to uncover novel pathways of investigation in IEMs providing alternative targets for 
therapeutic interventions. 
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1.1 Inborn errors of metabolism 
In 1902, Sir Archibald Edward Garrod described alkaptonuria, a condition with urine that 
has “the power of staining fabrics deeply”, or more simply, black urine, in an article titled 
“The Incidence of Alkpatonuria: A Study in Chemical Individuality”. [1] At that point, 
alkaptonuria was not thought to be a disorder but an alternative, slightly less efficient 
pathway in metabolism. However, Garrod’s observations, especially the observation of the 
high incidence of alkaptonuria in children of first cousins, led him to later coin the term 
“inborn errors of metabolism”. [2] In 1908, during the Croonian Lectures delivered by 
Garrod before the Royal College of Physicians of London, Garrod hypothesized that four 
metabolic disorders, alkaptonuria, pentosuira, cystinuria, and albinism, were congenital 
and inborn reflecting Mendelian inheritance. [2] In 1909, the Croonian Lectures were 
published as the first edition of Inborn Errors of Metabolism. [3] Fourteen years later in 
1923, the second edition was published with two additional inborn disorders, and now in 
2021, over 100 years since the first edition, its modern successor “The Online Metabolic 
& Molecular Bases of Inherited Disease” (OMMBID) describes over 500 inborn errors of 
metabolism. [4, 5] 
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Inborn errors of metabolism (IEM) are a heterogenous group of disorders in which 
a single gene defect results in the absence or abnormality of an enzyme or its cofactor. 
IEMs can be classified in many ways, but three major categories include small molecule 
disorders, disorders of energy deficiency, and complex molecule disorders. [6–8] Small 
molecule disorders result in intoxication from the accumulation of compounds proximal to 
the metabolic block, such as in methylmalonic acidemia (MMA, MIM#251000) and 
propionic acidemia (PA, MIM#606054). [6, 7] Disorders of energy deficiency are due to 
deficiencies in energy production or use, such as in Leber hereditary optic neuropathy 
(LHON, MIM# 308905). Lastly, complex molecular disorders encompass disorders that 
affect the synthesis, processing, quality control, and catabolism of complex molecules, 
such as in Barth syndrome (BTHS, MIM#302060).  
Individually, IEMs are rare, however, as a group IEMs are estimated to occur 1 out 
of 2,500 live births. [7] Clinically, IEMs will present either in one functional system or 
organ, or systemically affecting multiple processes and organs. [9] Presenting symptoms 
are diverse and can include; developmental delay, seizures, intoxication, hypogylcemia, 
lactic acidemia, hypotonia, myopathy, cardiomyopathy, failure to thrive, cardiac failure, 
circulatory collapse, sudden infant death syndrome, and congenital malformations. [6, 9] 
Treatment approaches for the IEMs include restoration of the biochemical 
imbalance between substrate and product due to a metabolic defect. This can be achieved 
through dietary restriction, substrate reduction therapy, and toxin removal. [10] 
Alternatively, enzyme replacement therapy, gene therapy, cell/organ transplantation, 
cofactor supplementation, and chaperone therapy are all treatments that aim to replace or 
enhance the absent or dysfunctional enzyme or cofactor. [10] 
 3 
From four disorders to hundreds, the breadth and scope of the diagnosis and 
treatment of IEMs has exponentially expanded since Garrod first coined the term over a 
100 years ago. Unfortunately, even with the vast expansion of knowledge, IEMs result in 
substantial mortality or long-term morbidity, representing 0.4% of all child deaths 
worldwide. [11] Continued research of IEMs will improve diagnosis, monitoring, and 
treatment, as well as ultimately reducing the global burden of IEMs. 
 
1.1.1 Methylmalonic acidemia 
Methylmalonic acidemia (MMA, MIM#251000) is a rare autosomal recessive IEM caused 
by pathogenic variants in the gene methylmalonyl-CoA mutase (MMUT, type: mut-MMA) 
or the biosynthesis of its vitamin B12 cofactor. [12–14] MMUT encodes a mitochondrial 
enzyme, MUT, that catalyzes the isomerization of L-methylmalonyl-CoA to succinyl-CoA, 
a key step in propionate metabolism that funnels metabolites from the breakdown of 
propionic acid, amino acids, odd-chain fatty acids, and cholesterol esters, into the 
tricarboxylic acid cycle (TCA cycle). [12–14] MUT deficiencies are subdivided into two 
subgroups, muto, with no MUT activity, and mut-, with low to moderate MUT activity in 
the presence of high concentrations of adenosylcobalamin (AdoCbl). [12, 13]  
MUT requires the adenosylcobalamin (AdoCbl) form of vitamin B12 for enzymatic 
function. As such, MMA can also be caused by deficiency of proteins involved in the 
generation of AdoCbl; methylmalonic aciduria type A protein (MMAA, type: clbA-MMA), 
methylmalonic aciduria type B protein (MMAB, type: cblB-MMA), or the methylmalonic 
aciduria and homocystinuria type D protein (MMADHC, type: cblD-MMA). [12] MMA 
can also be cause by the deficiency of methylmalonyl-CoA epimerase (MCE) an enzyme 
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that converts D-methylmalonyl-CoA epimer to L-methylmalonyl-CoA epimer, which is 
the substrate of MUT, though this form is very rare with less than 10 cases described in the 
literature. [12, 14] Overall, approximately 97% of MMA cases are caused by pathogenic 
variants in the genes MMUT (type: mut-MMA), MMAA (type: clbA-MMA), MMAB (type: 
cblB-MMA). [14]  
Due to the metabolic block, MMA is biochemically characterized and diagnosed 
by high levels of methylmalonic acid and propionylcarnitine in the blood and urine. [12] 
Normal mitochondrial function requires sufficient energy production through the TCA 
cycle and oxidative phosphorylation, therefore, MMA results in systemic chronic disease, 
particularly in organs with high energy needs such as the brain, heart, kidney, and eye. [15] 
Early-onset symptoms, which can present in the first days of life, may include lethargy, 
vomiting, hypotonia, hypothermia, respiratory distress, severe ketoacidosis, 
hyperammonemia, neutropenia, and thrombocytopenia. [12, 15, 16] In older infants and 
children, symptoms may include failure to thrive, kidney disease, hypotonia, 
developmental delay, and other acute and chronic neurologic symptoms. [12, 15, 16] 
Irreversible organ injury may eventually occur due to the accumulation of abnormal 
metabolites caused by MUT deficiency. [15] Treatment includes acute stabilization of 
symptoms at onset and during period of metabolic crisis, supplementation of vitamin B12 
in those cases that are vitamin responsive, and lifelong management with dietary protein 
restriction and carnitine supplementation. 
Despite aggressive management, patients with MMA typically experience severe 
morbidity and mortality. [15–19] 
 
 5 
1.1.2 Propionic acidemia 
Propionic acidemia (PA, MIM#606054) is a rare autosomal recessive IEM caused by 
pathogenic variants in the genes encoding the mitochondrial enzyme propionyl-CoA 
carboxylase (PCC), PCCA or PCCB. [20, 21] PCC catalyzes the carboxylation of 
propionyl-CoA to D-methylmalonyl-CoA, another key step in propionate metabolism, and 
the metabolic step upstream of MUT. [20, 21] 
PA is biochemically diagnosed by elevated propionylcarnitine in the blood and 
urine, and elevated methylcitrate (a byproduct of abnormal TCA metabolism) in the urine. 
[15, 16, 20] There is significant clinical overlap between MMA and PA, where PA also 
results in systemic chronic disease, particularly in organs with high energetic needs. [15] 
Early-onset symptoms include poor feeding, vomiting, progressive encephalopathy, 
lethargy, seizures, and coma. [15, 16, 20] Most individuals with PA become symptomatic 
with the first weeks of life, however, residual PCC function may delay the onset of 
symptoms to beyond the neonatal period. [20] Later-onset symptoms, that may occur due 
to a metabolic crisis, may include protein intolerance, failure to thrive, hypotonia, 
developmental regression, progressive encephalopathy, lethargy, seizures, and coma. [15, 
16, 20] In contrast to MMA, kidney disease is less severe and occurs later in the course of 
the disease, and in PA cardiomyopathy may be more severe and present at a younger age 
compared to MMA. [15] 
The treatment and management of PA is very similar to the treatment and 
management of MMA with the acute stabilization of presenting symptoms and lifelong 
management with dietary protein restriction and carnitine supplementation. [15, 16] 
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Patients with PA experience severe morbidity and mortality, with long term outcomes 
dependent on the age of onset, age of diagnosis, severity of disease, and treatment. 
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1.2 Mitochondrial dysfunction and Barth syndrome 
 
This original article has been published and was reprinted with permission: Anzmann AF, Claypool SM, 
Vernon H (2019) Mitochondrial dysfunction and Barth Syndrome. Handbook of 
Mitochondrial Dysfunction. S. I. Ahmad, Ed. (CRC Press/Taylor & Francis Group, 2019), pp. 61–77 
 
1.2.1 Abstract 
Barth syndrome (BTHS) is an X-linked inborn error of mitochondrial phospholipid 
metabolism, caused by pathogenic variants in the gene tafazzin (TAZ). TAZ encodes for a 
transacylase involved in the final remodeling step of cardiolipin (CL). The four acyl chains 
of CL allow for an array of CL species, however the determinants of the acyl chain 
composition of remodeled CL are still under debate. CL, localized to the inner 
mitochondrial membrane, has key roles in mitochondrial function including in cristae 
formation, organization of the mitochondrial respiratory chain, apoptosis, and mitophagy, 
among many others. As is typical of most primary mitochondrial diseases, BTHS is a multi-
system disorder and is characterized by cardiomyopathy, skeletal myopathy, and 
neutropenia. Though the primary biochemical defect in BTHS has been known for several 
decades, there are no disease specific treatments, and the burden of morbidity and mortality 
in affected individuals is high. Treatment strategies under investigation include: lipid 
replacement, enzyme replacement, gene replacement, and drug therapy. This review 




1.2.2 Barth Syndrome 
In 1980, Barth et al. described a novel X-linked mitochondrial disease affecting cardiac 
muscle, skeletal muscle and neutrophil leukocytes, at a Neuromuscular Disease 
Symposium held at Erasmus University.[1] Three years after this preliminary 
communication, Barth et al. reported a large Dutch family with cardiomyopathy, skeletal 
myopathy, neutropenia, and high infant mortality due to infection or cardiac failure.[2] 
These clinical characteristics have since become the cardinal features of what is now 
known as Barth syndrome (BTHS, MIM#302060) (Figure 1).[3–6] The incidence of BTHS 
is estimated to be about 1/300,000-400,000 live births, with fewer than 500 individuals 
worldwide included in the BTHS Registry & Repository. There is no known racial or ethnic 
predilection. [7,8]  
The majority of individuals with BTHS present with cardiomyopathy within their 
first two years of life. [7] Classically, the cardiomyopathy presents as dilated 
cardiomyopathy with a component of left ventricular noncompaction, however 
hypertrophic cardiomyopathy has also been described. Heart function in BTHS patients 
can follow a waxing and waning pattern, sometimes with a period of relative stability after 
the toddler years and before puberty. [4] Cardiac arrhythmia and Long QT syndrome have 
also been described in a number of affected individuals. [9] 
Skeletal myopathy and skeletal muscle fatigue are also important clinical features 
of BTHS. Affected individuals have decreased exercise endurance, weakness of proximal 
leg muscles, and overall lower activity levels. The skeletal muscle weakness and fatigue is 
independent of the cardiac dysfunction. [10] 
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Neutropenia is also seen in most affected individuals and can present as severe 
chronic neutropenia, cyclic neutropenia, or intermittent/non-cyclical neutropenia. Low 
neutrophil counts put affected individuals at risk for severe bacterial infections, ranging 
from mouth ulcers and gingival inflammation, to sepsis and multi-organ system failure. 
[7,11] 
 
Figure 1. Barth syndrome. Barth syndrome (BTHS) is an inborn error of mitochondrial 
phospholipid metabolism, caused by pathogenic variants in the gene tafazzin (TAZ) located 
in the gene rich region of distal Xq28. TAZ encodes for a transacylase involved in the final 
remodeling step of cardiolipin (CL), which is essential for CL maturation. TAZ deficiency 
results in altered CL metabolism, with an increased monolyso-CL:CL and an abnormal 
acyl chain pattern in the remaining CL. Clinically, BTHS is characterized by 









in the Gene !"#"$$%&  
Xq28
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Other clinical features seen in association with BTHS include failure to thrive, pre-
pubertal growth delay, gastrointestinal complaints, hypoglycemia, and scoliosis.[4,7,12] 
There is no specific therapy for BTHS, and treatments are directed towards individual 
symptoms, including granulocyte-colony stimulating factor (G-CSF) therapy for 
neutropenia and medical treatment for cardiac failure. In cases of intractable heart failure, 
cardiac transplantation is performed. [5,13] 
 
1.2.3 Tafazzin  
In 1991, almost ten years after BTHS was first described, and ten years before the Human 
Genome Project was completed, Bolhuis et al. analyzed the linkage between the disease 
locus of BTHS and X-chromosomal markers.[14] Multipoint linkage analysis of the first 
BTHS family reported by Barth et al., a multi-generational family with seven carriers, four 
patients, and eight unaffected sons of carriers, mapped the disease locus to the gene rich 
Xq28 region.[14] Mapping to the distal Xq28 region was further confirmed in 1993 and 
1995 by Ades et al. and Gedeon et al., respectively.[3,15] Then in 1996, Bione et al. 
reported the identification of the gene, termed G4.5, as responsible for BTHS.[16] The 
open reading frame of G4.5 suggested several putative proteins ranging from 129 to 229 
amino acids in length. Since these putative proteins did not have any homology to any 
previously identified nucleotide or protein sequence in GenBank at that time, they proposed 
that the novel proteins be named “tafazzins”.[16] This unique name pays homage to a 
comic from an Italian sports television show, Tafazzi, who repeatedly hits himself with an 
empty plastic bottle. 22 years later, the tafazzin gene/protein (TAZ/TAZ) maintains its 
reputation as a difficult subject for masochistic scientists. 
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 TAZ is conserved form yeast to humans and has 11 exons with multiple alternative 
splicing isoforms. [17,18] Of the identified isoforms there are four major isoforms; the full 
length transcript (NM_000116), a transcript without exon 5 (∆5, NM_181311), a transcript 
without exon 7 (∆7, NM_181312), and a transcript without both exon 5 and 7 (∆5∆7, 
NM_181313). 17 Of the four isoforms, the mRNA isoform ∆5 is the predominant isoform, 
followed by ∆5∆7, full-length, and ∆7. [17,19] Gene expression studies in patient 
lymphoblast lines and a TAZ deficient yeast model indicate that of the different isoforms, 
only two, the ∆5 and full-length isoforms, encode functional TAZ with transacylase (CL 
remodeling) activity.[17,20–22] Further, only a single polypeptide that co-migrates with 
the ∆5 isoform is expressed in human skin fibroblasts, Human embryonic kidney 293 
(HEK293) cells, and murine heart and liver mitochondria.[23] It is interesting to note that 
the inclusion of exon 5 arose in the hominoid primate lineage after it branched from the 
Old World monkey lineage, 15-20 million years ago, due to a variant in the splice acceptor 
consensus sequence (GG>AG).17 This primate-specific exon is predicted to correspond to 
an intrinsically unstructured region of TAZ and has been speculated to contribute to 
primate-specific molecular interactions. [24]  
As mentioned, when TAZ was first identified it had no sequence homology with 
any known nucleotide sequence. To date, the closest related protein with a known 3D 
structure is plant glycerol 3-phosphate acyltransferase (G3PAT), which has 20% sequence 
identity to human TAZ. [24] The mystery of TAZ function was cracked in 1997 when 
Neuwald reported, based on an alignment of human TAZ with two hypothetical proteins 
from yeast and worm, that TAZ belongs to a superfamily of acyltransferases with predicted 
roles in phospholipid biosynthesis.[25] Neuwald further suggested that the mitochondrial 
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dysfunction associated with BTHS may be due to alterations in the mitochondrial 
membrane phospholipids a prediction that was confirmed by Vreken et al. in 2000.[26] 
Indeed, TAZ is a ubiquitously expressed gene that encodes for a transacylase involved in 
the final remodeling step of cardiolipin (CL), a major phospholipid of the inner 
mitochondrial membrane (IMM).[27] 
 
1.2.4 Cardiolipin   
Mitochondria are unique organelles with two specialized membranes defining separate 
compartments within the mitochondrion, each with a distinct role and composition: the 
outer mitochondrial membrane (OMM), the intermembrane space (IMS), the IMM, and the 
matrix. The OMM, which is more typical of other membranes in terms of its protein to 
lipid ratio, is believed to be permeable to most metabolites due the presence of pore-
forming porins in its bilayer. In contrast, the highly folded IMM is a tight barrier to all ions 
and molecules, with an atypically high protein to phospholipid ratio. [28,29] The lipid 
composition of both membranes is characterized by high phosphatidylcholine (PC) and 
phosphatidylethanolamine (PE) content and low sterol and sphingolipid count. [28] 
Additionally, the IMM, and mitochondrial contact sites where the OMM and IMM are in 
close proximity, display an enrichment of CL, which accounts for up to 20% of total 
mitochondrial lipids. [28,30,31]  
CL was actually first purified in 1942 in an attempt to isolate a substance with 
serological utility in syphilis testing. Investigators termed the new non-nitrogenous 
phospholipid “cardiolipin” as it was isolated from bovine heart.[32] In 1964, its structure 
was first described as a phospholipid consisting of two phosphatidyl moieties, each with 
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two acyl chains, that are connected by a glycerol bridge.[33] The four acyl chains allow 
for an array of CL species that enable the observed tissue specific CL composition; CL in 
the brain is characterized by a diversified array of acyl chains including polyunsaturated 
chains, whereas in other tissues CL is predominantly characterized by the tetralinoleoyl 
form, (18:2)4 CL. [34–36] The enrichment of tetralinoleoyl-CL is most obvious in human 
heart and skeletal muscle where it accounts for up to 80% of the CL species present.[34] 
De Novo Synthesis and Remodeling 
In eukaryotes, most phospholipids are synthesized in the endoplasmic reticulum (ER); 
however, the biosynthetic pathway of CL occurs exclusively in the mitochondrion.[37,38] 
This multi-step process, elucidated over the past 40 years, begins with the generation of 
phosphatidic acid (PA), which can be potentially sourced from several pathways.[6] PA, 
synthesized in the ER, on the outer surface of the OMM, or in the IMS, is then transported 
to the matrix side of the IMM where a condensation reaction between PA and cytidine 
triphosphate (CTP), catalyzed by Tam41p (Human Gene Organization (HUGO) Gene 
Nomenclature Committee (HGNC): TAMM41, Saccharomyces Genome Database (SGD): 
TAM41), forms cytidine diphosphate diacylglycerol (CDP-DAG).[6,39,40] CDP-DAG and 
glycerol-3-phosphate (G3P) are then converted to phosphatidylglycerol phosphate (PG-P) 
by PG-P synthase (HGNC: PGS1, SGD: PGS1).[41,42] PG-P is rapidly dephosphorylated 
to PG by PG-P phosphatase (HGNC: PTPMT1, SGD: GEP4).[43,44] PG is then bound to 
another molecule of CDP-DAG by CL synthase (HGNC: CRLS1, SGD: CRD1), an integral 
IMM protein whose active site faces the mitochondrial matrix, through a condensation 
reaction that forms nascent CL (Figure 2).[45–48]  
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Figure 2. Cardiolipin biosynthesis and remodeling. Phosphatidic acid (PA), sourced 
from several pathways, is transported to the matrix side of the inner mitochondrial 
membrane (IMM) where a condensation reaction between PA and cytidine triphosphate 
(CTP), catalyzed by TAMM41, forms cytidine diphosphate diacylglycerol (CDP-DAG). 
CDP-DAG and glycerol-3-phosphate (G3P) are then converted to phosphatidylglycerol 
phosphate (PG-P) by PG-P synthase (PGP1). PG-P is rapidly dephosphorylated to PG by 
PG-P phosphatase (PTPMT1). PG is then bound to another molecule of CDP-DAG by CL 
synthase (CRLS1) through a condensation reaction that forms nascent CL. De novo 
synthesis of nascent CL is followed by CL remodeling, initiated with the removal of an 
acyl chain, which generates monolyso-CL (MLCL). In mammals, the enzyme(s) that de-
acylates nascent CL and generates MLCL is unresolved. Following de-acylation, MLCL is 
then re-acylated by one of three enzymes: TAZ, MLCL acyltransferase 1 (MLCLAT1), or 
acyl-CoA:lysocardiolipin acyltransferase-1 (ALCAT1). 
 
De novo synthesis of nascent CL, characterized by saturated acyl chains of variable 
length and asymmetry with respect to the two chiral centers due to the limited acyl substrate 












































maturation.[48,49] Remodeling is initiated with the removal of an acyl chain, which 
generates monolyso-CL (MLCL). In yeast, this is executed by Cld1p; however, there are 
no known Cld1p orthologs in higher eukaryotes.[50,51] In mammals, several calcium-
independent phospholipase A2 (iPLA2) members have been implicated, as these enzymes 
catalyze the hydrolysis of membrane glycerophospholipids into free fatty acids and lyso-
lipids. [52,53] Nonetheless, the question as to which enzyme(s) de-acylates nascent CL and 
generates MLCL in mammals remains unanswered. 
Following de-acylation, MLCL is then re-acylated by one of three enzymes: TAZ, 
MLCL acyltransferase 1 (MLCLAT1), or acyl-CoA:lysocardiolipin acyltransferase-1 
(ALCAT1) (Figure 2).[54–58] TAZ, the assumed predominant enzyme in CL remodeling, 
catalyzes a reversible transacylation that acts on both sn-1 and sn-2 positions, using any 
number of phospholipids (PLs) and lyso-PLs as acyl chain donors and acceptors, 
respectively.[27,56] Deficiency of TAZ results in an increase of the intermediate MLCL, 
a decrease in mature CL, and an abnormal acyl chain pattern in the remaining CL, the 
pathognomonic biochemical defect in BTHS.[19,26,59–62] Though the primary 
biochemical defect in BTHS has been known for several decades, the exact mechanism(s) 
by which the specific acyl-chain composition of mature CL is generated is still unresolved, 
and has become the subject of much debate. 
Determinants of the acyl chain composition of remodeled CL 
When considering the acyl specificity of TAZ the debate has centered on two points; 
whether TAZ specificity is attributed to the physical properties of lipids and the 
mitochondrial membrane or whether specificity is attributed to the selectivity of TAZ itself. 
Schlame et al. first proposed that in the presence of TAZ, transacylations will reshuffle the 
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acyl residues to optimize lipid packing in curved membranes.[63] In the mitochondrion, 
bilayer-prone PLs, such as PC, form a stable arrangement of tightly packed lipid molecules. 
Bending of the bilayer membrane disturbs the packing order of the bilayer PLs, which is 
thermodynamically unfavorable, but allows for the intermixing of PLs with non-bilayer 
characteristics such as CL. CL, which has a relatively small polar head group and four acyl 
chains, that in its mature form are primarily unsaturated, has a cone like structure and 
preferentially localizes in regions of high membrane curvature.[64] Therefore, acyl 
specificity is driven by the packing properties of mitochondrial membranes in the final 
equilibrium state. This is known as the thermodynamic remodeling hypothesis.  
 Others have proposed that the thermodynamic remodeling hypothesis does not 
account for all details of TAZ-mediated CL remodeling. Specifically, the model, which 
suggests that <1% of endogenous mitochondrial PLs participate in transacylation, does not 
account for the extensive degree of CL remodeling observed in the mammalian heart and 
skeletal muscle, where tetralinoleoyl-CL accounts for up to 80% of all CL. Secondly, the 
model suggests that transacylation only occurs in non-bilayer membranes. However, it has 
not been established whether the curvature of the mitochondrion, which forms the 
mitochondrial cristae, can be categorized as non-bilayer domains.[65] Third, since CL 
preferentially localizes in regions of high membrane curvature, it is difficult to distinguish 
whether the thermodynamic remodeling hypothesis is the key determinant of TAZ acyl 
chain specificity. Therefore, in 2016, Abe et al, based on their investigation of purified 
TAZ in liposomes composed of various sets of acyl donors and acceptors, suggested that 
TAZ does have acyl chain selectivity, and it may be one of the factors in determining the 
acyl composition of mature CL. [66] 
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 The debate between these two hypotheses has been ongoing. Schlame et al., after 
repeating and expanding upon the experiments performed by Abe et al., still maintained 
that acyl specificity of TAZ is driven by the packing properties of non-bilayered 
mitochondrial membranes in the final equilibrium state. Incubation of yeast TAZ with PC 
(18:2)2 and MLCL (18:2)3 produced CL (18:2)4 as expected, but incubation of yeast TAZ 
with PC (18:1)2 and MLCL (18:2)3 produced four different species. Schlame et al. suggest 
that the incorporation of multiple 18:1 residues in CL is only possible if TAZ transfers not 
only 18:1 from PC to MLCL, but also transfers 18:2 from CL to lyso-PC, and that the 
bidirectional exchange of acyl groups cannot be under kinetic control. Abe et al. do agree 
that there are multiple exchanges of acyl chains that occur in TAZ-mediated transacylation, 
but they continue to argue that transacylation can occur in rigid lipid bilayers, such as 
liposomes, and that TAZ does have a degree of acyl chain specificity. Using a series of 
liposomes composed of different derivatives of dipalmitoleoyl (16:1)2 PC they investigated 
the TAZ-mediated transacylation reaction between different PCs and MLCL, and found 
that TAZ strictly discriminates the molecular configuration of the PC acyl chains. Further, 
they suggest that the final acyl composition may result from a coordinated effort between 
a deacylase, Cld1p in yeast and yet to be identified in humans, and TAZ. 
 Recently, several groups have demonstrated that Cld1p, the deacylase upstream of 
Taz1p that was identified in yeast by Beranek et al., has selectivity as to which 
mitochondrial CLs it deacylates.[50,67,68] Specifically, biochemical studies and computer 
modeling confirmed the selectivity of Cld1p toward (16:0)4, (16:1)(16:0)3, and (18:0)4-CL 
substrates and the preservation of (18:1)4, and (18:2)4-CL species. Therefore, the 
specificity of Cld1p controls the MLCL available for Taz1p to re-acylate.[51,68] Even 
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though the deacylase acting upstream of human TAZ has yet to be identified, we must still 
consider the potential contribution of a deacylase in dictating the final acyl chain 
composition of CL. Additionally, another determinant of the acyl chain composition of CL 
could be the availability of acyl chain donors, as dietary supplementation can shift the acyl 
chain pattern of PLs.[69,70] As the debate continues, perhaps the explanation with regards 
to the acyl specificity of TAZ will be a combination of each component: the packing 
properties of the mitochondrial membrane, the acyl specificity of TAZ itself, the role of a 
deacylase acting upstream of TAZ, and the availability of acyl chain donors. 
Genotype-Phenotype Relationship: The role of MLCL:CL 
BTHS is a result of pathogenic variants within TAZ, which can be identified by molecular 
genetic testing. To date there are over 120 causative variants that have been reported in 
every exon except for exon 5, including missense, nonsense, splice variants, small 
insertions/deletions, and large deletions.[17] In addition to molecular genetic testing, a 
BTHS diagnosis can be established by an increased MLCL:CL ratio, which is detectable 
in multiple biological specimens including  bloodspots, lymphocytes, and muscle tissue. 
The measurement of MLCL:CL has a diagnostic sensitivity and specificity of 100%.  
Investigations of different yeast lines, representing 21 distinct and conserved 
human TAZ pathogenic variants, have established seven functional classes of TAZ genetic 
variation. The first and the largest class, includes variants that result in the production of 
little to no functional TAZ. The remaining classes include; (2) Mitochondrial 
mislocalization and aggregate prone; (3) Impaired macromolecular assembly; (4) 
Catalytically null; (5) Hypomorphs with residual transacylase activity; (6) Degradation due 
to impaired folding and assembly; and (7) Temperature sensitive.[71,72] Distinct loss of 
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function (LOF) classes with potential for residual TAZ function suggest a possible 
genotype-phenotype correlation; however, prior clinical phenotyping studies have not 
identified such a relationship. [71,72] 
Recently, a possible “CL metabotype”- phenotype relationship was established. In 
2015, Bowron et al. reported 7 BTHS individuals with a modified clinical phenotype, 
increased MLCL, and an increased MLCL:CL ratio, but a normal level of CL.[73] The TAZ 
variants identified in these individuals were: p.Arg57Leu, p.Asn40Asp, and p.Met185Val. 
The substitution, p.Met185Val (C.553A>G), generates a new splice donor site within exon 
7 resulting in the retention of intron 6 and a partial deletion of exon 7, confirming 
pathogenicity.[74] The variants, p.Arg57Leu (R57L) and p.Asn40Asp (N40D) have both 
been modeled in yeast; R57L/K65L is a temperature sensitive allele with reduced 
transacylase activity and N40D/N48D has activity identical to WT72. Therefore, the 
pathogenicity of N40D remains unproven.  
The presentation of a modified clinical phenotype associated with a modified 
metabotype (elevated MLCL and normal CL) was again identified in 2016 in a 
multidisciplinary investigation of 42 individuals with BTHS. In this study, researchers 
identified several individuals with a relatively milder skeletal muscle phenotype and the 
modified metabotype. These modified metabotype-phenotypes were associated with the 
genotypes c.583+5G>A and c.873_874dupCCTGG (p.Arg292LeufsX49). They further 
found that MLCL:CL was inversely correlated to skeletal muscle endurance and directly 
correlated to left ventricular size, offering further evidence for a genotype-metabotype-
phenotype relationship. As a rare disorder with isolated familial variants, continued efforts 
in establishing a genotype-metabotype-phenotype relationship will not only inform patient 
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care, but help elucidate the disease mechanism of TAZ deficiency and abnormal CL 
content. 
Cardiolipin function: everything but the kitchen sink 
Since its initial isolation in 1942, and throughout almost 2000 publications, CL has a been 
implicated in a laundry list of functions within the mitochondrion (Figure 3). Many proteins 
are known to interact with CL, in both structural and functional capacities, which 
establishes the foundation for CL’s multifaceted role within the mitochondrion.[75] The 
essentiality of CL is highlighted by the observation that ptpmt1-/- mice, an enzyme essential 
for CL synthesis, die in utero prior to E8.5.44. 
CL composes up to 20% of the phospholipid mass of the IMM and is critical for 
mitochondrial cristae formation, based on observations of abnormal IMM ultrastructure in 
CL-deficient models.[76–78] The mitochondrial cristae house the oxidative 
phosphorylation (OXPHOS) system. Therefore, it is not surprising that CL also plays a 
critical role in the efficiency and adaptability of the OXPHOS machinery. First, CL 
stabilizes the higher order assemblies of the individual respiratory complexes into 
respiratory supercomplexes (SCs), which are combinations of respiratory complexes I, III, 
and IV.[79–87] SC assembly is thought to increase the efficiency of electron transfer in 
OXPHOS, maximize OXPHOS function, minimize reactive oxygen species (ROS) 
production, and thereby reduce oxidative damage. Second, CL is proposed to act as a 
proton trap, restricting the diffusion of protons and funneling them toward ATP synthase 
to generate ATP.[88] Lastly, once ATP is formed by OXPHOS, it then passes across the 
IMM to the IMS via the ADP/ATP carrier. CL is needed for not only the stabilization of 
the carrier, but is also required for the association of the carrier with the OXPHOS 
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SCs.[89,90] Besides the ADP/ATP carrier, CL also plays a plays a protective and 
stabilizing role for various mitochondrial carriers (Figure 3).[91]  
 
Figure 3. Biological roles of cardiolipin. (A) Cardiolipin (CL) is critical for mitochondrial 
cristae formation.[76–78] Within the cristae, CL plays a critical role in the efficiency and 
adaptability of the oxidative phosphorylation (OXPHOS) machinery, by stabilizing the 
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assembly of respiratory supercomplexes (SCs). SC assembly is thought to increase the 
efficiency of electron transfer in OXPHOS, maximize OXPHOS function, minimize 
reactive oxygen species (ROS) production, and thereby reduce oxidative damage. [79–87] 
(B) Reduced functionality of OXPHOS decreases the mitochondrial membrane potential, 
which negatively affects protein import into the IMM and mitochondrial matrix by IMM 
translocases, TIM22 and TIM23.[92] Separately, CL is also important for the assembly and 
function of OM translocases, TOM and SAM.[93] Together, CL is critical for 
mitochondrial biogenesis, which requires the import of a large number of proteins from the 
cytosol. (C) CL is also crucial for mitochondrial fission and (D) fusion, where cells 
reorganize the highly dynamic mitochondrial organelles by altering their shape, 
localization, and cellular number. [94,95] (E1) Intra/extracellular externalized CL is a 
critical signaling component in mitophagy, apoptosis, and multiple distinct immune 
responses, such as inflammasome activation and phagocytosis.[107,112–114] Extracellular 
externalized CL can be bound by the phagocyte Toll-like receptor 4 (TLR4)/Md2, which 
acts as a structural homologue of antigenically inactive immature Lipid A and suppresses 
TLR4/Md2 driven cytokine production, thus acting as an immune suppressor.[107] (E2) 
Many proteins are known to interact with CL, and recently a role for CL in the activation 
of thermogenic adipocytes was defined. CL may be involved in the direct activation of the 
thermogenic effector, UCP1, and/or decrease UCP1’s binding affinity for inhibitory purine 
nucleotides. [117] Additionally, CL also physically interacts with creatine kinase (mtCK), 
an enzyme that drives thermogenesis in beige fat.[118] 
 
 CL is critical for mitochondrial biogenesis, which requires the import of a large 
number of proteins from the cytosol. Reduced functionality of OXPHOS in the absence of 
CL decreases the mitochondrial membrane potential, which negatively affects protein 
import into the IMM and mitochondrial matrix by IMM translocases, TIM22 and 
TIM23.[92] Separately, CL is also important for the assembly and function of OM 
translocases, TOM and SAM.[93] CL is also intimately involved in mitochondrial fusion 
and fission whose combined actions promote mitochondrial fitness and biogenesis (Figure 
3).[94,95] There are several superb reviews which thoroughly discuss the aforementioned 
CL-supported functions: Chicco and Sparangna 2007, Houtkooper and Vaz 2008, Lewis 
and McElhaney 2009, Klingenberg 2009, Claypool and Koehler 2012, Paradies et al. 2014, 
Li et al. 2015, Musatov and Sedlák 2017, Ikon and Ryan 2017.[14,91,96–103]  
 23 
 Recently, there has been an emphasis on CL as a signaling molecule. In healthy 
cells, CL is localized in the IMM, whereas in damaged cells, CL externalizes to the OMM 
as an elimination signal. Once externalized, CL can bind and activate LC3-II, which 
initiates autophagosome formation resulting in mitophagy, the selective degradation of 
mitochondria. Further, under oxidative stress, the production of ROS results in the 
peroxidation of CL by Cytochrome c (Cyt c) and its subsequent externalization to the 
OMM as a damage signal for apoptosis, programmed cell death (Figure 3).[104–106] 
Extracellular externalized CL (e.g. outside of plasma membrane) is thought to have an 
additional role in some immune responses, such as the attraction of phagocytes through the 
cell surface receptor CD36, resulting in rapid degradation of the cell with extracellular 
externalized CL.[107] In addition to signaling the rapid removal of mitochondria and 
bacteria by phagocytosis, externalized CLs may also play a role in regulating the 
inflammatory response elicited by bacteria. CL can be bound by the phagocyte Toll-like 
receptor 4 (TLR4)/Md2, which acts as a structural homologue of antigenically inactive 
immature Lipid A and suppresses TLR4/Md2 driven cytokine production, thus acting as 
an immune suppressor.[107] If the innate immune system fails, or if there is a constant 
release of mitochondria/mitochondrial fragments with externalized CL due to cell death, 
the continuous presence of CL can activate antigen-presenting cells (APCs). This then 
stimulates an adaptive immune response resulting in the production of anti-CL antibodies 
and potentially autoimmune disease.[108,109] In addition to extracellular externalized CL, 
intracellular externalized CL (e.g. exposed to cytosol) has also been suggested to directly 
activate inflammasomes, such as NLRP3.[110,111]  To summarize, CL and its oxidized 
products are critical signaling components in mitophagy, cell death, and multiple distinct 
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immune responses (Figure 3).[112–114] As an already diverse signaling molecule, there 
are likely further undiscovered roles for CL in this regard. 
Recently, researchers have defined a role for CL in the activation of thermogenic 
adipocytes. Brown adipose tissue (BAT) converts carbohydrate and lipid substrates to 
thermal energy in response to cold environments. Lynes et al. measured cold-activated lipid 
landscapes in blood and adipose tissue by MS/MSALL, and among the 1,600 unique lipid 
species profiled, they identified the CL biosynthetic pathway as coordinately activated in 
brown and beige fat by cold.[115] Further, they found CRLS1, the gene encoding CL 
synthase, to be significantly enriched in cold-induced interscapular BAT as compared with 
other metabolic tissues, and that loss of CRLS1, and therefore CL, abolished the 
thermogenic capacity of the adipose tissue.[116] This suggests that CL is likely to have 
brown and beige fat-specific functions in thermogenesis. Previous studies have 
demonstrated that CL binds to the uncoupling protein, UCP1, and assists its proper folding.  
Therefore, CL may function through the direct activation of the thermogenic effector 
UCP1.[117] Additionally, CL also physically interacts with creatine kinase, an enzyme that 
drives thermogenesis in beige fat.[118] Together, this suggests that CL is critical for 
thermogenic mechanisms, adding to the ever growing list of CL functions (Figure 3). 
Cardiolipin metabolism and mitochondrial dysfunction in human health: Not just Barth 
Syndrome 
BTHS, a severe multi-system disorder caused by abnormal CL remodeling, highlights the 
importance of CL in human health (Figure 1). In addition to the cardinal clinical 
phenotypes of BTHS (cardiomyopathy, neutropenia, etc), metabolite profiles of a BTHS 
cohort compared to age-matched controls revealed broad metabolic dysregulation with vast 
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cellular implications that include: insulin regulation of fatty acid metabolism, lipid 
metabolism, biogenic amine metabolism, amino acid metabolism, endothelial nitric oxide 
synthase signaling, and tRNA biosynthesis.[119]  
As a prominent player in both mitochondrial and cellular activities, it is not 
surprising that altered CL content and/or quantity is associated with mitochondrial 
dysfunction in an array of metabolic and aging-related pathological 
conditions.[96,100,101,120] Mitochondria, and specifically CL, are thought to be 
intimately involved in the aging process, characterized by the gradual deterioration of 
various physiologic and metabolic processes, with increased oxidative stress and an 
attenuated ability to respond to other stresses.[121] While aging itself may not be 
considered pathologic, with aging there is an increased risk of acquiring age-associated 
disorders, especially with regards to brain and heart function.[122–125] In Alzheimer’s 
(AD) and Parkinson’s (PD), two common age-related neurological disorders, CL is 
suggested to have a role in disease pathogenesis.[126–128] In an AD transgenic mouse 
model, lipidomics revealed not only an overall reduction in CL amount, but an altered CL 
species profile, specifically reduced levels of unsaturated acyl chains.[126] Studies in 
induced pluripotent stem cells (iPSC) and embryonic stem cells (ESC) expressing variants 
in SNCA (encoding α-synuclein (α-syn)), the causal gene in familial PD, revealed that CL 
translocates to the OMM and binds to α-syn where it facilitates the folding of α-syn to its 
α-helical, ordered state.[127,128] Therefore, altered CL content and/or composition, may 
result in misfolding and aggregation of α-syn, a key molecular event in the pathogenesis of 
PD. Additionally, with age, an individual is also at risk for ischemia/reperfusion (I/R) 
injury, which contributes to pathology in a range of conditions, such as myocardial 
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infarction and ischemic stroke. In multiple organs, such as the brain, heart, and liver, I/R 
injury significantly changes the distribution of CL molecular species with an accumulation 
of oxidized CL. [129–131]  
Diabetes and obesity, with systemic oxidative stress and mitochondrial 
dysfunction, is also associated with altered CL content.[70,120,132–135] In a type I 
diabetic mouse model, there is depletion of tetralinoleoyl-CL as well as a diversification in 
its molecular speciation in heart tissue, with a significant increase in CL species containing 
fatty acyl chains longer than 18 carbons.[132,133] Similar to the type I model, a type II 
diabetic mouse model also has an altered CL profile.[132,133] Cardiac tissue from obese 
mice, due to a high fat diet, display a significantly altered CL species profile, specifically 
an increase in n-6 and n-3 polysaturation.[70] 
Abnormalities in CL, including CL peroxidation, have also been associated with 
nonalcoholic fatty liver disease (NAFLD), one of the most common forms of liver disease, 
which has the potential to advance to nonalcoholic steatohepatitis (NASH), liver fibrosis, 
and liver failure.[136,137] As further evidence for the role of CL in NASH, in a choline-
deficient rat model of induced fatty liver disease total CL content is significantly reduced, 
and peroxidized CL is increased.[138,139] It is currently unclear if the abnormal CL is a 
product of increased oxidative stress and IMM dysfunction in this disease, or if 
abnormalities in CL are a primary factor with downstream effects on OXPHOS and 
augmented production of ROS. Regardless, CL represents a target of interest in unraveling 
the pathophysiology of NAFLD and NASH. 
Abnormalities in CL also have been shown in several models of malignancy.  TAZ 
expression gradually increases from normal cervical tissue to squamous cervical 
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carcinoma, suggesting that TAZ and CL remodeling may contribute to the progression of 
cervical cancer.[140]  Further, shotgun lipidomics from subcutaneously grown brain 
tumors, including astrocytomas, stem cell tumors, and microgliomas, revealed major 
abnormalities in CL content/composition.[141] Together, these findings suggest that 
altered CL is associated with malignant cell metabolism,  possibly via inhibition of 
apoptosis or as a driver of adaptations in global cellular bioenergetics (i.e. the Warburg 
theory).[140,141]  
Abnormalities in CL are the primary cellular defect underlying the Mendelian 
disease Barth syndrome, as well as part of the pathologic process in multiple common, 
multifactorial diseases. As such, models of BTHS have the potential to not only elucidate 
the underlying disease mechanism of TAZ deficiency in BTHS, but to inform the 
pathophysiology of common and complex diseases associated with altered CL metabolism. 
 
1.2.6 Barth Syndrome Models 
Since the identification of the gene responsible for BTHS, several models of TAZ 
deficiency have been generated, which all recapitulate the primary BTHS biochemical 
abnormality; an increased MLCL:CL ratio and an abnormal acyl chain composition of the 
remaining CL (Table 1). The first model generated was the S. cerevisiae yeast model, 
taz1∆, which contains a null variant in the homologue of human TAZ. [142,143] Studies in 
yeast, which represent a proven model for mitochondrial disease, encompass the majority 
of our understanding of the role TAZ deficiency and abnormal CL metabolism in 
mitochondrial dysfunction. [144,145] Characterization of the yeast model, taz1Δ, has 
connected altered CL metabolism with OXPHOS dysfunction with or without aberrant SC 
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assembly, IMM uncoupling, increased oxidative stress, and impaired iron homeostasis 
(Table 1).[142,143,146–149]  
 Three animal models of TAZ deficiency have been developed: a TAZ knockout 
(TAZKO) fruit fly, a morpholino induced TAZ knockdown (TAZKD) zebrafish, and a 
doxycycline short hairpin RNA-induced TAZKD mouse model.[77,78,150,151] TAZKO 
fruit flies exhibit motor weakness, reduced flying and climbing abilities, and reduced 
endurance, which parallels the exercise intolerance of many BTHS individuals.[150,152] 
TAZKD zebrafish have severe developmental and growth retardation with the cardiac 
phenotypes of bradycardia, pericardial effusions, and generalized edema.[151]  TAZKD 
mice recapitulate many of the cardiac phenotypes in BTHS, including left ventricular 
dilation, reduced left ventricular mass, and reduced ejection (Table 1). [77,78]  
 There are also numerous in vitro cellular models of both primary and immortalized 
cells; BTHS patient neutrophils, BTHS patient-derived fibroblasts and lymphoblast cell 
lines, TAZKO and TAZKD mouse embryonic stem cell (ES) lines, TAZKD Human pro-
myelocytic HL-60 progenitor (HL60) cell lines, TAZKO and TAZ knock-in (TAZKI) 
HEK293 cell lines, patient derived and engineered TAZKO induced pluripotent stem cell 
(iPSC) lines, TAZKO C2C12 myoblast cell lines, and TAZKO H9c2 cell lines (Table 
1).[21,119,161,153–160] Collectively, these cellular models display low basal respiration, 
low membrane potential, diminished OXPHOS, and destabilization OXPHOS SCs. Two 
models of note, the TAZKO and TAZKI HEK293s and patient derived and engineered 




Table 1. Barth Syndrome model systems 
Model Gene Gene Location Protein System Phenotypes Ref. 
Yeast TAZ1 ChrXVI: 814,349–  
815, 536 
taz1 (KO) taz1Δ • OXPHOS dysfunction 
with or without aberrant 
SC assembly 
• IMM uncoupling 
• Increased oxidative stress 









Taz (KO) TAZ -/- • Motor weakness 
• Reduced flying and 
climbing abilities 






Taz (KD) asMO-mediated • Severe developmental and 
growth retardation 
• Cardiac phenotypes: 
bradycardia, pericardial 
effusions, and generalized 
edema 
151 
Mouse Taz ChrX: 
74,281,912–
74,290,151 
TAZ (KD) Dox induction • Cardiac phenotypes: left 
ventricular dilation, 
reduced left ventricular 
mass, and reduced ejection 
77,78 
Human TAZ ChrX: 
154,411,518–
154,421,726 
TAZ • BTHS Patient 
neutrophils 
• BTHS patient – 
derived fibroblasts 
• BTHS patient – 
derived 
lymphoblasts 
• BTHS patient – 
derived iPSCs 
• KO/KI engineered 
iPSCs 
• KD Human pro – 
myelocytic 
• (HL60) cells 
• KO/KI Human 
embryonic kidney 
cells (HEKs) 
• KO C2C12 
myoblast cells 
• KO H9c2 cells 
• Low basal respiration 
• OXPHOS dysfunction 
• Aberrant SC assembly 





To establish a novel mammalian BTHS model, Lu et al. utilized TALEN-mediated 
genome editing in Flp-In 293 cells, modified HEK293s which contain a single stably 
integrated FRT site, to generate a TAZKO line, tazTALEN.[23] A detailed characterization of 
endogenous TAZ in the tazTALEN line revealed that mammalian TAZ, as previously 
determined in yeast, is localized to the mitochondrion, where it associates non-integrally 
with IMS-facing membranes and assembles in a range of complexes. Further, using the 
integrated FRT site to express two TAZ variants of interest, R57L and H69Q, Lu et al. 
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confirmed LOF mechanisms previously modeled in yeast. This human cellular model 
substantiated the power of modeling BTHS in yeast, as well as provided a framework with 
which to investigate the consequences of individual TAZ variants, which could prove 
invaluable in therapeutic discovery and validation. 
Like the TAZKO and TAZKI HEK293 cell lines, the recent development of iPSCs 
allows for the investigation of TAZ deficiency and abnormal CL metabolism in a TAZ-
variant specific context. Additionally, unlike the HEK293s, the use of iPSCs allow for 
investigations in a disease relevant cell type. This is of particular interest in BTHS, which 
clinically affects specific tissue types and metabolically affects CL composition, which is 
inherently tissue specific. Wang et al. established two BTHS patient derived iPSC lines, 
one with a deletion resulting in a frameshift (c.517delG, BTHH) and one with a missense 
variant (c.328C>T, BTHC), as well as two engineered lines using CRISPR-Cas9 genome 
editing, one with the same deletion (PGP1-TAZc.517delG) and one with a 14 base pair 
insertion (PGP1-TAZc.517ins).156 Extensive characterization following differentiation into 
cardiomyocytes (iPSC-CMs), which recapitulated the characteristic BTHS cardiolipin 
findings, revealed smaller and fragmented mitochondria, reduced peak OXPHOS function, 
and decreased ATP production in the absence of TAZ. When seeded on micropatterned 
fibronectin rectangles designed to mimic adult cardiomyocytes, BTHS iPSC-CMs 
assembled into sparse and irregular sarcomeres, and when seeded onto muscular thin film 
(MTF) chips the irregular sarcomeres displayed weak contraction.  
Each unique model has provided mechanistic insight into the pathophysiology of 




1.2.6 Barth Syndrome Therapies 
Currently, there are no disease specific treatments for BTHS. Affected individuals are 
treated symptomatically with vigilant surveillance and management by medical specialists 
in metabolism, cardiology, hematology, genetic counseling, physical therapy, and 
nutrition.  Therapeutic development has focused on four main therapeutic strategies; lipid 
replacement, enzyme replacement, gene replacement, and drug therapy (Figure 4). 
The pathognomonic metabolic defect in BTHS is an increase in MLCL and a 
decrease in mature CL, specifically tetralinoleoyl-CL, resulting in an overall increased 
MLCL:CL. In order to compensate for TAZ activity, the supplementation of CL, or lipid 
replacement, may be a reasonable approach (Figure 4). This approach was previously 
tested in vitro, where BTHS fibroblasts, supplemented with linoleic acid, showed a time 
and dose dependent increase in tetralinoleoyl-CL. [162] Additionally, TAZKD HL-60 cells 
incubated with CL nanodisks (ND), which delivered tetralinoleoyl-CL to mitochondria, 
displayed an attenuated apoptotic response. [163] Based on this research, Ikon et al. sought 
to determine the feasibility of this approach in an in vivo model. Unfortunately, lipidomics 
revealed that the CL-ND failed to alter the CL profile of WT or doxycycline short hairpin 
RNA-induced TAZKD mice. [164] Though CL-ND are not a viable option, this research 
highlights the importance of using both in vitro and in vivo modeling in therapeutic 
discovery and testing.  
In another approach to lipid replacement, Ball et al. suggested supplementing 
ethanolamine (Etn) in order to increase cellular PE.[165] PE, which can function in an 
overlapping manner with CL, could then potentially rescue the respiratory chain defects of 
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cells with altered CL metabolism. Interestingly, using the yeast models, taz1∆ and crd1∆, 
Ball et al. showed that Etn ameliorates mitochondrial function, however, without 
increasing PE levels. Instead, Etn restored OXPHOS SC formation through increased 
expression of complex III and IV subunits. As an area of ongoing research it will be 
interesting to see the viability of this approach in mammalian models (in vitro and in vivo), 
especially since previous research has demonstrated the difficulties in translating 
successful treatments between in vivo and in vitro models. 
 
Figure 4. Barth syndrome therapeutic strategies. BTHS patients are treated 
symptomatically with vigilant surveillance and management by clinical teams composed 
of medical specialists in genetics, cardiology, physical therapy, hematology, metabolism, 
and nutrition. Therapeutic research has focused on four main areas of therapeutic strategies; 
gene, replacement, enzyme replacement, lipid replacement, and drug therapy. 
 
Direct replacement of the TAZ enzyme is also a therapeutic approach under 
investigation (Figure 4). Working towards this goal, Dinca et al. have identified the 
mitochondrial localization signals in TAZ, TAZ (84–95) and TAZ (185–220). The TAZ 
(84-95) sequence, located in exon 3, targets TAZ exclusively to the mitochondrion and is 
sufficient to direct eGFP to mitochondria in TAZ deficient cells.161 The identification of 
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this 12 amino acid localization sequence may be the first step towards engineering a TAZ 
protein sequence that can be used for enzyme replacement therapy (ERT). Research into 
the in vivo applicability of TAZ ERT is currently underway. 
Replacement of the defective TAZ gene, or gene replacement therapy, is another 
therapeutic approach (Figure 4). As with enzyme replacement, delivery is the biggest 
hurdle in gene replacement. Recombinant adeno-associated virus (rAAV) vectors are often 
used for gene delivery because these vectors are derived from a nonpathogenic virus that 
elicits a minimal immune response and do not carry a risk of insertional mutagenesis. In 
order to optimize an AAV vector for TAZ delivery, Suzuki-Hatano et al. compared three 
AAV2/9-TAZ vectors with different promoters following their intravenous administration 
into doxycycline short hairpin RNA-induced TAZKD mice.[166] Of the three promoters, 
the desmin (Des) promoter was found to provide significant improvement in various 
assessments as compared to TAZKD controls. Of the 28 listed measurements, the Des-TAZ 
treated mice showed significant improvement in 6 measurements: TAZ transcription, TAZ 
translation, force mechanics, mitochondrial area, mitochondrial width, and mitochondrial 
oxygen consumption. It is not yet known how the effects of this gene replacement strategy 
will translate to patients. 
 In terms of small molecule/ drug therapies for BTHS (Figure 4), there is an ongoing 
clinical trial testing the safety, tolerability, and efficacy of Elamipretide in Barth Syndrome 
sponsored by Stealth BioTherapeutics Inc. (ClinicalTrials.gov Identifier: NCT03098797). 
[167] Elamipretide, also known as SS-31 (D-Arg-dimethylTyr-Lys-Phe-NH2), was first 
developed in 2004 by Zhao et al. as part of a series of peptide antioxidants, Szeto-Schiller 
peptides (SS peptides), that are targeted to the mitochondrion and concentrated in the 
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IMM.[168] Since its development, it has been reported that SS-31 binds with high affinity 
to CL and that the SS-31/CL complex inhibits CL peroxidation by Cyt. C and optimizes 
OXPHOS.[169–172] In addition to its therapeutic potential, a greater understanding SS-
31’s mechanism of action in improving mitochondrial function may provide insight into 
the pathophysiology of BTHS. 
 
1.2.7 Conclusion 
Even with the significant advancements described in this review, our understanding of the 
pathophysiology of BTHS remains relatively limited. Specifically, the role of TAZ in 
determining of the acyl chain composition of remodeled CL (Figure 3), and how TAZ 
deficiency results in the cardinal phenotypes of BTHS (Figure 1) have not been resolved. 
In addition to BTHS, altered CL metabolism is also observed in various common and 
complex diseases are associated with altered CL metabolism. Therefore, additional studies 
with a variety of model systems (Table 1), including human-based models that are variant 
and tissue specific, will not only provide answers relevant to BTHS, but address the role 
of CL metabolism in other common and complex diseases. 
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1.3 Identifying novel pathways of interest in 
mitochondrial disorders 
 
Methylmalonic acidemia (MMA), propionic acidemia (PA), and Barth syndrome (BTHS), 
are three genetic disorders of mitochondrial intermediary metabolism where the primary 
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genetic defects are well-established, yet knowledge of the downstream cellular effects are 
limited. Investigating these downstream mechanisms of cellular pathogenesis has the 
potential to provide novel targets for disease monitoring and treatment.  
To investigate the diverse cellular effects that result from the primary metabolic 
defects in MMA, PA, and BTHS, we performed hypotheses generating multi-omics 
investigations in both patient and novel CRISPR/Cas9 edited cellular models. “Omics”, 
branches of investigation that end in the suffix -omics such as genomics, proteomics, 
metabolomics, is the collective characterization and quantification of pool of biological 
molecules that translate into structure, function, and dynamics. The two branches of omics 
harnessed in our investigations were proteomics and metabolomics. 
Proteomics is the study of the proteome, the entire protein complement of the 
genome. [1–3] Contrary to the previously suggested and accepted one gene, one protein 
maxim, research has made it increasingly obvious that the proteome is as complex as 
genetic variation. The proteome consists of all the proteins present in a cell or individual, 
such as proteins that result from direct translation of the genetic code or those that result 
after alternative splicing and extensive post-translational modification. Since proteins are 
the executors of the prescribed genetic code, they are thereby responsible for or involved 
in almost every cellular function or regulatory mechanism. Therefore, the proteome is 
responsible for the phenotype of the cell and ultimately that of the entire individual. Like 
the genome, the proteome can be altered by disease states, including by changes in protein 
expression, modification, or processing. Proteomics is specifically aimed at identifying and 
characterizing these protein changes that occur as a result of disease state or chronic stress. 
[1–3] 
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Metabolomics is the study of the metabolome, the complete collection of 
metabolites or small molecule chemical such as amino acids or organic acids. [4, 5] Like 
the genome and proteome, which can be altered by disease, the metabolome of is sensitive 
to internal and external variables such as genetics, age, gender, and diet. [4, 5] More 
importantly, a single gene defect as in IEMs, can lead to a 10,000-fold change in a single 
endogenous metabolite levels, with far-reaching downstream metabolite perturbations. [4]  
Using the data generated from untargeted quantitative proteomics and 
metabolomics to perform functional analyses and annotation, we aimed to unveil novel 
pathways perturbed by disease. By identifying novel pathways of interest and expanding 
our knowledge of the downstream cellular effect of the single gene defect, we can 
ultimately identify new targets for therapy and clinical monitoring in MMA, PA, and 
BTHS, three IEMs with a significant burden of morbidity and mortality.   
 
1.3.1 References 
1. A. F. M. Altelaar, J. Munoz, A. J. R. Heck, Next-generation proteomics: Towards an 
integrative view of proteome dynamics. Nat. Rev. Genet. 14, 35–48 (2013). 
2. C. Monti, M. Zilocchi, I. Colugnat, T. Alberio, Proteomics turns functional. J. Proteomics 
198, 36–44 (2019). 
3. B. Aslam, M. Basit, M. A. Nisar, M. Khurshid, M. H. Rasool, Proteomics: Technologies and 
their applications. J. Chromatogr. Sci. 55, 182–196 (2017). 
4. D. S. Wishart, Metabolomics for investigating physiological and pathophysiological 
processes. Physiol. Rev. 99, 1819–1875 (2019). 
5. A. C. Schrimpe-Rutledge, S. G. Codreanu, S. D. Sherrod, J. A. McLean, Untargeted 
Metabolomics Strategies—Challenges and Emerging Directions. J. Am. Soc. Mass Spectrom. 







Multi-omics studies in cellular models of 
methylmalonic acidemia and propionic 
acidemia reveal dysregulation of serine 
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methylmalonic acidemia and propionic acidemia reveal dysregulation of serine metabolism. Biochimica 
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2.1 Abstract 
Background: Methylmalonic acidemia (MMA) and propionic acidemia (PA) are related 
disorders of mitochondrial propionate metabolism, caused by defects in methylmalonyl-
CoA mutase (MUT) and propionyl-CoA carboxylase (PCC), respectively. These 
biochemical defects lead to a complex cascade of downstream metabolic abnormalities, 
and identification of these abnormal pathways has important implications for 
understanding disease pathophysiology. Using a multi-omics approach in cellular models 
of MMA and PA, we identified serine and thiol metabolism as important areas of metabolic 
dysregulation. 
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Methods: We performed global proteomic analysis of fibroblasts and untargeted 
metabolomics analysis of plasma from individuals with MMA to identify novel pathways 
of dysfunction. We probed these novel pathways in CRISPR-edited, MUT and PCCA null 
HEK293 cell lines via targeted metabolomics, gene expression analysis, and flux 
metabolomics tracing utilization of 13C-glucose. 
Results: Proteomic analysis of fibroblasts identified upregulation of multiple proteins 
involved in serine synthesis and thiol metabolism including: phosphoserine amino 
transferase (PSAT1), cystathionine beta synthase (CBS), and mercaptopyruvate 
sulfurtransferase (MPST). Metabolomics analysis of plasma revealed significantly 
increased levels of cystathionine and glutathione, central metabolites in thiol metabolism. 
CRISPR-edited MUT and PCCA HEK293 cells recapitulate primary defects of MMA and 
PA and have upregulation of transcripts associated with serine and thiol metabolism 
including PSAT1. 13C-glucose flux metabolomics in MUT and PCCA null HEK293 cells 
identified increases in serine de novo biosynthesis, serine transport, and abnormal 
downstream TCA cycle utilization. 
Conclusion: We identified abnormal serine metabolism as a novel area of cellular 




Serine is a non-essential amino acid that can be synthesized de novo from glucose via 3-
phosphoglycerate, a glycolytic and gluconeogenic intermediate. Serine has multiple critical 
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roles in the synthesis of fundamental cellular metabolites including phosphatidylcholine, 
creatine, one-carbon metabolites, and S-adenosylmethionine, the key methyl donor in cells 
[1]. 
Recently, alterations in serine metabolism have been described in several models 
of mitochondrial disease including the Deletor mouse model of mtDNA deletions, as well 
as in affected humans with POLGassociated disease, Myoclonic epilepsy with ragged red 
fibers (MERRF) and Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like 
episodes (MELAS) [2–4]. Evidence points towards redirected flux towards one carbon 
metabolism and glutathione as a protective mechanism for managing mitochondrial 
bioenergetic stress. Interestingly, similar changes have also been reported in multiple 
studies of various forms of malignancy [5–8], suggesting that serine metabolism represents 
a central response to diverse forms of mitochondrial metabolic challenges. In this study, 
we explored the role of serine metabolism in propionic acidemia (PA) and methylmalonic 
acidemia (MMA). 
PA and MMA are closely related autosomal recessive disorders of isoleucine and 
valine metabolism and result in defective entry of propiogenic metabolites into the TCA 
cycle at the level of succinyl CoA [9,10]. PA is caused by genetic defects in propionyl CoA 
carboxylase (encoded by PCCA and PCCB). MMA is caused by genetic defects in 
methylmalonyl-CoA mutase (encoded by MUT), or in vitamin B12 metabolism, among 
other rarer causes [10–13]. There is a strong clinical overlap between these disorders, but 
also important phenotypic differences [9,14–16]. In both disorders, there are multiple 
layers of evidence for mitochondrial dysfunction and oxidative stress [17–19]. 
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We used global proteomic analysis to identify novel pathways of cellular 
dysfunction in fibroblasts from individuals with PA and MMA. In both disorders, we 
uncovered enrichment of proteins involved in serine biosynthesis and thiol metabolism. 
We next employed untargeted metabolomics to evaluate the plasma of individuals with PA 
and MMA and identified increased excretion of key metabolites associated with serine 
metabolism, cystathionine and glutathione. 
In order to obtain further mechanistic insight into disturbances of serine metabolism 
in PA and MMA, we developed CRISPR/Cas9 edited PCCA-null and MUT-null HEK293 
cell lines, which showed increased expression of genes associated with serine metabolism, 
notably phosphoserine amino transferase (PSAT). Finally, we employed flux 
metabolomics and showed significant increases in de novo serine metabolism in these cells. 
 
2.3 Methods 
Fibroblast cell culture 
Primary fibroblast lines were derived from unrelated individuals with mut0 MMA (n = 2), 
PA (n = 2), and healthy controls (n = 2). Patient fibroblast experiments and the collection 
of clinical history had institutional IRB approval via Johns Hopkins University protocols 
NA_00026986 and NA_00036487. Individuals were diagnosed with MMA via lack of 
MUT enzyme activity in fibroblasts, the molecular confirmation of two pathological 
variants in MUT, and a clinical history of diagnostic urine organic acid analysis that 
includes massive elevations of methylmalonic acid. Individuals were diagnosed with PA 
via lack of functional PCC enzyme activity in fibroblasts, the molecular confirmation of 
 48 
two pathological variants in PCCA, and a clinical history of diagnostic urine organic acid 
analysis that includes massive elevations of propionylglycine, methylcitrate, and 
tiglyglycine. Additionally, all 4 individuals, with MMA or PA, had a clinical history 
consistent with the infantile onset, severe form of the respective disease. The primary 
fibroblast cell lines were grown in RPMI 1640 medium (Gibco, Thermo Fisher Scientific) 
with 10% FBS (Gemini BioProducts) at 37 °C with 5% CO, unless otherwise noted. 
Control fibroblasts were obtained from healthy individuals without a known metabolic 
disorder. 
Prior to harvesting, each primary fibroblast cell line (n = 2 for each condition) was 
grown to 70% confluence and then maintained in serum-free medium for 12 h. Cells were 
lysed and the protein concentration was estimated using BCA assay (Pierce). Sample 
processing for proteomics was performed based on modified filter aided sample 
preparation (FASP) protocol. 100 μg of protein lysate from each cell line was subjected to 
filtration using 30 kDa filters and 8 M urea to reduce the amount of SDS in the lysate. The 
reduced protein lysate was alkylated using 20 mM iodoacetamide (IAA) and incubated for 
10 min in the dark at room temperature (RT). Prior to digestion, the concentration of urea 
was reduced to < 1 M using 50 mM Triethylammonium bicarbonate buffer (TEABC). 
Trypsin digestion was performed using 6-(1-tosylamido-2-phenyl) ethyl chloromethyl 
ketone (TPCK) treated trypsin (Promega) at an enzyme: substrate ratio of 1:20 for 12–16 
h at 37 °C. 
Global proteomics 
Tandem mass tag (TMT) labeling and reversed phase liquid chromatography (RPLC) 
fractionation of proteins.  
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Digested peptide samples (n = 2 for each condition) were labeled using TMT 6-plex 
reagents as per manufacturer's instruction (Thermo Fischer Scientific). Briefly, peptide 
digests from each condition were reconstituted in 50 mM TEABC buffer and mixed with 
the TMT reagent and incubated at RT for 1 h. After incubation, the reaction was quenched 
by adding 5% hydroxylamine. The TMT-labeled samples were pooled at 1:1:1:1:1:1 ratio, 
evaporated to dryness and subjected to desalting using SepPak C18 cartridges. Peptides 
were fractionated by bRPLC [20]. Briefly, TMT-labeled and lyophilized peptide mixtures 
were resuspended in buffer A (10 mM TEABC) and fractionated by bRPLC 
chromatography on an Agilent 1100 LC system using a linear gradient of 8–60% buffer B 
(10 mM TEABC in 90% acetonitrile (ACN)) for 60 min at a flow rate of 1 mL/min. A total 
of 96 fractions were collected, concatenated to 12 fractions, vacuum dried and stored at 
−80 C until LC-MS/MS analysis. 
LC-MS/MS analysis 
TMT-labeled samples were analyzed on LTQ-Orbitrap Velos mass spectrometer (Thermo 
Fisher Scientific) interfaced with Proxeon Easy nLC system (Thermo Fisher Scientific). 
Each fraction was loaded and concentrated on a trap column (75 μm × 2 cm) packed in-
house using C18 material (Magic C18AQ, 5 μm, 100 Å, Michrom Biosciences Inc.) with 
a flow rate of 3 μL/min and resolved on an analytical column (75 μm × 30 cm, Magic 
C18AQ, 5um, 100A, Michrom Biosciences Inc.) at a flow rate of 200 nl/min using a linear 
gradient of 5–30% ACN over 90 min. Precursor MS scan (m/z 350–1700) and MS/MS was 
acquired with a mass resolution of 60,000 and 30,000 at 400 m/z in orbitrap mass analyzer 
respectively. The top ten intense peaks were selected for MS/MS fragmentation in each 
scan and fragmented using higher-energy collision dissociation (HCD) mode with 45% 
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normalized collision energy. The isolation width was set to 1.9 m/z. Acquired ions selected 
in a given scan were selectively excluded for 30 s. The maximum ion accumulation time 
was set to 200 msec for MS and 300 msec for MS/MS scans. The lock mass option was 
enabled using polysiloxane ion (m/z, 445.120025) from ambient air for internal calibration. 
Proteomic data analysis 
Mass spectrometry-derived data were processed and quantified using Proteome Discoverer 
(Version 1.4) software suite (Thermo Fisher Scientific). The data were searched against 
NCBI Human RefSeq protein database (Release 59) containing common contaminants 
using Mascot (version 2.2.0) and Sequest search algorithms. The precursor mass tolerance 
was set to 10 ppm and the fragment mass tolerance was set to 0.05 Da. The search 
parameters included oxidation of methionine set as a dynamic modification, 
carbamidomethylation of cysteine (+57.0215 Da) and TMT tag (+229.1629 Da) at N-
termini of peptides and lysine residues. A maximum of 2 missed cleavage were allowed 
for tryptic peptides. Identified peptides were validated using a Percolator algorithm with a 
q-value threshold of 0.01. The ratios were calculated by the quantitation node in proteome 
discoverer. Protein signals (as a proxy for quantity) were analyzed as log base 10 ratios of 
relative abundance between cell lines. Using the statistical program “R” for analysis, we 
confirmed that each result set showed a normal Gaussian distribution, (R Core Team (2013) 
[48]. R: A language and environment for statistical computing. R Foundation for Statistical 
Computing, Vienna, Austria. URL http://www.R-project.org/). In order to increase the 
specificity and avoid false positives, only proteins that were within two standard deviations 
of the mean within genotypes (MMA1 vs. MMA2, PA1 vs. PA2, WT1 vs. WT2) were 
considered for further analysis. Therefore, proteins which were highly discordant in 
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abundance within each genotype were discarded. Subsequently, in order to determine 
differentially expressed proteins in MMA and PA fibroblast cell lines, the ratios of protein 
abundance were analyzed as log base 10 ratios of relative abundance between disease 
groups (MMA vs. control, PA vs. control, MMA vs. PA). Proteins that were at least 2 
standard deviations from the mean were assessed for functional annotation. 
Functional annotation of differentially expressed proteins in fibroblasts 
To appreciate the functional characteristics of the differentially expressed proteins, we 
employed the DAVID Bioinformatics Resource v6.7 to determine the KEGG pathways 
and GO terms that are enriched proteins differentially expression in PA and MMA as 
compared to WT [21,22]. Pathways and GO terms were tested for significant enrichment 
via Fisher Exact test. 
Untargeted metabolomics analysis 
Metabolomics subjects 
Fifty-two plasma samples were selected to identify discriminating biomarkers that 
correlate with PA and MMA. Samples included: 17 samples from individual with 
phenotypes consistent with the classical, neonatal onset form of PA (average age 10y 9.6 
m; age range 4y 2 m to 25y 9.9 m), 15 samples from individuals with the classical mut0 
type of MMA (average age 12y 3 m; age range 8 m to 31y 0m, and 20 sexmatched control 
samples (average age 9y 8.8 m; age range 7 m to 25y 6 m). Control samples were obtained 
from individuals who underwent routine laboratory testing and were not known to have a 
genetic or metabolic condition. All samples were acquired during a “well” outpatient visit 
to mitigate effects of intercurrent illness or metabolic decompensation. Patient plasma 
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experiments had institutional IRB approval via Johns Hopkins University protocol 
NA_00069372. 
Metabolomics sample preparation and analysis 
Sample preparation, data acquisition and analysis were performed as previously described 
[23–25]. Briefly, each of the fifty-two plasma samples were prepared by adding 400 μl 
cold methanol with tryptophan-d5 internal standard to 50 μl of plasma for protein 
precipitation. After centrifugation at 16,000 rcf, 350 μl of supernatant was lyophilized 
overnight and re-constituted in 100 μl of 95:5 water:methanol. In addition, phenotypic 
pooled samples were prepared by combining 30 μl from each of the study samples 
belonging to the same phenotype (MMA, PA, Control). In addition, total pools were 
created by taking a 250 μl aliquot from each of the phenotypic pools. Pooled plasma 
samples (phenotypic and total) were prepared identically to the individual study samples. 
Samples were analyzed on a SYNAPT G2-Si QTOF mass spectrometer coupled to 
an Acquity UPLC (Waters Corporation, MA). Prior to analyzing the study samples, the 
column and the system were equilibrated with five injections of quality control samples. 
The compounds were separated on a Waters Acquity UPLC HSS T3 column (2.1 × 100 
mm, 1.8 μm particle size) operating at 50 °C using a reversed-phase chromatographic 
method. A gradient mobile phase consisting of water with 0.1% formic acid (A) and 
methanol with 0.1% formic acid (B) were used. All MS data were collected over 50–1000 
m/z in electrospray ionization (ESI) positive ion mode. Leucine enkephalin was used as 
the lock mass and a lock mass scan was collected every 45 s and averaged over 3 scans to 
perform correction for any mass drift over the course of the analytical run. Source and 
desolvation temperatures were set at 110 °C and 400 °C, respectively. 
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Metabolomics data processing 
The raw mass spectrometric data was processed (alignment and peak picking) using 
Progenesis QI (Waters Corporation). The normalized data were mean centered and scaled 
by dividing by the standard deviation and multivariate analysis methods (principal 
component analysis (PCA), orthogonal partial least squares discriminant analysis (OPLS-
DA)) were used to reduce the dimensionality and to visualize the study groups (SIMCA 
14.1, MKS Umetrics, Umea, Sweden) [26,27]. The PCA scores plot was used to ensure 
that the quality control samples clustered in the center of the study samples from which 
they were derived, which has become a standard method for assessing the quality of 
untargeted metabolomics data. OPLS-DA, which is a supervised analysis method, was used 
to identify peaks important to differentiating the study groups. Loadings plots and variable 
influence on projection (VIP) plots were inspected. All models used a 7-fold cross-
validation to assess the predictive variation of the model (Q2). Descriptive statistics and t-
tests using the Satterthwaite approximation for unequal variances were conducted using 
SAS 9.4 (SAS Institute Inc., Cary, NC). In this exploratory study, p-values were not 
adjusted for multiple testing. Peaksthat had a VIP ≥ 2.0 with a jack-knife confidence 
interval that did not include 0 or had a p-value < 0.001 were determined to be important 
for differentiating the study groups. 
Putative identification of the signals differentiating the study groups was made 
using a database search against the ERCMRC's in-house exact-mass-retention-time library 
of standards and the Human Metabolome Database (HMDB). Peaks that could not be 
library-matched were classified as unknown. 
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MUT-null and PCCA-null CRISPR/Cas9 edited cells 
Development of MUT-null and PCCA-null CRISPR/Cas9 edited 
HEK293 cells 
Cas9-nickase with two adjacent guide RNAs (gRNAs) was used to make the null HEK293 
cell lines as previously described [28]. MUT exon 5 and PCCA exon 12 were targeted for 
editing, based on the location of previously reported human disease-causing mutations 
[12,29]. gRNAs were designed using http://tools.genome-engineering.org (Supplementary 
Table 1) [30]. Synthesized gRNAs were inserted into a CR-BluntII-TOPO plasmid 
(Invitrogen) and transformed into E.coli. A plasmid co-expressing Cas9 and GFP 
(Addgene) was co-transfected with the gRNA-plasmids into WT HEK293 cells via 
lipofectamine. GFP positive single cells were FACS sorted into 96-well plates. Positive 
clones were identified by PCR and Sanger sequencing (Supplementary Table 2). For whole 
cell lysate extraction, confluent culture dishes were lysed with RIPA lysis buffer (1% (v/v) 
Triton X-100, 20 mm HEPES–KOH, pH 7.4, 50 mm NaCl, 1 mm EDTA, 2.5 mm MgCl2, 
0.1% (w/v) SDS) spiked with 1 mm PMSF). Insoluble material was removed by 
centrifugation, the supernatant collected, and protein quantified using a BCA assay 
(Pierce). Absence of expressed PCCA (Novus Biologicals) or MUT (Abcam) protein was 
then confirmed in whole cell lysates via immunoblot of 3 individual cell passages for each 
genotype. 
HEK293 cells were obtained from Thermo Fisher Scientific (Waltham, MA). Cells 
were cultured with DMEM (Corning Cellgro, ThermoFisher Scientific) supplemented with 
10% FBS (Gemini BioProducts), and 1% L-glutamine (Gibco, Thermo Fisher Scientific), 
and grown at 37 °C with 5% CO, unless otherwise noted. 
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Metabolite measurements in HEK293 cells 
Acylcarnitines were analyzed in spent media from confluent cell culture 6-wells at 4 days, 
11 days and 18 days after cell plating via tandem mass spectrometry (MS/MS) without 
chromatographic separation in the positive-ion mode using multiple-reaction monitoring 
(MRM) as previously published [31,32]. Methylmalonate was quantified in spent media 
from confluent cell culture 6-wells at 4 days, 11 days and 18 days via stable-isotope dilution 
and gas chromatography/mass spectrometry (GC/MS) as previously published [33]. 
Metabolite measurements were performed with n = 3 (3 individual 6-well cell 
culture wells assayed of each genotype for each metabolite at all time points). 
Gene expression in HEK293 cells 
150,000 cells from each genotype (MUT-null, PCCA-null, and WT HEK293 cells) were 
plated in 6-well culture dishes. Following plating, gene expression was measured at day 1, 
2, 4 and 8. SYBR green (BioRad) labeled reverse transcription-quantitative PCR (RT-
qPCR) was carried out on cDNA derived from cells as previously described [34] for 
expression of the following genes: PSAT1, CBS, ASNS, SLC7A5, SLC3A2 and 18S rRNA 
(as a loading control) (Supplementary Table 3). Gene expression from each genotype at 
each time point was tested in triplicate. Each of the three measurements was made on cells 
derived from individual wells. 
Glucose-13C6 flux metabolomics 
Cell preparation for flux metabolomics 
225,000 cells from each genotype (MUT-null, PA-null, WT) were plated into five 100 mm 
culture dishes (n = 5 per genotype) in DMEM (Gibco, Thermo Fisher Scientific) with 10% 
FBS (Gemini Bio-Products) and 1% L-glutamine (Gibco, Thermo Fisher Scientific). When 
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cells reached 70% confluency, log phase of growth, growth media was replaced with 
DMEM-no glucose (Gibco, Thermo Fisher Scientific), with 10% FBS (Gemini Bio-
Products), 1% L-glutamine (Gibco, Thermo Fisher Scientific), and D-Glucose-13C6 to a 
final concentration of 4500 mg/L (Cambridge Isotope Laboratories, Inc.). After 8 h, cells 
were washed, and metabolites were extracted from each dish (n = 5 for each genotype). An 
internal control (Human Metabolome Technologies, Inc.) was added to each sample, 
followed by ultrafiltration of cell extracts and sample evaporation. Samples were stored at 
−80 °C. 
Metabolite measurements 
The metabolite samples were further processed and analyzed by Human Metabolome 
Technologies (HMT). Briefly, the compounds were measured in the Cation and Anion 
modes of Capillary Electrophoresis Time-of-Flight Mass Spectrometry (CE-TOFMS) 
followed by metabolome analysis on an Agilent CE-TOFMS system (Agilent Technologies 
Inc.) Cationic samples were run in ESI positive mode and anionic samples were run in ESI 
negative mode [35,36]. 
Data processing and quantification 
Peaks detected by CE-TOFMS analysis were extracted using automatic integration 
software (MasterHands ver. 2.17.1.11 developed at Keio University) in order to obtain 
peak information including m/z, migration time (MT), and peak area. Putative metabolites 
were then assigned from HMT's target library and their isotopic ions on the basis of m/z 
and MT. Absolute quantification was performed for total amount of each detected 
metabolite. All the metabolite concentrations were calculated by normalizing the peak area 
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of each metabolite with respect to the area of the internal standard and by using standard 
curves, which were obtained by single-point (100 μM) calibrations. 
 
2.4 Results 
Differentially expressed proteins in fibroblasts from patients with propionic acidemia 
(PA) and methylmalonic acidemia (MMA) 
Discovery proteomics analysis was performed on fibroblasts from individuals with PA (n 
= 2), MMA (n = 2), and WT (n = 2) in order to generate hypotheses about novel adaptive 
pathways in MMA and PA, with the goal of performing targeted studies downstream to 
validate pathways of interest. A total of 4086 proteins were identified across the MMA, 
PA and WT fibroblast cohorts. To eliminate intra-cohort discordance, we removed all 
proteins that fell beyond 2 standard deviations of the mean protein abundance for each 
matched pair (i.e. MMA1/MMA2, PA1/PA2, and WT1/WT2). After this exclusion, 3449 
proteins were considered for inter-cohort analysis (Fig. 1, Supplementary Fig. 1).  
We then identified proteins with significant differential expression between disease 
groups (inter-cohort) by selecting proteins that fell beyond 2 standard deviations from the 
mean protein abundance across all proteins measured for each disease pair (i.e. PA/WT 
and MMA/WT). In the control vs PA fibroblast cohort comparison, a total of 103 proteins 
fell at least 2 standard deviation below the mean, and 95 proteins fell at least 2 standard 
deviations above the mean. In the control vs MMA fibroblast cohort comparison, a total of 
111 proteins fell at least 2 standard deviations below the mean, and 69 proteins fell at least 
2 standard deviations above the mean (Fig. 1). The 378 differentially expressed proteins 
were then assessed via in silico functional analysis using DAVID to determine KEGG 
 58 
pathways and GO terms enriched for the proteins of interest (Supplementary Table 4). 
Pathways were tested for significant enrichment via Fisher Exact test. 
 
Figure 1. Workflow for proteomics analysis. A total of 4086 proteins were identified 
across the MMA (n = 2), PA (n = 2) and WT (n = 2) fibroblast cohorts. We removed all 
proteins that fell beyond 2 standard deviations of the mean protein abundance for each 
matched pair from further analysis. After this exclusion, 3449 proteins were considered for 
further analysis to determine differentially expressed proteins between cases and controls. 
Proteins with abundances that fell above +2 or below −2 standard deviations when 
comparing PA/Control and MMA/Control were then considered for functional analysis. 
MMA, methylmalonic acidemia. PA, propionic acidemia. 
 
Of the 69 proteins with significantly increased abundance in the MMAfibroblast 
group, KEGG pathway analysis showed significant enrichment for proteins involved in the 
biosynthesis of amino acids (p = 2.3e−3), and cysteine and methionine metabolism (p = 
8.2e−3). Significantly enriched GO terms included: cellular amino acid biosynthetic 
processes (p =1.1e−4), neutral amino acid transport (p = 4.6e−2), hydrogen sulfide 
biosynthetic processes (p = 1.4e−2), and transsulfuration (p = 1.8e−2). Of the 95 proteins 









































































showed increased enrichment of proteins involved in biosynthesis of amino acids 
(approaching statistical significance, p = 7.1e−2). Significantly enriched GO terms 
included: cellular amino acid biosynthetic processes (p = 7.1e−3), hydrogen sulfide 
biosynthetic processes (p = 1.9e−2), and transsulfuration (p = 2.4e−2) and neutral amino 
acid transport (p = 1.3e−2). 
Of the 111 proteins with significantly decreased abundance in MMA fibroblast 
group, KEGG pathway analysis showed significant enrichment of proteins in pyruvate 
metabolism (p = 3.8e−3), valine, leucine and isoleucine degradation (p = 6.00e−3), among 
other pathways. Significantly enriched GO terms included: oxidation-reduction process (p 
= 2.7e−4), autophagy (p = 9.1e−3), and response to hypoxia (p = 2.1e−2). Of the 103 
proteins with significantly decreased abundance in PA fibroblast group, KEGG pathway 
analysis showed significant enrichment of proteins in the following pathways: valine, 
leucine and isoleucine degradation (p = 4.60e−4), protein digestion and absorption (p = 
3.1e−2), and pyruvate metabolism (p = 3.9e−2), and other pathways. Significantly enriched 
GO terms included: oxidationreduction process (p = 2.4e−3), response to hypoxia (p = 
5.1e−4) and branched-chain amino acid catabolic process (5.40e−3). 
Plasma metabolomics shows altered levels of metabolites in patients with MMA and PA 
Supervised multivariate data analysis (OPLS-DA) showed clear differentiation of control 
subjects with MMA (Fig. 2A, R2X = 0.45, R2Y = 0.98, Q2 = 0.75) and PA (Fig. 2B, R2X 
= 0.37, R2Y = 0.97, Q2 = 0.78). 
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Figure 2. OPLS-DA score plots show clustering of cohorts. Plots showing the separation 
of (A) PA (black filled circles) to control (white filled circles) and (B) and MMA (grey 
filled circles) to control (white filled circles) show that disease cohorts are tightly clustered, 
and there are no significant outliers. MMA, methylmalonic acidemia. PA, propionic 
acidemia. 
 
Seven hundred ninety five (795) peaks were identified as being important to 
differentiating individuals with PA compared to controls (VIP ≥ 2.0 with a jack-knife 
confidence interval that did not include 0 or a p-value < 0.001) and 60 peaks were library-
matched to metabolites. Thirty four (34) individual metabolites were significantly reduced 
compared with controls (range of−43.3-fold to−1.3-fold), and 25 metabolites were 
significantly increased compared with controls (range of 1.5-fold to 199.6-fold). Of the 5 
metabolites with the most highly increased abundance, one is a known metabolite of 
propionic acid (propionylcarnitine, 64-fold increase) (Fig. 3). Cystathionine sulfoxide was 
increased 52-fold compared with controls, which is consistent with the upregulation of 
sulfur metabolism found in our proteomics studies (Fig. 3). The other three most highly 
increased metabolites were homocitric acid, which was increased 38-fold, methyl sorbate, 




Figure 3. Metabolites with increased abundance in propionic acidemia (PA) and 
methylmalonic acidemia (MMA) plasma samples. Fold change of the top 5 increased 
plasma metabolites (p < 0.001) in PA and MMA compared to controls. 
 
Eight hundred fifty seven (857) peaks were identified as being important to 
differentiating individuals with MMA compared to controls (VIP ≥ 2.0 with a jack-knife 
confidence interval that did not include 0 or a p-value < 0.001) and 56 peaks were library-
matched to metabolites. Twenty (20) metabolites had increased abundance compared with 
controls (range of 2.5-fold to 103.6-fold), and 36 metabolites had decreased abundance 
compared with controls (range of 1.3-fold to 21.3-fold). Of the 5 metabolites with the most 
highly increased abundance in samples from MMA patients, one is a well-known 
metabolite of propionic acid (propionylcarnitine, 71.5-fold increase). Cystathionine 
sulfoxide was increased 92.9-fold compared with controls, which is consistent with the 
upregulation of sulfur metabolism found in functional protein annotation. Similar to the 
PA individuals, methyl sorbate had a 76.5-fold increase, which is flavoring agent and may 
be a formula artifact but is also a biological product that has precursor structures similar to 
MMA. The remaining two metabolites of the top 5 include ursodeoxycholic acid 3-sulfate 
(103.6-fold increase) and 3,4 methylenesebacic acid (27.3-fold increase), whose 


















glutathione (15.2-fold) and S-formylmethylglutathione (16.3-fold) were also significantly 
increased in MMA individuals. 
Characterization of CRIPSR edited MUT-null and PCCA-null  HEK293 cells 
CRISPR/Cas9 editing of HEK293 cells targeting exon 12 of PCCA resulted in a 
homozygous 13 bp deletion (PCCAE12Δ13) (Fig. 4C). Immunoblotting against PCCA 
revealed no detectable expression of PCCA (Fig. 4A). CRISPR/Cas9 editing of HEK293 
cells targeting exon 5 of MUT resulted in a homozygous 22 bp insertion (MUTE5Δ22) (Fig. 
4D). Immunoblotting against MUT revealed no detectable MUT protein (Fig. 4B).  
 
Figure 4. Generation of MUT-null and PCCA-null HEK293 cells. (A) Immunoblot 
shows absent expression of PCCA in PCCAE12Δ13cells (n = 3, serial passages) compared to 
WT cells (n = 3, serial passages). β-Actin was used as a loading control. (B) Immunoblot 
shows absent expression of MUT in MUTE5Δ22 cells (n = 3, serial passages) compared to 
WT cells (n = 3, serial passages). β-Actin was used as a loading control. (C) Sanger 
sequencing trace of PCCAE12Δ13 highlights a 13 bp deletion in exon 12 of PCCA. (D) Sanger 
sequencing trace of MUTE5Δ22 cells highlights a 22 bp insertion within exon 5 of MUT. 
 
Propionylcarnitine (C3) was measured in spent media from confluent PCCAE12Δ13 
(n = 3, individual 6-well culture wells), MUTE5Δ22 (n = 3, individual 6-well culture wells), 
and WT (n = 3, individual 6-well culture wells) HEK293 cells at days 4, 11 and 18. Both 
PCCAE12Δ13and MUTE5Δ22 cells showed a significant increase in the excretion of 
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Methylmalonylcarnitine (C5DC) was below the limit of detection in all 3 cell lines. 
Methylmalonic acid was measured in spent media confluent PCCAE12Δ13 (n = 3, individual 
6-well culture wells), MUTE5Δ22 (n = 3, individual 6-well culture wells), and WT (n = 3, 
individual 6-well culture wells) HEK293 cells at days 4, 11 and 18. At days 11 and 18, 
MUTE5Δ22 cells had significantly increased excretion of methylmalonic acid compared to 
both control and PCCAE12Δ13 cells (Fig. 5B). Additionally, the methylmalonic acid in spent 
media was decreased in PCCAE12Δ13 cells compared to controls, which is expected because 
the metabolic block in PA inhibits the production of methylmalonic acid. 
 
Figure. 5. Metabolites in spent media from in PCCAE12Δ13, MUTE5Δ22 cells and WT 
cells. (A) Propionylcarnitine (C3) levels are significantly higher in spent media at 11 and 
18 days of growth in PCCAE12Δ13 (dashed line) and MUTE5Δ22 cells (dotted line) cells 
compared to WT (solid line). (B) Methylmalonate levels are significantly higher in spent 
media at 11 and 18 days of cell growth in MUTE5Δ22 cells (dotted line) compared to 
PCCAE12Δ13 (dashed line) and WT (solid lines) cells, and in WT compared to PCCAE12Δ13 
cells. (n= 3, individual 6-well culture wells of each genotype for each metabolite at all time 
points). 
 
Altered gene expression in PCCAE12Δ13, MUTE5Δ22, and WT cells 
Based on our proteomic and metabolomic findings we selected 5 genes to assess for mRNA 
expression in the PCCAE12Δ13 and MUTE5Δ22 cells: CBS, PSAT, SLC7A5, SLC3A2, and 
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significantly increased protein expression in MMA and PA patient-derived fibroblasts. 
SLC7A5 and SLC3A2 are involved in the transport of serine across the cellular membrane 
and have increased expression in MMA and PA patient derived fibroblasts. ASNS is a 
canonical target of the ATF4 transcription factor, which helps to regulate the integrated 
cellular stress response [37]. 
We measured RNA expression in PCCAE12Δ13 (n = 3, individual culture wells), 
MUTE5Δ22 (n = 3, individual culture wells) and WT cells (n = 3, individual culture wells) 
at 1, 2, 4 and 8 days after plating to capture gene expression through the log phase of growth 
and at confluence (Supplementary Fig. 2). Each experiment was carried with n = 3, 3 
individual 6-well culture wells analyzed per genotype per time point. 
At day 4 (~70% confluence, log phase of growth), MUTE5Δ22 had increased 
expression of serine transporter gene SLC7A5 (1.6-fold) and SLC3A2 (1.7-fold) compared 
to WT. PCCAE12Δ13 had increased expression of ASNS compared to WT (2.7-fold). 
Additionally, PCCAE12Δ13 had decreased expression of both serine transporters gene 
SLC7A5 and SLC3A2 (0.3-fold and 0.5-fold, respectively) compared to WT. CBS and 
PSAT1 expression was comparable to WT for both MUTE5Δ22 and PCCAE12Δ13 (Fig. 6A). 
At day 8 (cells at confluence), PCCAE12Δ13 and MUTE5Δ22 had increased expression 
of ASNS (1.4-fold and 1.7-fold, respectively) and PSAT1 (2.0-fold and 3.1-fold, 
respectively) compared to WT. Additionally, both PCCAE12Δ13 and MUTE5Δ22 had 
decreased expression of SLC7A5 (0.1-fold and 0.3-fold, respectively) and SLC3A2 (0.2-
fold and 0.9-fold, respectively) compared to WT (Fig. 6B). 
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Figure 6. mRNA expression in PCCAE12Δ13 and MUTE5Δ22 cells at 4 and 8 days of 
growth. (A) At day 4 (log phase of growth), MUTE5Δ22 had increased expression of serine 
transporter gene SLC7A5 (1.6-fold) and SLC3A2 (1.7-fold) compared to WT, though this 
did not reach statistical significance. Additionally, PCCAE12Δ13 had significantly decreased 
expression of both serine transporters gene SLC7A5 andSLC3A2 (0.3 fold and 0.5-fold, 
respectively) compared to WT. (B) At day 8 (cells at confluence), PCCAE12Δ13 and 
MUTE5Δ22 had increased expression of ASNS (1.4-fold and 1.7-fold, respectively) and 
PSAT1 (2.0-fold and 3.1-fold, respectively) compared to WT. Additionally, PCCAE12Δ13 
had significantly decreased expression of SLC7A5 (0.1-fold) and SLC3A2 (0.2-fold) 
compared to WT. (n=3, 3 individual 6-well culture wells per genotype per time point) (n=3, 
3 individual 6-well culture wells analyzed per genotype per time point). *indicates a 
statisticially significant change (p < 0.05) compared to WT. 
 
Flux metabolomics reveals alteration in serine synthesis and transport 
From CE-TOFMS measurement, 231 peaks (112 in Cation and 119 in Anion Mode, 
respectively) of isotopic ions and their total amount for each compound were identified.  
De novo serine synthesis from glucose was increased in both PCCAE12Δ13 and 
MUTE5Δ22 cells compared to WT, as shown by the amount of serine with all 3 carbons 
labeled with 13C (Fig. 7A-B). Additionally, glucose-6-phosphate, with all 6 carbons 
labeled with 13C, was significantly reduced in both PCCAE12Δ13 and MUTE5Δ22 compared to 
WT (0.4-fold reduction (p=5.7e-04) and 0.6-fold reduction (p=0.019) respectively) 
indicating a rapid flux towards serine biosynthesis, as glucose-6-phosphate is a pool of 
“trapped” intracellular glucose for cellular metabolite biosynthesis. Lastly, glycine with 
both carbons labeled with 13C, which is the product of SHMT from serine, was significantly 
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increased in PCCAE12Δ13 compared to WT (1.2-fold increase, p=0.018) but not MUTE5Δ22 
compared to WT (data not shown). Interestingly, serine transport (as measured by serine 
with no 13C labeled carbons) was only increased in MUTE5Δ22 (Fig. 7C). 
 
Figure 7. Serine biosynthesis and transport in MUTE5Δ22 and PCCAE12Δ13 cells. (A) 13C 
labeled glucose (13C-Glucose) is metabolized to 13C labeled serine (13C-Serine). (B) 
MUTE5Δ22 (n = 5, individual culture dishes) and PCCAE12Δ13 (n = 5, individual culture 
dishes) cells have significantly increased de novo synthesis of serine from extracellular 
glucose compared to WT cells (n = 5, individual culture dishes) (1.4-fold increase 
(p = 0.001) and 1.2-fold increase (p = 0.007), respectively). (C) Additionally, the 
intracellular pool of unlabeled serine (12C-Serine) is significantly higher in MUTE5Δ22 
compared to both WT and PCCAE12Δ13 (1.7-fold increase (p = 5.6e−05) and 1.8 fold 
increase (p = 4.6e−05), respectively) indicating increased uptake from the extracellular 
milieu. Values (y-axis) are represented as average MS peak heights±standard deviation for 
each genotype. Raw values were corrected for protein content. *indicates a statistically 
significant (p < 0.05) compared to WT. 
 
In addition to evaluating serine biosynthetic intermediates, we also evaluated the 
entrance of pyruvate with all three carbons labeled with 13C, into the TCA cycle (Fig. 8). 
The TCA cycle intermediates we assessed are from the first “turn” of the cycle and 




















































intermediates, with the exception of isocitrate, are significantly decreased compared to WT 
(Fig. 8B-E). In PCCAE12Δ13 cells, we found that the proximal TCA cycle intermediates are 
not significantly different compared to WT. Proximal intermediates include: citrate, 
aconitate, isocitrate, and alpha-ketoglutarate. However, the distal TCA cycle intermediates 
malate and fumarate are significantly decreased compared to WT (Fig. 8F-G). The 
differences noted are not due to the availability of labeled pyruvate, since the amount of 
pyruvate at the start of the cycle is not significantly different between cell types (Fig. 8A). 
 
Figure 8. 13C-labeled TCA intermediates MUTE5Δ22 and PCCAE12Δ13 cells. (A) 13C 
labeled pyruvate is not significantly different in and MUTE5Δ22 (n = 5, separate culture 
dishes) and PCCAE12Δ13 cells (n = 5, separate culture dishes) compared to WT (n = 5, 
separate culture dishes) (B) Citrate is significantly lower in MUTE5Δ22 compared to WT 
(0.7-fold, p = 0.045). (C) Aconitate is significantly lower in MUTE5Δ22 compared to WT 
(0.7-fold, p = 0.035). (D) Isocitrate is not significantly different between cell types. (E) 
Alpha-ketoglutarate is significantly lower in MUTE5Δ22 compared to WT (0.6-fold, 
p = 0.025). (F) Fumarate is significantly lower in MUTE5Δ22 and PCCAE12Δ13 compared to 





















































































































































significantly lower in MUTE5Δ22 and PCCAE12Δ13 compared to WT (0.6-fold (p = 7.8e−04) 
and 0.6 fold (p = 3.6e−05) respectively). Values (y-axis) are represented as average MS 
peak heights±standard deviation for each genotype. Raw values were corrected for protein 
content.13C labeled succinate, succinyl CoA, oxaloacetate and acetyl CoA were not 
measured in this assay due to technical limitations. *indicates a statistically significant (p 
< 0.05) change compared to WT. 
 
2.5 Discussion 
Disturbances in serine metabolism are increasingly implicated as a mechanism of response 
to mitochondrial stress in primary mitochondrial disease [2–4,38]. Evidence points towards 
shifting of serine flux towards synthesis of one-carbon metabolite intermediates and 
glutathione [2,3]. In this study, we provide multiple lines of evidence to demonstrate 
similar secondary metabolic disturbances in methylmalonic acidemia (MMA) and 
propionic acidemia (PA), suggesting that adaptations in serine metabolism represent a 
central theme of the cellular response to diverse mitochondrial stressors. This has 
significant implications for identifying both novel targets for therapeutic intervention, and 
targets for clinical monitoring in both primary and secondary disorders of mitochondrial 
function. 
We employed a discovery proteomics approach in fibroblasts from individuals with 
PA and MMA, in order to generate hypotheses about novel adaptive pathways in these 
disorders. Here we uncovered potential adaptations in serine and thiol metabolism. We 
then undertook a series of targeted studies downstream to validate these adaptations, and 
to understand their potential role in the pathogenesis of MMA and PA. 
In PA and MMA patient derived fibroblasts, we uncovered an enrichment of 
proteins involved in serine and thiol metabolism, including phosphoserine 
aminotransferase (PSAT), cystathionine beta synthase (CBS), and mercaptopyruvate 
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sulfurtransferase (MPST). Additionally, we also identified increased expression of 
multiple canonical proteins whose corresponding gene expression is regulated by the 
transcription factor ATF4. This is particularly relevant because ATF4 activation is known 
to activate serine biosynthesis and has also been reported in various models of primary 
mitochondrial disease [2]. In the MMA fibroblasts, proteins with significantly increased 
expression correspond with classic ATF4 response genes BCAT, ASNS, SLC7A5, and 
PSAT. These same genes had increased protein expression in the PA fibroblasts, as well 
as one other classic ATF4 response gene, SLC38A2 (SNAT2) [39,40]. Activation of ATF4 
in response to mitochondrial stress results in the upregulation of genes involved in the 
integrated response to adapt and alter cellular metabolism [37]. 
We chose to model MMA and PA in HEK293 cells due to their well characterized 
mitochondrial function, retention of relevant biochemical pathways, amenability to 
metabolomic tracer studies, and prior evidence for in vivo relevance in other disorders of 
mitochondrial intermediary metabolism [2,41]. Once our PCCA-null and MUT-null 
CRISPR edited HEK293 cells were shown to faithfully replicate the canonical biochemical 
defects in MMA and PA, we showed that these cells had alterations in expression of genes 
associated with serine biosynthesis and ATF4 regulation. Serial measurements of gene 
expression during the lag, exponential (log), and stationary phases of cell growth of the 
PCCA-null and MUT-null cells show differential expression compared to WT. Genes 
encoding for neutral amino acid transport including serine (SLC3A2 and SLC7A5) had 
increased expression during early phases of growth, while genes associated with amino 
acid metabolism had increased expression during later phases of growth (ASNS, PSAT). 
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In order to determine the biochemical etiology and downstream intracellular fate of 
serine, we performed 13C-labeled glucose flux experiments in PCCA- and MUT-null 
HEK293 cells. We found that both cell types have an increased de novo synthesis from 
extracellular glucose. In addition to elevations of 13C-serine in MUT-null cells, we also 
observed increased unlabeled serine compared to WT and PCCA-null cells. This could 
indicate either increased transport of serine from the periphery in the MUT-null cells, or 
increased serine biosynthesis from other intracellular sources. At this time, it is not clear 
why the MUT and PCCA-null cells are different in this regard. 
Interestingly, 13C-flux experiments also showed increased de novo synthesis of 
glycine from 13C-serine in PCCA-null cells. Massive elevations in plasma glycine are 
commonly seen in individuals with PA. In fact, before the canonical organic acid was 
identified, PA disorder was originally named “non-ketotic hyperglycinemia” [42,43]. It has 
been previously hypothesized that the increased plasma glycine could be due to inhibition 
of the glycine cleavage system [44]. However, our results would suggest that increased 
synthesis from serine may contribute to elevated plasma levels of glycine found in PA 
compared to unaffected individuals [43]. We did not observe an increase in de novo glycine 
synthesis in the MUT-null cells. While increased glycine levels may also be seen in MMA 
compared to unaffected individuals, typically it is at a significantly lower level than the 
plasma glycine levels observed in PA [43]. Perhaps introduction of mitochondrial stress in 
the MUT-null cellular model could induce elevated glycine synthesis. 
In addition to alterations in biosynthesis of serine, we also examined the flux of 
13C-labeled glucose into the TCA cycle. Anaplerotic deficiencies of the TCA cycle have 
been previously described in MMA and PA, and anaplerotic therapy has been suggested as 
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a mechanism of treatment in these disorders [45,46]. These deficiencies are intuitive 
considering that the metabolic flux of propionyl-CoA metabolism is towards succinyl-
CoA. However, we found that MUT-null cells have proximal defects in the TCA cycle, 
which may represent defective conversion of pyruvate to acetyl CoA at the step of pyruvate 
dehydrogenase. Thus, the TCA cycle defects in MMA cannot be solely due to limited flux 
of propionyl-CoA into succinyl-CoA. 
Furthermore, in PCCA-null cells, we found that flux of 13C labeled alpha-
ketoglutarate to the distal segment of the TCA cycle is limited. This could be at the step of 
either alpha-ketoglutarate dehydrogenase or succinate dehydrogenase. Within the current 
experiment, we were unable to measure 13C labeled succinate, and therefore we are unable 
to resolve the precise location of this relative metabolic inhibition. However, as seen in 
MUT-null cells, the anaplerotic abnormalities in PA are not solely due to limited flux of 
propionyl-CoA into succinyl-CoA. 
From a clinical standpoint, abnormally low plasma serine has been reported in a 
number of individuals with various primary mitochondrial disorders, and has also been 
reported in an individual with MMA after liver/kidney transplant [4,47]. Importantly, re-
disturbed flux of serine has been shown to paradoxically deprive some biologically 
important synthetic pathways of serine (i.e. sphingolipid synthesis), thus resulting in 
biochemical and clinical pathogenesis [4]. Therefore, correction of serine deficits is 
potentially highly clinically relevant. 
Further studies are necessary to determine if serine levels vary with metabolic 
stress, i.e. depletion of bioenergetic precursors. Our evidence would suggest that provision 
of glucose is particularly important for the de novo biosynthesis of serine in MMA and PA. 
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It follows, that serine supplementation could represent an avenue for therapy, though our 
evidence would suggest that this could be more beneficial in MMA, where transport of 
extracellular serine (as opposed to de novo synthesis) may be the dominant mechanism. 
There are several limitations to this work. The measurements of unlabeled TCA cycle 
intermediates in our experiment are unable to differentiate between cytoplasmic and 
mitochondrial metabolites. Therefore, we are unable to estimate the total amounts of 
mitochondrial TCA intermediates. Additionally, while HEK293 cells are derived from 
human kidney cells, they do not necessarily represent the affected tissues in MMA and PA. 
Therefore, we cannot be sure our HEK293 cellular models are capturing the full extent of 
the adaption and alteration of cellular metabolism in response to mitochondrial stress in 
MMA and PA. However, the confluence of evidence from the three biological 
experimental systems (patient-derived fibroblasts, patient-derived plasma, and cellular 
modeling) provides a strong argument for the importance of serine metabolism in the 
cellular pathogenesis of these disorders. 
In future work, we plan to expand upon these findings, and explore how substrate 
utilization differs in the setting of bioenergetic stress, such as starvation or increased 
reactive oxygen stress. This may provide insight into the biochemical adaptations that 
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2.7 Supplementary Information 
 
Supplemental Figure 1. Histogram of the protein expression fold change across 3,449 
proteins measured via shotgun proteomics in (A) Propionic acidemia fibroblasts 
compared to controls (PA) and (B) Methylmalonic acidemia (MMA) fibroblasts compared 
to controls. In both PA and MMA, SLCA7A5, CBS, BCAT1, PSAT1 and ASNS have an 













































































Supplementary Figure 2. mRNA expression in PCCAE12Δ13 and MUTE5Δ22 cells at 1, 2, 
4 and 8 days of growth. (A) At day 1 after seeding culture wells, MUTE5Δ22 (n=3, separate 
culture wells) had significantly increased expression of ASNS (1.4-fold), CBS (1.2-fold), 
and SLC3A2 (1.6-fold) compared to WT. PCCAE12Δ13 had significantly increased 
expression of PSAT1 (1.9-fold) and SLC7A5 (1.4 fold) compared to WT. Increased 
expression of SLC3A2 approached significance in PCCAE12Δ13 compared to WT (2.2 fold, 
P-value 0.06). (B) At day 2 (prior to log phase of growth), PCCAE12Δ13 had significantly 
increased expression of ASNS (8.1-fold)and PSAT1 (1.6-fold) compared to WT. (C) At day 
4 (log phase of growth), MUTE5Δ22 (n=3, separate culture wells) had increased expression 
of serine transporter gene SLC7A5 (1.6-fold) and SLC3A2 (1.7 fold) compared to WT (n=3, 
separate culture wells), though this did not reach statistical significance. Additionally, 
PCCAE12Δ13 had significantly decreased expression of both serine transporters gene 
SLC7A5 and SLC3A2 (0.3 fold and 0.5-fold, respectively) compared to WT. (D) At day 8 
(cells at confluence), PCCAE12Δ13 and MUTE5Δ22had increased expression of ASNS (1.4-
fold and 1.7-fold, respectively) and PSAT1 (2.0-fold and 3.1-fold, respectively) compared 
to WT. Additionally, both PCCAE12Δ13 had significantly decreased expression of SLC7A5 
(0.1-fold) and SLC3A2 (0.2-fold) compared to WT. *indicates p<0.05. 
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Supplemental Table 1 
sgRNA sequences for MUT and PCCA 
Gene Exon sgRNA1 (5’ – 3’) sgRNA2 (5’ – 3’) 
MUT 5 CACACTGTCAGACATCTGGA (TGG) CCTAAAAACTCAAAATCTCT (TCT) 
PCCA 12 TGGGACCGTGGAGTTCCTTG (TGG) CCAGAGCAGTAAAATATTCC (TCT) 




Supplemental Table 2 
Primer sequences for Surveyor Assay screening and sequencing of edited clones 
Gene Exon Forward Primer (5’ – 3’) Reverse Primer (5’ – 3’) 
MUT 5 TGTACGTGCACTGATCTTAATTC TTAACCACCAGAGGGAGACAA 
PCCA 12 AAAGTTGACTTATTTGAGCATGTTATG GATGTCTTAGCACAAGCATAAAAAC 
 
 
Supplemental Table 3 
qRT-PCR Primer sequences for mRNA expression in HEK293 cells 
Gene Forward (5’ – 3’) Reverse (5’ – 3’) 
SLC3A2 CTGGTGCCGTGGTCATAATC TGCTCAGGTAATCGAGACGCC 
SLC7A5 TCATCATCCGGCCTTCATCG TCACGCTGTAGCAGTTCACG 
PSAT1 TCTACGTCATGGGCTTGGTTC TCTTGCTTCTATTTTGGGGCTC 
CBS GGGTCCCCAGAGGATAAGGA GGGGTGTCCCCGATTTTCTT 
ASNS TGTTGGATGGTGTGTTTGCAT TCGCGGAGTGCTTCAATGTA 




Supplemental Table 4A 
Significantly enriched GO terms and KEGG pathways identified by DAVID 
analysis of proteins with reduced abundance in fibroblast cells from individuals 
with methylmalonic acidemia (MMA). 
Term P-Value 
GO Terms, Biological Process 
extracellular matrix disassembly 1.00E-04 
oxidation-reduction process 2.70E-04 
cyclooxygenase pathway 1.60E-03 
autophagy 9.10E-03 
response to vitamin B1 1.20E-02 
positive regulation of reactive oxygen species metabolic process 1.40E-02 
response to hypoxia 2.10E-02 
negative regulation of extracellular matrix disassembly 2.40E-02 
negative regulation of cell proliferation involved in contact inhibition 2.40E-02 
renal absorption 2.40E-02 
cell-cell adhesion 2.60E-02 
muscle contraction 2.80E-02 
response to oxidative stress 3.00E-02 
positive regulation of adaptive immune response 3.00E-02 
proteolysis 3.40E-02 
proteolysis involved in cellular protein catabolic process 3.50E-02 
doxorubicin metabolic process 4.80E-02 
response to selenium ion 4.80E-02 
daunorubicin metabolic process 4.80E-02 
response to calcium ion 4.90E-02 
KEGG Pathways 
Pyruvate metabolism 3.80E-03 
Valine, leucine and isoleucine degradation 6.00E-03 
Amino sugar and nucleotide sugar metabolism 6.40E-03 
Arachidonic acid metabolism 1.30E-02 
Histidine metabolism 1.40E-02 
Metabolic pathways 2.60E-02 
Pentose and glucuronate interconversions 3.30E-02 
Tryptophan metabolism 4.00E-02 
Fatty acid degradation 4.80E-02 
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Supplemental Table 4B 
Significantly enriched GO terms and KEGG pathways identified by DAVID 
analysis of proteins with increased abundance in fibroblast cells from individuals 
with methylmalonic acidemia (MMA). 
Term P-Value 
GO Terms, Biological Process 
cellular amino acid biosynthetic process 1.10E-04 
response to virus 7.50E-03 
negative regulation of cell proliferation 1.40E-02 
hydrogen sulfide biosynthetic process 1.40E-02 
nuclear transport 1.80E-02 
transsulfuration 1.80E-02 
establishment of integrated proviral latency 2.90E-02 
organ morphogenesis 4.40E-02 
neutral amino acid transport 4.60E-02 
KEGG Pathways 
Biosynthesis of amino acids 2.30E-03 
Cysteine and methionine metabolism 8.20E-03 
Metabolic pathways 2.30E-02 
Biosynthesis of antibiotics 4.00E-02 
Glycerophospholipid metabolism 4.60E-02 
 
 
Supplemental Table 4C 
Significantly enriched GO terms and KEGG pathways identified by DAVID 
analysis of proteins with reduced abundance in fibroblast cells from individuals 
with propionic acidemia (PA). 
Term P-Value 
GO Terms, Biological Process 
extracellular matrix disassembly 8.10E-05 
response to hypoxia 5.10E-04 
oxidation-reduction process 2.40E-03 
positive regulation of osteoblast differentiation 5.20E-03 
branched-chain amino acid catabolic process 5.40E-03 
protein localization 5.40E-03 
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memory 5.70E-03 
response to cadmium ion 9.30E-03 
angiogenesis 9.90E-03 
response to vitamin B1 1.20E-02 
positive regulation of I-kappaB kinase/NF-kappaB signaling 1.50E-02 
positive regulation of vasoconstriction 1.50E-02 
apoptotic process 1.80E-02 
protein homooligomerization 2.00E-02 
negative regulation of cell proliferation involved in contact inhibition 2.30E-02 
valine catabolic process 2.30E-02 
negative regulation of extracellular matrix disassembly 2.30E-02 
negative regulation of protein ubiquitination 2.40E-02 
response to oxidative stress 2.70E-02 
proteolysis 2.70E-02 
cellular response to lipopolysaccharide 2.80E-02 
peripheral nervous system axon regeneration 2.90E-02 
positive regulation of adaptive immune response 2.90E-02 
cellular response to amino acid stimulus 3.10E-02 
proteolysis involved in cellular protein catabolic process 3.20E-02 
response to drug 3.30E-02 
leukocyte migration 3.50E-02 
defense response to Gram-negative bacterium 4.10E-02 
response to calcium ion 4.50E-02 
response to mechanical stimulus 4.70E-02 
KEGG Pathways 
Proteoglycans in cancer 1.40E-04 
Valine, leucine and isoleucine degradation 4.60E-04 
Glyoxylate and dicarboxylate metabolism 1.90E-02 
Protein digestion and absorption 3.10E-02 
Pyruvate metabolism 3.90E-02 
Metabolic Pathways 4.50E-02 





Supplemental Table 4D 
Significantly enriched GO terms and KEGG pathways identified by DAVID 
analysis of proteins with increased abundance in fibroblast cells from individuals 
with propionic acidemia (PA). 
Term P-Value 
GO Terms, Biological Process 
extracellular matrix organization 3.90E-04 
cell adhesion 3.90E-04 
cellular amino acid biosynthetic process 7.10E-03 
glycosaminoglycan metabolic process 8.80E-03 
cell migration 1.00E-02 
cell-cell adhesion 1.00E-02 
amino acid transport 1.30E-02 
adherens junction organization 1.40E-02 
muscle contraction 1.50E-02 
collagen fibril organization 1.60E-02 
hydrogen sulfide biosynthetic process 1.90E-02 
transsulfuration 2.40E-02 
heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules 2.50E-02 
cerebral cortex development 3.10E-02 
regulation of cell shape 3.10E-02 
elastic fiber assembly 3.40E-02 
cardiac muscle fiber development 3.80E-02 
KEGG Pathways 
Focal Adhesion 3.30E-02 
Vascular smooth muscle contraction 3.30E-02 
Biosynthesis of antibiotics 3.60E-02 
Metabolic pathways 4.80E-02 
Cell adhesion molecules (CAMs) 5.10E-02 







Barth syndrome cellular models have 
dysregulated respiratory complex I and 
mitochondrial quality control due to 
abnormal cardiolipin 
 
This original article has been published and was reprinted with permission: Anzmann AF, Sniezek OL, 
Pado A, Busa V, Vaz FM, Kreimer SD, Cole RN, Le A, Kirsch BJ, Claypool SM, Vernon HJ (2021) Barth 
syndrome cellular models have dysregulated respiratory chain complex I and mitochondrial quality control 
due to abnormal cardiolipin. bioRxiv doi: https://doi.org/10.1101/2021.01.06.425502  
 
3.1 Abstract 
Objectives: Barth syndrome (BTHS) is an X-linked genetic condition caused by defects 
in TAZ, which encodes a transacylase involved in the remodeling of the inner mitochondrial 
membrane phospholipid, cardiolipin (CL). CL has been implicated in numerous 
mitochondrial functions, and the role of defective CL in the clinical pathology of BTHS is 
under intense investigation.  
Methods: We used untargeted proteomics, shotgun lipidomics, gene expression analysis, 
and targeted metabolomics to identify novel areas of mitochondrial dysfunction in a new 
model of TAZ deficiency in HEK293 cells.  
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Results: Functional annotation analysis of proteomics data revealed abnormal regulation 
of mitochondrial respiratory chain complex I (CI), driven by the reduced abundance of 6 
CI associated proteins in TAZ-deficient HEK293 cells: MT-ND3, NDUFA5, NDUFAB1, 
NDUFB2, NDUFB4, and NDUFAF1. This resulted in reduced assembly and function of 
CI in TAZ-deficient HEK293 cells as well as BTHS patient derived lymphoblast cells. We 
also identified increased abundance of PARL, a rhomboid protein involved in the 
regulation of mitophagy and apoptosis, and abnormal downstream processing of PGAM5, 
another mediator of mitochondrial quality control, in TAZ-deficient cells. Lastly, we 
modulated CL via the phospholipase inhibitor bromoenol lactone and the CL targeted SS-
peptide, SS-31, and showed that each is able to remediate abnormalities in CI abundance 
as well as PGAM5 processing.  
Conclusions: Mitochondrial respiratory chain CI and PARL/PGAM5 regulated 
mitochondrial quality control, both of whose functions localize to the inner mitochondrial 
membrane, are dysregulated due to TAZ deficiency and are partially remediated via 
modulation of CL. 
 
3.2 Introduction 
Barth syndrome (BTHS, MIM#302060) is a rare X-linked inborn error of mitochondrial 
phospholipid metabolism caused by variants in the gene TAFAZZIN (TAZ) [1-3]. TAZ 
encodes a transacylase essential for the remodeling and maturation of the mitochondrial 
phospholipid cardiolipin (CL) [1,4]. CL, primarily localized to inner mitochondrial 
membrane, has many key functions, including roles in maintaining mitochondrial cristae 
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structure, organization of respiratory complexes, protein import, fusion, fission, and 
cellular signaling [1]. TAZ deficiency results in abnormal CL content, including an 
accumulation of the remodeling intermediate monolysocardiolipin (MLCL), decreased 
remodeled CL, and a shift towards saturated CL species [1,5]. An elevated MLCL:CL ratio 
is the pathognomonic metabolic defect in BTHS and is found in 100% of affected 
individuals [6].  
BTHS is a multisystem disorder characterized by prenatal onset of left ventricular 
noncompaction, early onset cardiomyopathy, skeletal myopathy, growth abnormalities, 
and neutropenia among other features, and is the only known Mendelian disorder of CL 
metabolism [1, 7-9]. Despite knowledge of the primary metabolic defect in BTHS, there is 
limited knowledge of downstream mechanisms of cellular pathogenesis, and consequently 
there is a dearth of targets for therapeutic intervention and clinical monitoring [10]. In 
addition to BTHS, CL abnormalities have been described in common conditions such as 
idiopathic cardiomyopathy, fatty liver disease, and diabetes [1, 11-14]. Consequently, 
studies in BTHS have the potential to illuminate pathophysiology in a range of common 
diseases. 
To identify novel and unappreciated cellular pathways impacted by TAZ deficiency 
we employed a discovery-based approach in a new HEK293 TAZ-deficient cellular model, 
starting with untargeted proteomics followed by functional analysis, and validation of 
pathways of interest in both HEK293 TAZ-deficient cells and patient-derived 
lymphoblastoid cell lines (LCLs). With this approach we characterized two major areas of 
dysfunction in the inner mitochondrial membrane: complex I (CI) of the mitochondrial 
respiratory chain and mitochondrial quality control (MQC).  
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 Prior studies seeking to define the mitochondrial pathology of TAZ deficiency have 
described abnormal assembly and function of the mitochondrial respiratory complexes [15-
17]. In agreement with these findings, we identified aberrations in mitochondrial 
respiratory chain protein abundance and enzymatic function, specifically in CI. 
Significantly, our findings show that TAZ deficiency results in the reduced CI mRNA 
expression with evidence for distinct regulation in differing cell types.  
 In addition to expanding our current understanding of respiratory chain 
abnormalities in TAZ deficiency, we also identified novel abnormalities in regulators of 
MQC.  We uncovered aberrant abundance of the MQC protein PARL, which was 
accompanied by altered cleavage of the downstream MQC mediator and PARL target, 
PGAM5. PGAM5 cleavage abnormalities were further amplified by uncoupling of 
mitochondrial oxidative phosphorylation, suggesting that baseline MQC abnormalities in 
TAZ-deficient cells can be exacerbated with additional stress.  
Finally, we found that modulating CL normalizes gene expression of CI subunits, 
normalizes the abundance of CI holoenzyme, and remediates the aberrant ratio of cleaved 
to full length PGAM5. Thus, abnormal CL in TAZ deficiency has a direct role in 
dysregulating both CI of the mitochondrial respiratory chain and MQC.  
 
3.3 Methods 
Cell lines and culture conditions. 
HEK293 WT cells were purchased from ATCC (293 [HEK-293]x ATCC® CRL-1573™). 
Collection of control (LCL Control #1) and BTHS patient (LCL BTHS #1-5) derived LCL 
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lines had institutional IRB approval via Johns Hopkins University protocols 
#IRB00098987 (Table S11). Individuals were diagnosed with BTHS via an increased 
MLCL:CL ratio. Additional control LCL lines (n=9) were acquired through the following 
sources: Biochemical Genetics Laboratory at Kennedy Krieger Institute (LCL Control #2-
3), Valle Laboratory (LCL Control #4-5), Coriell NINDS Biobank (LCL Control #6-9) 
(Table S11). 
 LCL lines were transformed by the Biochemical Genetics Laboratory at Kennedy 
Krieger Institute and the Valle Laboratory used the following protocol. Peripheral blood 
samples were centrifuged for 15 minutes at 3000 rpm. The “buffy coat” was then 
resuspended in RPMI and further centrifuged for 10 minutes at 1000 rpm. The resulting 
cell pellet was resuspended in RPMI and incubated with Epstein-Barr (EB) virus and T-
cell growth factor (TCGF) at 37C for 48-72 hours. After incubation period, additional 
RPMI was added to the flask. Cells were monitored and fed RMPI for two weeks, after 
which the established transformed cell lines were passaged for experiments and/or 
freezing. LCL lines acquired through the Coriell NINDS Biobank were also transformed 
via EB virus. 
All cells were grown at 37°C, 5% CO2. HEK293 WT and TAZD45 were maintained 
in DMEM with L-glutamine and 4.5 g/L Glucose (Corning Cellgro Cat. #10-017) 
containing 10% fetal bovine serum (FBS, Gemini) and 2 mM L-glutamine (Gibco, Cat. 
#25030149). Patient derived lymphoblastoid cells (LCLs) were maintained in RPMI 1640 
(Gibco, Cat. # 11875119) containing 10% FBS (Gemini). Mycoplasma contamination was 
routinely monitored and not detected. 
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For CCCP treatment, HEK293s were seeded into 6-well plates. At confluence, cells 
were either treated with 20uM CCCP (Sigma, Cat. #C2759) for 0,10,30,60,90, and 120 
mins, or 0,10,20,40,80,100uM CCCP for 45 mins.  
For BEL treatment, HEK293s (400K) were seeded into 6-well plates. 48hrs later, 
at 80-90% confluence, cells were treated with 2.5uM BEL (Sigma, Cat. #B1552) for 48hrs. 
For SS-31 treatment, HEK293s (50K) were seeded into 6-well plates. For 7 days, 
cells were fed fresh 100nM SS-31 (Provided by Stealth Therapeutics). 
CRISPR/Cas9 genome editing 
sgRNAs (Figure S1 & Table SI) targeting exon 2 of TAZ were designed at 
www.crispr.mit.edu and selected based on the scoring algorithm detail in Hsu et al. 2013 
(Table S1) (55, 56). Synthesized sgRNA 1 and sgRNA 2 were individually cloned into 
pSpCas9(BB)-2A-Puro (PX459) V2.0 vector pSpCas9(BB)-2A-Puro (PX459) V2.0 was a 
gift from Feng Zhang (Addgene plasmid # 62988 ; http://n2t.net/addgene:62988 ; 
RRID:Addgene_62988 (55). HEK293 WT cells were transfected with both sgRNA vectors 
using Lipofectamine 2000 (Invitrogen). 24-hours after transfection cells were subjected to 
Puromycin selection (2ug/mL) for approximately 48 hours. Following selection, cells we 
passaged in order to isolate single cell clones. Confluent colonies of single cell clones were 
collected using a cloning cylinder and expanded for DNA isolation and screening. 
Screening and genotyping 
Genomic DNA was extracted from an aliquot of 3 x 106 cells using the Gentra Purgene Kit 
(Qiagen). The genomic region surrounding the CRISPR/Cas9 target site (741 bp) was PCR 
amplified using AccuPrime GC-Rich DNA Polymerase (Invitrogen) (Table S1). The PCR 
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product was then used for screening with Surveyor Assay Kit (IDT). The PCR product of 
Surveyor-Positive clones was further analyzed by Sanger sequencing. 
RT-PCR 
RNA was extracted from an aliquot of 3 x 106 cells using the RNeasy Plus Kit (Qiagen). 
cDNA was synthesized from extracted RNA using the iScript cDNA Synthesis Kit 
(BioRad). The region surrounding the CRISPR/Cas9 target site was PCR amplified using 
AccuPrime GC-Rich DNA Polymerase (Invitrogen) (Forward Primer: 5’ 
TACATGAACCACCTGACCGT 3’, Reverse Primer: 5’ 
CAGATGTGGCGGAGTTTCAG 3’). PCR products were resolved on a 0.8% agarose gel. 
Whole Cell Lysate Extraction 
An aliquot of 3 x 106 cells was centrifuged for 4 minutes at 1000rpm. The resultant cell 
pellet washed twice with ice-cold PBS and lysed with RIPA lysis buffer (1% (v/v) Triton 
X-100, 20 mm HEPES–KOH, pH 7.4, 50 mm NaCl, 1 mm EDTA, 2.5 mm MgCl2, 0.1% 
(w/v) SDS) spiked with 1 mm PMSF for 30 min at 4°C with rotation. Insoluble material 
was removed by centrifugation for 30 min at 21000g at 4°C, the supernatant collected, and 
protein quantified using a bichichronic acid (BCA) assay (Pierce). 
Mitochondrial Isolation 
Mitochondrial isolation of HEK293s was performed as previously described by Lu et 
al.[3]. Mitochondrial isolation of LCLs was also performed as previously described, with 
slight modification. LCLs were grown in maintenance media until total cell count exceeded 
100 x 106 cells. LCLs were then centrifuged for 4 minutes at 1000rpm before beginning 




Whole cell extracts or mitochondria, resuspended in XT Sample Buffer (BioRad) and 
Reducing Agent (BioRad), were resolved on Criterion XT 12% Bis-Tris gels (BioRad) in 
XT MOPS Running buffer (BioRad). Proteins were transferred to Immuno-Blot PVDF 
(BioRad) at 100V for 1 hour. Following transfer, membranes were blocked with 5% milk, 
0.05% Tween-20 in PBS (Blocking Buffer) for 1 hour at room temperature or at 4C if 
longer, with rocking. Following blocking, membranes were briefly washed with PBST 
(PBS with 0.2% Tween-20) and then incubated with primary antibody in PBST with 0.02% 
Na-Azide overnight at 4C with rocking. Following three successive 10-minute washes with 
PBST at room temperature, HRP-conjugated secondary antibodies were added and 
incubated for 45 min at room temperature. The membranes were then washed three times 
for 10 minutes with PBST and twice for 10 minutes with PBS. Immunoreactive bands were 
visualized using ECL Western Blotting Detection (Amersham) or SuperSignal West Pico 
PLUS (Pierce). Images were captured with a Fluorchem Q (Cell Biosciences, Inc.) or on 
film. Film was scanned before quantification. Quantitation of bands was performed using 
ImageJ and protein expression values were normalized to loading controls.  
Antibodies 
Antibodies against the following proteins were used; b-actin (loading control, Life 
Technologies #AM4302), GRP75 (loading control, 75-127), TAZ (#2C2C9, Epitope: 237-
TDFIQEEFQHL, exon 11)[3], NDUFAF1 (Abcam, #ab79826), PARL (Abcam #ab45231, 
Proteintech #26679-1-AP, Langer Laboratory), UQCRC2 (Abcam, #ab14745), NDUFA9 
(Abcam, #ab14713), NDUFS3 (Abcam, #ab110246), NDUFB6 (Abcam, #ab110244). Two 
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HRP-conjugated secondary antibodies were used; goat anti-rabbit (Abcam, #ab6721), goat 
anti-mouse (Abcam, #ab205719). 
Lipidomics 
Lipids were extracted from cell pellets (3 x 106 cells) and analyzed as previously described 
by Vaz et al. [57]. 
Proteomics 
Samples (HEK293 WT n=3, and TAZD45 n=3, serial passages) were reduced in 5 mM DTT 
for 1 hour at 56C, alkylated in 10 mM iodoacetamide for 30 minutes in the dark at room 
temperature, and precipitated in cold (-20C) acetone 10% trichloroacetic acid. The 
precipitate was pelleted by centrifugation at 16,000 g for 15 minutes, the supernatant was 
discarded, and the pellet was rinsed with cold acetone and dried at room temperature. The 
samples were reconstituted in 50 µL of 20% acetonitrile 80 mM triethyl ammonium 
bicarbonate (TEAB) and digested with 3.3 µg of trypsin/Lys-C mix (Promega) at 37C 
overnight. The digested samples were labeled with TMT 10-plex reagent (Thermo, Lot 
#SK257889) and combined. The sample was lyophilized and reconstituted in 0.5 mL of 10 
mM TEAB and fractionated by high (8-9) pH reversed phase chromatography into 84 
fractions which were concatenated into 24. Each of the 24 fractions was lyophilized and 
reconstituted in 2% acetonitrile 0.1% formic acid and separated over a 90-minute low (2-
3) pH reversed phase gradient (120 minutes run time) for mass spectrometry (MS) analysis 
on an Orbitrap Fusion. 
 MS data were acquired using serial data-dependent fragmentation of individual 
precursor ions (DDA). An intact precursor ion scan (MS1) spanning 400 - 1600 Th was 
acquired every 3 seconds at a resolution of 120,000 (at m/z = 200). Fragmentation scans 
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(MS2) were acquired at 60,000 resolution between precursor scans by isolation of 
individual precursor ions at 0.6 Th resolution, accumulation to 5 x104 automatic gain 
control for a maximum injection time of 250 ms, and activation with beam collision (HCD) 
at 38% energy. Mass accuracy was maintained throughout the experiment by internal 
calibrant lock mass. 
 The acquired data were searched against the SwissProt Human database by 
MASCOT using 4 ppm and 0.01 Da precursor and fragment maximum mass error, 
respectively. TMT labeled lysine and peptide N-termini and carbamidomethylation of 
cysteine were set as static modifications. Oxidation of methionine and deamidation of 
asparagine and glutamine were set as dynamic modifications. The results were rescored by 
Percolator in Proteome Discoverer 2.2 and quantitative analysis was carried out based on 
reporter ion intensities. 
Functional Annotation 
We selected proteins with a protein abundance fold change (FC, TAZD45/ WT) less than or 
equal to 0.80 (FC ≤ 0.80) and proteins with a FC greater than or equal to 1.2 (FC ≥ 1.20). 
Each subset was individually uploaded to DAVID 6.8 and compared to the background 
“Homo sapiens” [18-19]. With the functional annotation tool, we pulled all KEGG 
pathways and GO terms for further analysis.  
Quantitative RT-PCR 
Total RNA was extracted from an aliquot of 3 x 106 cells using the RNeasy Plus Kit 
(Qiagen). cDNA was synthesized from extracted RNA using the iScript cDNA Synthesis 
Kit (BioRad) in 20 μl reactions according to the manufacturer’s suggested protocol using 
1 ug of RNA. cDNA was subsequently diluted 10-fold with water. 2.4 μl of cDNA was 
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analyzed in 12 μl reactions using the SsoAdvanced Universal SYBR Green Supermix (Bio-
Rad) according to the manufacturer’s instructions and included each respective forward 
and reverse gene-specific primers (Table S12). Each sample-primer reaction was plated in 
triplicate per plate. Each plate also included both no reverse-transcriptase controls (No-
RT) for each cDNA sample and no template controls (No-Template) for each primer pair. 
The reaction conditions were as follows: 2 min at 95°C, followed by 40 two-temperature 
cycles of 5 s at 95°C and 30 s at 60°C. For nuclear genes, expression of each gene was 
analyzed by the comparative CT (ΔΔCT) method with TBP and HPRT1 being averaged as 
endogenous reference genes. For mitochondrial genes (MT-ND3), expression of each gene 
was analyzed by the comparative CT (ΔΔCT) method with MT-RNR1, MT-CO1, and MT-
ATP6 being averaged as endogenous reference genes. Values were represented as average 
fold change relative to respective wildtype or untreated controls. 
1D BN-PAGE 
Cell pellets (100,000 cells, ~120ug) were solubilized for 30 min on ice in 20 mm Bis-Tris, 
10% glycerol, 50 mM NaCl, supplemented with 1% (v/v) Triton X-100 and protease 
inhibitors (PMSF, Leupeptin, Pepstatin). Extracts were clarified by centrifugation for 30 
min at 21 000g at 4C and analyzed by 1D BN/SDS–PAGE as described by Claypool et al. 
[58]. 
Complex I and II activity assays 
The activity of complex I was measured using the Complex I Enzyme Activity Microplate 
Assay Kit (Abcam, #ab109721) according to the manufacturer’s instructions using 200ug 
of isolated mitochondria for both HEK293s and LCLs. The activity of complex II was 
measured using the Complex II Enzyme Activity Microplate Assay Kit (Abcam, 
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#ab109908) according to the manufacturer’s instructions using 200ug of isolated 
mitochondria for both HEK293s and LCLs. 
NDUFAF1 Transfection 
HEK293 cells were seeded into 15 cm plates. When cells reached ~80% confluency cells 
were transiently transfected with NDUFAF1(NM_016013) C-Myc/DDK-tagged plasmid 
(Origene #RC200029) with Lipofectamine 3000 (Thermo #L3000001) according to 
manufacturer’s instructions. 75.4 ug of plasmid was transfected with 105 uL of 
Lipofectamine 3000 per 15 cm plate. The cells were grown in galactose media for 48hrs 
before mitochondria extraction performed as described previously. 
Metabolomics 
HEK and LCL cell samples undergoing metabolic analysis were initially kept on ice and 
washed with ice-cold PBS prior to collection, followed by centrifugation at 1500RPM and 
4°C. Metabolites within the cell pellet were extracted with 80% HPLC-grade methanol 
(Fisher Scientific) and 20% mass-spec (MS)-grade water as previously described (59). The 
extraction solution was then collected and evaporated using a speed-vac and a lyophilizer 
which resulted in a white powder of dried metabolites. The collected metabolites were 
subsequently resuspended in 50% (vol/vol) acetonitrile diluted with MS-grade water and 
analyzed via an Agilent 1260 HPLC and 6490 triple-quadrupole (QQQ) mass spectrometer. 
The Agilent 1260 HPLC-autosampler system was kept at 4°C for the entirety of the 
run to prevent any degradation within the samples. Optimal separation was achieved with 
a reverse phase chromatography system with an aqueous mobile phase of MS-grade water 
with 0.1% formic acid and an organic mobile phase of 98% acetonitrile with 0.1% formic 
acid. The Discovery® HS F5 HPLC Column (3µm particle size, L × I.D. 15 cm × 2.1 mm, 
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Sigma) with a compatible guard column (Sigma) were used and maintained at a 
temperature of 35°C. The injection volume was 2µL and the runtime was 50 minutes per 
sample. The flow rate, buffer gradient, and mass spectrometer parameters for the method 
were the same as previously described [60].  
Data from pure standards of each compound of interest were acquired prior and 
simultaneously with samples in identical setting: precursor and product ion transitions, 
collision energy, and ion polarity. Agilent MassHunter and Agilent Qualitative and 
Quantitative Analysis Software packages were used to analyze the metabolic profiles. The 
metabolite peaks were integrated for raw intensities and then normalized by protein 
concentration collected from the original cell pellet. Protein concentration was determined 
using a FilterMax F5 microplate reader and a Bovine Serum Albumin (BSA) standard.  
Data Analysis 
All statistical analyses were performed using R version 3.3.2 (2016-10-31) [61]. Between-
group comparisons were performed using Welch’s two-sample t-test. Outliers, outside 1.5x 
the interquartile range above the upper quartile and below the lower quartile were only 
removed for statistical analyses of the isogenic HEK293 cell lines. 
 
3.4 Results 
Generation of a HEK293 TAZ-deficient model, TAZΔ45 
We used CRISPR/Cas9 genome editing in HEK293s to create a novel TAZ-deficient 
cellular model. Using two single guide RNAs (sgRNAs) targeting exon 2 of TAZ, we 
isolated 3 individual clones with a resultant 45bp deletion at the 3’- end of exon 2; TAZD45.4, 
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TAZD45.5, TAZD45.6 (Fig. S1). The deletion encompasses a predicted acyltransferase domain 
and covers an area of TAZ where multiple pathological variants have been described, such 
as p.R57L and p.H69Q (Fig. S1) [3]. The 45bp in-frame deletion is not predicted to result 
in NMD (Fig. 1A). However, the deletion resulted in undetectable expression of TAZ in 
all three clones (Fig. 1B). In the absence of TAZ there was no significant difference in the 
abundance of cytosolic and mitochondrial proteins/immunoblotting controls; GRP75, ß-
actin, VDAC1, and TOM20 (Fig. S2). 
Shotgun lipidomics via mass spectrometry revealed a significant decrease in CL, a 
significant increase in MLCL, and a significantly increased MLCL:CL ratio (p=0.03, p=4.9 
x 10-5, p=4.6 x 10-6, respectively) (Fig. 1C). TAZ-based remodeling is characterized by the 
incorporation of unsaturated acyl chains compared to nascent CL. Of the 31 CL species 
assessed, the TAZD45 clones had a significant increase in CL containing 1 to 3 double bonds 
(p=0.007, p=1.5 x 10-9, p=7.4 x 10-6, respectively) and a significant decrease in CL 
containing 4 to 6 double bonds (p=0.03, p=0.003, p=4.2 x 10-9, respectively), highlighting 
the loss of TAZ-based remodeling (Fig. 1D). Collectively, the TAZD45 clones recapitulate 
the pathognomonic metabolic defect of BTHS and validate the TAZD45 clones as TAZ-
deficient cellular models of BTHS. 
We amplified and Sanger sequenced 5 of the top 10 predicted off-target sites, 5 off-
target sites per sgRNA, which revealed no detectable off-target CRISPR/Cas9 genome 
editing activity (Table S1). The other 5 off-target sequences were not able to be amplified 
likely due to highly repetitive sequences and/or increased GC base pair content. None of 
the top 10 predicted off-target sites were located in coding regions. In order to mitigate 
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consequences of undetected off-target editing in any one of the clones, the clones, TAZD45.4, 
TAZD45.5, TAZD45.6, were combined at a 1:1:1 ratio to create the cellular model TAZD45. 
 
Figure 1. TAZD45 HEK293 genetic characterization, CL profiling and proteomics 
analysis. (A) RT-PCR of RNA extracted from the HEK293 TAZD45 clones using primers 
specific to the region of TAZ being edited. (B) Whole cells lysate (45ug) of the indicated 
cell lines immunoblotted for TAZ and loading control b-actin. (C) The abundance of CL 
and MLCL in WT (n=3) and TAZD45 clones (n=3, per clone) was determined by shotgun 
lipidomics via mass spectrometry. (D) The distribution of double bonds across CL species 
was determined as a percentage of total CL. (E) 7713 proteins were identified and 
quantified with TMT 10-plex mass spectrometry of whole cell lysate (200ug) of TAZD45 
(n=3) and WT cells (n=3). Protein abundance fold change (FC) calculated by dividing the 
average abundance per protein identified in TAZD45 cells by WT average abundance per 
protein. The genes that encode the most significantly reduced proteins in TAZD45 cells are 
GAS1 (FC=0.35, p=2.5 x 10-4), CD44 (FC=0.367, p=6.6 x 10-4), MOCOS (FC=0.45, 
p=0.011), ANAX1 (FC=0.478, p=0.01), and PLEC (FC=0.491, p=2.7 x 10-4). The genes 
that encode the most significantly increased proteins in TAZD45 cells are PRELID1 
(FC=2.125, p=8.4 x 10-4), CT45A5 (FC=1.909, p=0.023), PARL (FC=1.815, p=0.016), 
PRELID3B (FC=1.795, p=3.9 x 10-4), and DHRS1 (FC=1.774, p=0.016). Proteins with a 
fold change (FC) ≤ 0.80 are highlighted in grey (n=215) and proteins with a FC ≥ 1.20 are 
highlighted in black (n=621). Significant differences are indicated; * ≤ 0.05, ** ≤ 0.005, 
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Differentially abundant proteins in TAZD45 cells reveal downstream cellular dysfunction 
due to TAZ deficiency 
Shotgun proteomics analysis identified a total of 7713 proteins in HEK293 WT and TAZD45 
cells. To focus our downstream workflow on proteins with differential abundance between 
the WT and TAZD45 cells, we selected proteins with a protein abundance fold change (FC, 
TAZD45/ WT) less than or equal to 0.80 (FC ≤ 0.80) and proteins with a FC greater than or 
equal to 1.2 (FC ≥ 1.20) (Fig. 1E). Based on these criteria, there were a total of 836 
differentially abundant proteins, 215 with a FC ≤ 0.80 and 621 with a FC ≥ 1.20 (Fig. 1E). 
Functional annotation of the differentially abundant proteins, with KEGG pathway and 
gene ontology (GO) term enrichment analysis, identified multiple pathways of interest in 
TAZD45 cells (Table S2A-B) [18-19].  
We identified 86 significantly enriched (p ≤ 0.05) KEGG pathways and GO terms 
for proteins with a FC ≤ 0.80, such as: oxidative phosphorylation (p=2.7 x 10-6), 
mitochondrial respiratory chain complex I assembly (p=7.9 x 10-5), mitochondrial chain 
complex I (p= 2.1 x 10-4), response to oxidative stress (p=1.6 x 10-3), NADH 
dehydrogenase (ubiquinone) activity (p=2.1 x 10-3), and metabolic pathways (p=0.019) 
(Table S2A). We identified 127 significantly enriched (p ≤ 0.05) KEGG pathways and GO 
terms for proteins with a FC ≥ 1.20, such as: mitochondrion (p=2.2 x 10-4), metabolic 
pathways (p=3.1 x 10-3), positive regulation of apoptotic process (p=4.2 x 10-3), AMPK 




Functional annotation analysis: proteins of respiratory complex I and mitochondrial 
quality control 
Defects in OXPHOS function have been previously described in BTHS, and consistent 
with these previous studies, we found that of the 86 terms significantly enriched for 
proteins with FC ≤ 0.80 in TAZD45 cells, 18 reference the mitochondrion and/or OXPHOS, 
including the OXPHOS KEGG pathway (Table S2A). Specifically, 11 proteins with a FC 
≤ 0.80 are encoded by genes associated with the OXPHOS KEGG pathway (Fig. S3). Of 
these 11 proteins, 5 are subunits of complex I (CI) and the remaining 6 proteins are subunits 
of complex III, IV, and V (Fig. S3). When we further examined the 18 terms that reference 
the mitochondrion and/or OXPHOS, we found that 4 specifically reference CI of OXPHOS 
(Table S2A).  
The enrichment of the CI-associated terms in our functional annotation analysis 
was driven by 7 proteins encoded by the genes: MT-ND3, NDUFAF1, NDUFA5, 
NDUFAB1, NDUFB2, NDUFB4, and OXA1L (Fig. 2A). Five are subunits of CI (MT-ND3, 
NDUFA5, NDUFAB1, NDUFB2, NDUFB4), one is a CI assembly factor (NDUFAF1), and 
one assists with inserting proteins into the mitochondrial membrane and has been 
implicated in CI biogenesis (OXA1L) [20-21]. In total, proteomics identified and quantified 
56 CI associated proteins in WT and TAZD45 cells, and 45/56 had reduced abundance in 
TAZD45 cells (FC range=0.608-0.998) (Table S3). Together, the functional annotation 
analysis highlights a decreased abundance of proteins associated with complex I, further 
delineating a previously described pathway in BTHS. 
When we analyzed the top five proteins with significantly increased abundance, we 
identified PARL as a candidate for further study due to its role in regulating mitochondrial 
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responses to stress, such as membrane depolarization and increased reactive oxygen 
species [22-24]. Additionally, dysregulation of PARL substrates has been implicated in 
cardiomyopathy and cardiac development, further highlighting the potential role of PARL 
dysregulation in BTHS [25-27]. Upon further investigation of the 127 terms significantly 
enriched for proteins with a FC > 1.20, we observed that 20 terms reference the 
mitochondrion or mitochondrial dynamics, including: metabolic pathways (p=3.1 x 10-3), 
positive regulation of the apoptotic process (p=4.2 x 10-3), and mitochondrial inner 
membrane (p=5.2 x 10-3) (Table S2B). The functional annotation analysis revealed other 
genes of interest due to their potential roles in apoptosis, lipid trafficking, and/or 
mitochondrial quality control (MQC), such as; PRELID1, PRELID3B, CASP2, CASP7, 
CASP8, and CASP9 [28-30]. Together with the proteomics findings, the functional 
annotation analysis suggests an increased abundance of proteins involved in MQC, a 
pathway not previously described in BTHS. 
Reduced complex I holoenzyme and activity in HEK293 TAZD45 cells and BTHS patient 
derived lymphoblastoid cells  
To assess the biological significance of reduced CI associated proteins identified via 
proteomics, we further investigated CI subunit/holoenzyme mRNA expression, protein 
abundance, and function. We measured the relative mRNA expression of NDUFAF1, the 
most significantly reduced protein identified by proteomics (FC=0.797, p=0.004), in both 
HEK293 and BTHS patient derived lymphoblastoid cells (LCLs). In TAZD45 cells, 
NDUFAF1 had reduced mRNA expression (0.80, p=6.4 x 10-4), whereas in BTHS LCLs 
there was no significant difference in mRNA expression (Fig. 2B).  
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Figure 2. Reduced complex I (CI) holoenzyme abundance and activity in HEK293 
TAZD45 cells and BTHS patient-derived lymphoblastoid cells. (A) The enrichment of 
the CI-associated terms is driven by 7 genes; MT-ND3, NDUFAF1, NDUFA5, NDUFAB1, 
NDUFB2, NDUFB4, OXA1L. (B) Relative mRNA expression of NUDFAF1, determined 
by qRT-PCR and DDCT quantification. Data plotted relative to WT/CTRL expression; WT 
n=6, TAZD45 n=6, CTRL n=10, BTHS n=15. (C) Whole cell lysate (45 ug) of the indicated 
lines were immunoblotted for the indicated proteins. (D) Band intensities, relative to the 
loading control GRP75, were quantified and plotted relative to WT/CTRL abundance; WT 
n=27, TAZD45 n=26, CTRL n=49, BTHS n=48. (E) BN-PAGE of HEK293 WT and TAZD45 
or CTRL and BTHS LCL cells (100-250K cells) solubilized in 1% Triton X-100 
immunoblotted for the indicated proteins. (F) Band intensities were quantified, and CI 
abundance was represented as the ratio of CI band intensity to CIV (COXIV) or CII 
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TAZD45 n=16, CTRL n=12, BTHS n=12), CI:CII (WT n=10, TAZD45 n=13, CTRL n=9, 
BTHS n=9). (G) CI activity measured in HEK293 WT and TAZD45 or CTRL and BTHS 
LCLs mitochondria (200 ug total protein) on a microplate reader (450nm) by following the 
oxidation of NADH to oxidized nicotinamide adenine dinucleotide (NAD+). Activity 
plotted relative to WT/CTRL abundance; WT n=25, TAZD45 n=26, CTRL n=36, BTHS 
n=42. (H) CII activity measured in HEK293 WT and TAZD45 or CTRL and BTHS LCLs 
mitochondria (200 ug total protein) on a microplate reader by following the production of 
ubiquinol by CII coupled to the reduction of the dye diclorophenolindophenol (DCPIP, 
600nm). Activity plotted relative to WT/CTRL abundance; WT n=12, TAZD45 n=12, CTRL 
n=10, BTHS n=12. Targeted metabolomics was used to measured (I) NADH, NAD+, and 
(J) cellular AMP via mass spectrometry in HEK293 WT (n=3), HEK293 TAZD45 (n=3), 
CTRL LCL (n=5) and BTHS LCL (n=5) cells. Significant differences are indicated; * ≤ 
0.05, ** ≤ 0.005, *** ≤ 0.0005, **** ≤ 0.00005 
 
We also measured the relative mRNA expression the 5 other CI associated proteins 
that had a FC ≤ 0.80 (MT-ND3, NDUFA5, NDUFB2, NDUFAB1, and NDUFB4), as well 
as 3 additional CI associated proteins (NDUFA9, NDUFS3, and NDUFB6), which did not 
have a FC ≤ 0.80 but had been previously shown to have reduced protein abundance in 
BTHS LCLs (Fig. S4) [17]. Of these 8 genes, 4 had significantly reduced mRNA 
expression in TAZD45 cells (NDUFB2 p=0.04, NDUFAB1 p=0.001, NDUFB4 p=0.02, and 
NDUFB6 p=0.01) (Fig. S4). NDUFA5, NDUFA9, and NDUFS3 had reduced mRNA 
expression in TAZD45 cells but this reduction did not reach statistical significance (Fig. S4). 
There were no significant differences in the mRNA expression between control and BTHS 
LCLs, however there was significant variability in mRNA expression of all genes between 
the 5 individual BTHS LCL lines (Fig. S5). These individual differences could be due to 
the individual patient’s genetic background or the EBV transformation of the LCLs and 
may obfuscate the biological significance of mRNA expression in patient-derived LCLs. 
Immunoblotting of HEK293 and LCL whole cell lysate for NDUFAF1 confirmed 
reduced protein abundance in TAZD45 cells (FC=0.69, p=4.89 x 10-10) and BTHS LCLs 
(FC=0.75, p=7.69 x 10-7) (Fig. 2C-D). We also immunoblotted HEK293 and LCL 
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mitochondria for the 3 additional CI subunits that had been previously shown in a prior 
publication to have reduced protein abundance [17]. There was a subtle trend towards 
reduced NDUFA9, NDUFS3, and NDUFB6 abundance in TAZD45 cells (p=ns, p=0.04, 
p=0.05, respectively), and a strong reduction in BTHS LCLs (p=7.6 x 10-6, p=1.8 x 10-7, 
p=5.1 x 10-6, respectively) (Fig. S6). The abundance of NDUFA9, NDUFS3, and NDUFB6 
in TAZD45 cells aligns with our proteomics findings, that found no significant difference in 
the abundance of these proteins between WT and TAZD45 cells (Fig. 2A, Fig. S6). In order 
to determine whether TAZ deficiency affected the protein abundance of subunits from 
other respiratory complexes, we also immunoblotted for UQCRC2, a subunit of respiratory 
complex III. We found no significant difference in UQCRC2 abundance between WT and 
TAZD45 cells, and a subtle but significantly reduced abundance of UQCRC2 in BTHS LCLs 
compared to controls (Fig. S6).  
To determine the total abundance of CI holoenzyme, HEK293 and LCL cells were 
solubilized with Triton X-100 and resolved by BN-PAGE for the quantification of 
individual respiratory complexes. CI was the most significantly reduced complex, and the 
ratio of CI to CIV (CI:CIV) or CI:CII was significantly reduced in both TAZD45 vs. WT 
(p=2.32 x 10-5, p=1.62 x 10-4, respectively) and BTHS LCLs vs. controls (p=0.001, 
p=0.005, respectively) (Fig. 2E-F). Since NDUFB6 steady-state abundance was 
significantly reduced in BTHS LCLs (Fig. S6), it is difficult to interpret the LCL results, 
as the reduction could be due to reduced steady-state levels of NDUFB6 or an overall 
reduction of CI holoenzyme.  By comparing starting material and the cellular pellet 
following solubilization via immunoblotting, we found no significant difference in the 
solubilization of TAZD45 and WT cells (87% and 88% solubilization efficiency, 
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respectively). There was a minimal though statistically significant difference in the 
solubilization of BTHS and control LCLs (84% and 79% solubilization efficiency, 
respectively, p=0.03). Therefore, the observed differences were not due to an effect of 
altered CL on Triton X-100 solubilization. 
 Using a colorimetric CI enzyme activity assay that detects the oxidation of NADH 
to NAD+, we found a significant reduction in CI activity in both TAZD45 cells and BTHS 
LCLs (p=9.4 x 10-5 & p=1.8 x 10-4, respectively) (Fig. 2G). Using a colorimetric CII 
enzyme activity assay, we found no significant difference in CII activity between WT and 
TAZD45 cells or between control and BTHS LCLs, emphasizing the preeminent role of CI 
in BTHS-associated OXPHOS dysfunction (Fig. 2H). There was a wide range of CII 
function in LCLs derived from different individuals (Fig. S7). Overexpression of 
NDUFAF1, a CI assembly factor and the most significantly reduced CI associated protein 
in TAZD45 cells, did not normalize the CI functional deficiency in TAZD45 cells (Fig. S8A-
B). The expression vector used was previously shown to produce a functional protein that 
is localized to the mitochondrion, which we confirmed with immunoblotting of isolated 
mitochondria for NDUFAF1 (Fig. S8C) [31]. This indicates that CI dysfunction is due to 
a combination of the reduced expression and abundance of CI subunits and assembly 
factors. 
 Measurement of intracellular NADH and NAD+ showed a trend towards an 
increase in the ratio of NADH to NAD+ in both TAZD45 and BTHS LCLs compared to either 
WT or controls, though neither reached statistical significance (Fig. 2I). There was also an 
increase in intracellular AMP in both TAZD45 cells and BTHS LCLs compared to either WT 
or controls, with a significant increase in the BTHS LCLs (p=0.002) (Fig. 2J). This 
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moderate disturbance in energy homeostasis is consistent with the modest perturbations we 
observed in CI from mRNA expression, to protein expression, and ultimately activity in 
TAZ-deficient cells.  
Increased PARL abundance correlates with increased cleavage of downstream target 
PGAM5 
To confirm the proteomics finding of increased PARL abundance (FC=1.815, p=0.016) in 
TAZ-deficient HEK293 cells, we immunoblotted HEK293 and LCL whole cell lysate for 
PARL. Using a PARL-KO HEK293 cell line generously provided by the Langer 
Laboratory, we identified a single band at ~33kD present in both WT and TAZD45 cells and 
absent in the PARL-KO cells, consistent with the band representing the mature 
mitochondrial PARL (MAMP-PARL), referred to as PARL (Fig. S9) [24].  
In TAZD45 cells there was a significant increase in the abundance of PARL 
(FC=1.51, p=1.81 x 10-10) (Fig. 3A-B). There was a subtle but significant increase in the 
relative mRNA expression of PARL in TAZD45 cells (WT=0.97, TAZD45=1.09, p=0.02) (Fig. 
3C). Immunoblotting of LCL whole cell lysate for PARL showed a significant reduction 
in PARL abundance, however, there was extreme variability in PARL abundance in the 
CTRL lines (CTRL 1-3 vs CTRL 4-5) (Fig. S10A). There was no significant difference in 
the mRNA expression of PARL between CTRL and BTHS LCLs or across the 5 different 
BTHS LCL lines (Fig. S10B-C). Thus, increased PARL in TAZ-deficient HEK293 cells 
may be regulated both at the transcriptional and protein expression levels, and lack of 
consistent findings in BTHS LCLs may be due to cell-type specific differences in PARL 




Figure 3. Increased cleavage of PGAM5 by PARL in HEK293TAZD45 cells. (A) Whole 
cell lysate (45 ug) of the indicated lines were immunoblotted for the indicated proteins. (B) 
Band intensities, relative to loading control GRP75, were quantified and plotted relative to 
WT abundance; WT n=54, TAZD45 n=48 (C) Relative mRNA expression of PARL 
determined by qRT-PCR and DDCT quantification; WT n=18, TAZD45 n=17. (D) Whole cell 
lysate (45 ug) of WT and TAZD45 cells were immunoblotted for PGAM5 and loading control 
GRP75. Band intensities, relative to the loading control GRP75, for both full-length and 
cleaved PGAM5 were individually quantified and plotted as the percent of cleaved 
PGAM5 (cleaved/full+cleaved); WT n=41, TAZD45 n=41. (E) HEK293 WT and TAZD45 
cells were treated with 20uM CCCP for serial time points from 0 to 120 minutes. Whole 
cell lysate (45 ug) of the indicated lines and treatment times were immunoblotted for the 
indicated proteins. (F) Band intensities, relative to the loading control GRP75, were 
quantified and plotted relative to WT abundance; WT 0 mins n=54, WT 10 mins n=5, WT 
30 mins n=6, WT 60 mins n=6, WT 90 mins n=5, WT 120 mins n=6, TAZD45 0 mins n=48, 
TAZD45 10 mins n=5, TAZD45 30 mins n=5, TAZD45 60 mins n=5, TAZD45 90 mins n=5, 
TAZD45 120 mins n=6. (G) HEK293 WT and TAZD45 cells were treated with 20uM CCCP 
for serial time points from 0 to 120 minutes. Whole cell lysate (45 ug) of the indicated lines 
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relative to the loading control GRP75, for both full-length and cleaved PGAM5 were 
individually quantified and plotted as the percent of cleaved PGAM5 
(cleaved/full+cleaved); WT 0 mins n=41, WT 10 mins n=8, WT 30 mins n=8, WT 60 mins 
n=8, WT 90 mins n=5, WT 120 mins n=7, TAZD45 0 mins n=41, TAZD45 10 mins n=8, 
TAZD45 30 mins n=7, TAZD45 60 mins n=5, TAZD45 90 mins n=7, TAZD45 120 mins n=7. (I) 
Relative mRNA expression of PGAM5 determined by qRT-PCR and DDCT quantification; 
WT 0 mins n=14, TAZD45 0 mins n=16, WT 120 mins n=16, TAZD45 120 mins n=16. (J) 
Whole cell lysate (45 ug) of the indicated lines were immunoblotted for the indicated 
proteins. Band intensities, relative to the loading control GRP75, for both full-length and 
cleaved PGAM5 were individually quantified, and the percent of cleaved PGAM5 
(cleaved/full+cleaved) is indicated for each lane (n=1). Significant differences are 
indicated; * ≤ 0.05, ** ≤ 0.005, *** ≤ 0.0005, **** ≤ 0.00005. 
 
To investigate the biological significance of increased PARL abundance in TAZD45 
cells, we assessed a downstream proteolytic target of PARL, PGAM5. Previous evidence 
suggests that PGAM5 is cleaved by PARL and another stress-activated IMM protease, 
OMA1, in response to loss of mitochondrial membrane potential (DYm) [32]. Cleaved 
PGAM5 is released into the cytoplasm to integrate multiple MQC pathways through 
reciprocal dephosphorylation of BCL-xL (to mediate apoptosis, in response to severe 
mitochondrial stress) and FUNDC1 (to mediate mitophagy, in response to moderate 
mitochondrial stress) [33-34]. Deficiency of PGAM5-mediated mitophagy results in the 
accumulation of damaged, abnormal mitochondria and increased reactive oxygen species 
(ROS) [33,35,36]. At baseline, we observed a significant increase in the percent of cleaved 
PGAM5 in TAZD45 cells (p=1.5 x 10-7) (Fig. 3D). There was no significant difference in the 
percent of cleaved PGAM5 between CTRL and BTHS LCLs (Fig. S10D) 
Upon treatment with membrane depolarizer carbonyl cyanide m-chlorophenyl 
hydrazine (CCCP), with serial time point measurements, we observed that TAZD45 cells 
maintained a significantly greater abundance of PARL until the final timepoint of 120 mins 
(Fig. 3E-F, Table S4). This increase in PARL abundance with CCCP correlates with the 
increase in PGAM5 cleavage observed in both WT and TAZD45 cells (Fig. 3G-H, Table S5). 
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We observed an increase in the percentage of cleaved PGAM5 in WT cells and TAZD45 
cells, where TAZD45 cells maintained a significantly greater percentage of cleaved PGAM5 
at all time points tested (Fig. 3G-H, Table S5). The difference in the percentage of cleaved 
PGAM5 between WT and TAZD45 cells increased over time, from a 11% difference at 0 
mins to a 18% difference at 120 mins (Fig. 3G-H, Table S5). Immunoblotting showed that 
the increased percent of cleaved PGAM5 in TAZD45 cells was largely due to reduction in 
full-length PGAM5 (Fig. 3G). We examined PGAM5 mRNA expression relative to WT 
and found no significant difference between WT and TAZD45 cells at 0 mins or 120 mins 
(Fig. 3I). There is a subtle but significant reduction in expression between WT at 0 mins 
and WT at 120 min (Fig. 3I). This suggests that the observed increase in the percent of 
cleaved PGAM5 in TAZD45 cells at baseline and with CCCP treatment may be due to the 
increased cleavage and degradation of PGAM5 rather than reduced biosynthesis of 
PGAM5. 
We further demonstrated that PGAM5 cleavage was absent and reduced in PARL-
KO cells at baseline or treated with CCCP, respectively, underscoring that PGAM5 is 
predominantly cleaved by PARL (Fig. 3J). In summary, we observed baseline 
abnormalities in PARL abundance and PGAM5 cleavage which is exacerbated upon 
mitochondrial depolarization in TAZ-deficient HEK293 cells. 
Targeting CL with bromoenol lactone and SS-31 normalizes downstream cellular 
dysfunction 
To determine if targeting CL and CL metabolism would affect the dysregulation observed 
in respiratory CI and/or MQC, TAZD45 and WT cells were treated with either bromoenol 
lactone (BEL) or SS-31. Previous studies have shown that treatment with BEL, an inhibitor 
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of calcium-independent PLA2 (iPLA2), partially remediates CL abnormalities by reducing 
MLCL accumulation and CL depletion [37-38]. SS-31, a cell permeable mitochondria-
targeted tetrapeptide, selectively binds CL where it has been shown to stabilize cristae 
morphology and preserve mitochondrial bioenergetics [39-40].  
The relative abundance of NDUFAF1 in TAZD45 cells increased following BEL 
treatment and significantly increased following SS-31 treatment (p= 2.8 x 10-5) (Fig. 4A, 
Table S6). NDUFAF1 relative mRNA expression significantly increased in TAZD45 cells 
following both BEL and SS-31 treatment (p= 0.05 and p= 0.01, respectively) (Fig. 4B, 
Table S7). The relative mRNA expression was also measured for the other 4 CI associated 
genes that had significantly reduced levels in TAZD45 cells at baseline (NDUFB2, 
NDUFAB1, NDUFB4, and NDUFB6). Following BEL treatment, these significant 
differences in expression between TAZD45 vs. WT were no longer observed in any of the 4 
genes tested, and following SS-31 treatment, the significant differences were no longer 
observed in 3 of the 4 genes tested (Fig. S11, Table S7).  
Next, CI holoenzyme abundance was measured in BEL and SS-31 treated cells by 
BN-PAGE. CI remained the most significantly reduced complex in TAZD45 cells after BEL 
or SS-31 treatment (Fig. 4D). However, both treatments had a subtle effect on the ratio of 
both CI to CIV (CI:CIV) and CI to CII (CI:CII) (Fig. 4D-E, Table S8). The CI:CIV relative 
abundance increased from 0.59 in untreated TAZD45 cells to 0.77 in TAZD45-BEL cells and 
0.80 in TAZD45-SS-31 cells (Fig. 4E, Table S8). The CI:CII relative abundance significantly 
increased from 0.66 in untreated TAZD45 cells to 0.89 in TAZD45-BEL cells (p= 6.1 x 10-3) 
and to 0.83 in TAZD45-SS-31 cells (Fig. 4E, Table S8). Overall, treatment with either BEL 
or SS-31 showed a subtle increase in CI holoenzyme abundance. 
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Figure 4. Targeting CL or CL metabolism with bromoenol lactone and SS-31 modifies 
mitochondrial dysfunction. (A) HEK293 WT and TAZD45 cells were treated for 48 hours 
with 2.5uM bromoenol lactone (BEL) and 7 days with 100nM SS-31. Whole cell lysate 
(40-45 ug) of the indicated lines were immunoblotted for the indicated proteins. (B) Band 
intensities, relative to the loading control GRP75, were quantified and plotted relative to 
WT abundance; WT n=27, TAZD45 n=26, WT-BEL n=9, TAZD45-BEL n=9, WT-SS-31 n=9, 
TAZD45-SS-31 n=9. (C) Relative mRNA expression of NDUFAF1 determined by qRT-PCR 
and DDCT quantification using each respective control; WT n=6, TAZD45 n=6, WT-BEL 
n=3, TAZD45-BEL n=3, WT-SS-31 n=3, TAZD45-SS-31 n=3 per gene. (D) BN-PAGE of 
HEK293 WT and TAZD45 cells treated for 48 hrs with 2.5uM BEL (120 ug total protein) 
and 7 days with 100nM SS-31 solubilized in 1% Triton X-100 immunoblotted for the 
indicated proteins. All samples were resolved on a single gel and exposed for the same 
duration. The WT lane indicated with the asterisk was not used for quantification due to 
air bubbles. (E) Band intensities were quantified, and CI abundance was represented as the 
ratio of CI band intensity to CIV or CII. Abundance was plotted relative to respective 
control; CI:CIV(WT n=13, TAZD45 n=16, WT-BEL n=9, TAZD45-BEL n=11, WT-SS-31 
n=4, TAZD45-SS-31 n=6), CI:CII (WT n=10, TAZD45 n=13, WT-BEL n=9, TAZD45-BEL 
n=10, WT-SS-31 n=4, TAZD45-SS-31 n=6). (F) Whole cell lysate (40-45 ug) of the 
indicated lines and treatment conditions were immunoblotted for the indicated proteins. 
(G) Band intensities, relative to the loading control GRP75, for both full-length and cleaved 
PGAM5 were individually quantified and plotted as the percent of cleaved PGAM5 
(cleaved/full+cleaved); WT n=41, TAZD45 n=41, WT-BEL n=16, TAZD45-BEL n=16, WT-
SS-31 n=9, TAZD45-SS-31 n=8. (H) Whole cell lysate (40-45 ug) of the indicated lines and 
treatment conditions were immunoblotted for the indicated proteins. (I) Band intensities, 
relative to the loading control GRP75, were quantified and plotted relative to WT 
abundance; WT n=54, TAZD45 n=48, WT-BEL n=11, TAZD45-BEL n=11, WT-SS-31 n=10, 
TAZD45-SS-31 n=12. Significant differences are indicated; * ≤ 0.05, ** ≤ 0.005, *** ≤ 
0.0005, **** ≤ 0.00005. 


















































































































































































































































































Immunoblotting of BEL and SS-31 treated HEK293 whole cell lysate for PGAM5 
showed a significant decrease in the percentage of cleaved PGAM5 in TAZD45-BEL (18%, 
p= 0.01) and TAZD45-SS-31 (13%, p= 2.6 x 10-4) cells compared to TAZD45-untreated cells 
(23%) (Fig. 4F-G, Table S9). There was no significant difference in the percentage of 
cleaved PGAM5 in TAZD45-BEL versus WT-BEL cells or TAZD45-SS-31 versus WT-SS-31 
cells (Fig. 4G, Table S9). Further, immunoblotting of BEL and SS-31 treated HEK293 
whole cell lysate for PARL showed a significant decrease in the relative abundance of 
PARL in TAZD45-BEL (FC= 0.93, p= 7.1 x 10-15) and TAZD45-SS-31 (FC= 1.11, p= 9.9 x 
10-5) cells compared to TAZD45-untreated cells (FC= 1.53) (Fig. 4H-I, Table S10), which 
was essentially restored to WT levels. Collectively, these results indicate that drugs that 
target CL partially rescue the defects in CI and MQC observed in TAZ-deficient cells. 
 
3.5 Discussion 
As a central phospholipid of the IMM, CL has been shown to have diverse roles in 
mitochondrial function [1]. Yet, these diverse roles are currently underappreciated in the 
pathophysiology of Barth syndrome, which is the only known Mendelian disorder of CL 
metabolism. In this study, we took an untargeted approach to identify dysregulated proteins 
in TAZ-deficient HEK293 cells and pursued two areas of dysregulation for further study: 
complex I (CI) of the respiratory chain and components of mitochondrial quality control 
(MQC).  
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Previous work has linked TAZ deficiency and mitochondrial respiratory chain 
dysfunction, with several studies pointing towards CI as the most impacted respiratory 
chain complex [15,17,41]. In this work we confirmed that CI abundance and function are 
abnormal in TAZ deficiency. We further showed that this dysfunction is potentially driven 
by the reduced abundance of 5 subunits of mitochondrial CI, MT-ND3, NDUFA5, 
NDUFAB1, NDUFB2, NDUFB4, and CI assembly factor, NDUFAF1. There are several 
possibilities for the mechanism by which these specific deficiencies could disrupt CI 
function, including disruption of the coordinated modular assembly of CI and further 
studies into CI modular assembly in BTHS could prove to be revealing [20,42]. 
Alternatively, abnormal CL itself may have a direct effect on disrupting CI assembly or 
function. Further studies may clarify the mechanism of reduced CI mRNA expression and 
ultimately function.  
We further identified abnormal expression and regulation of MQC associated 
proteins including PARL and PGAM5. MQC, involving the processes of mitochondrial 
proteostasis, biogenesis, dynamics, and mitophagy, is emerging as a central theme for the 
pathogenesis of various diseases [43-45]. PARL participates in MQC via reciprocal 
proteolysis of PGAM5 and PINK1 [22,32]. Upon mitochondrial depolarization, PARL 
upregulation accelerates PGAM5 proteolysis which drives mitochondrial fragmentation 
[32]. Defective mitochondrial quality control, particularly as it affects cellular energy 
production and stress responsiveness, is increasingly recognized for its role in diverse 
forms of cardiac dysfunction and may be central to the cardiac pathogenesis of BTHS [46]. 
In order to determine if the abnormalities we identified are directly associated with 
abnormal CL, we tested the ability of a BEL, pharmacological inhibitor of PLA2γ, and SS-
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31, a CL binding peptide, to ameliorate the two TAZ-deficient phenotypes we established. 
Indeed, we showed that targeting CL and CL metabolism with BEL and SS-31 is sufficient 
to modulate CI subunit gene expression and protein abundance, PARL abundance, and 
PGAM5 cleavage. Thus, targeting multiple aspects of CL metabolism may be a feasible 
therapeutic approach in BTHS. 
It is notable that among the CI subunits that we identified as having altered 
expression in TAZ deficiency, NDUFAB1 has an essential role in fatty acid biosynthesis 
due to its dual role as the mitochondrial acyl carrier protein (mt-ACP) [47]. In fact, the GO 
term “protein lipoylation” was identified in the functional annotation of proteins with a FC 
≤ 0.80 (Table S2A). In this role, abnormal expression of NDUFAB1/mt-ACP in TAZ 
deficiency may have further implications beyond affecting CI assembly and function, 
including affecting CL acyl chain content. Additionally, mt-ACP is involved in the 
assembly of the mitochondrial ribosome, and therefore mt-ACP expression and abundance 
may further influence changes in mitochondrial gene expression [48]. Further examining 
the essential role of NDUFAB1, outside of CI assembly and function, may provide a 
mechanistic link between altered CL metabolism and altered bioenergetic metabolism. 
Defects in MQC pathways, have been implicated in the pathogenesis of various cardiac 
pathologies relevant to BTHS. Additionally, enlarged mitochondria have been observed in 
BTHS patient and mouse model derived cardiac tissue, consistent with impaired mitophagy 
[49-52]. Thus, further examining these pathways in an appropriate cellular context could 
provide insight into potential therapeutic targets for BTHS and other conditions resulting 
from MQC dysfunction. 
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Finally, it is important to note that some of our results were cell-type specific. We 
identified a reduction in CI subunit protein abundance, holoenzyme abundance, and CI 
activity in both HEK293 TAZ-deficient cells and BTHS LCLs; however, in BTHS LCLs 
reduced mRNA expression of CI subunits was not observed. The differences in mRNA 
expression observed between the HEK293s and the LCLs could be due to epigenetic and 
transcriptomic differences observed in EBV transformed LCL lines, the genetic differences 
between the BTHS individuals, and/or cell type specific regulation of CI associated 
genes/proteins [53].  We also found that HEK293s and LCLs differed in PARL abundance, 
which is consistent with previous studies confirming cell-type specific expression and 
regulation of PARL, and introduces further questions about whether cell-type specific 
mechanisms of MQC contribute to the tissue distribution of disease in BTHS [54]. This 
hypothesis emphasizes the need for a clearer understanding of the cell-specific effects of 
abnormal CL content.  To explore these questions, we are presently exploring respiratory 
chain and MQC dysfunction in diverse TAZ-deficient cell types in order to understand how 
these pathways are associated with the tissue specific expression of BTHS. 
 
3.6 Conclusions 
We identified and characterized two cellular pathways impacted by TAZ deficiency by 
employing a discovery-based approach in a new HEK293 TAZ-deficient cellular model: 
complex I (CI) of the mitochondrial respiratory chain and mitochondrial quality control 
(MQC). We, not only confirmed reduced CI protein and holoenzyme abundance, but 
expanded our current understanding of respiratory chain abnormalities by showing reduced 
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CI mRNA expression with evidence for distinct regulation in differing cell types. 
Additionally, we uncovered aberrant abundance of the MQC protein PARL, which was 
accompanied by altered cleavage of the downstream MQC mediator and PARL target, 
PGAM5. Finally, we found that modulating CL normalizes CI gene expression, protein, 
and holoenzyme abundance, as well as ameliorating PARL abundance and the aberrant 
ratio of cleaved to full length PGAM5. Thus, abnormal CL in TAZ deficiency has a direct 
role in dysregulating both CI of the mitochondrial respiratory chain and MQC. 
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3.10 Supplementary Information 
 
Figure S1. CRISPR/Cas9 genome editing with two single guide RNAs (sgRNAs) 
targeting exon 2 of TAZ results in a 45 bp deletion. The 45 bp deletion, noted by dashes, 
encompasses a predicted acyltransferase domain and covers an area of TAZ where multiple 
pathological variants have been described, such as p.R57L (c.170G>T) and p.H69Q 







Figure S2. Comparable abundance of cytosolic and mitochondrial proteins in the 
absence of TAZ. Whole cell lysate (40 ug) of the indicated lines (A) HEK293 and (B) 
LCL lines were immunoblotted for the indicated proteins. Band intensities were quantified 
and plotted relative to ß-actin (blue), VDAC1 (red), and TOM20 (yellow); WT n=9, TAZD45 
n=9, CTRL n=9 (C1 n=3, C5 n=3, C8 n=3), BTHS n=18 (B1 n=3, B2 n=3, B3 n=3, B4 
n=3, B6 n=3, B5 n=3). Significant differences are indicated; * ≤ 0.05, ** ≤ 0.005, *** ≤ 
0.0005, **** ≤ 0.00005. 
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Table S1. CRISPR/Cas9 sgRNA guide sequences and predicted off-target sites. 




GCCCGTCAAGAAGCGAGGCCCAG 2.4 3 chr9:-136416984 Y 
GCTCATTGTTAAGCGAGGCCTAG 0.9 3 chr5:-164071618 Y 
CTTCAGCCAGAAGCGAGGCCAAG 0.8 4 chr13:+111688858 Y 
CCCCATCGAGAAGCGCGGCCAAG 0.6 3 chr4:-132956077 N 




GAGATGTAGCTCGTCCATGCTGG 1.5 3 chr3:+173436340 Y 
GTTCAGAGGGTCGTCCATGCAAG 1.3 3 chr7:-70923313 Y 
GATATGAGGGGAGTCCATGCAGG 0.7 3 chrX:-12667869 N 
GACAAGAGGTTGGTCCATGCCAG 0.6 4 chr7:+65692780 N 
CTGGTGAGGGTCTTCCATGCCAG 0.6 4 chr8:-125971306 N 
1 Off-target score calculated at cripsr.mit.edu based on scoring algorithm from Hsu et al. 2013 (2) 
2 The number of mismatches between the guide sequence and the “off-target” sequence 






Table S2A. Significant KEGG & GO terms determined by functional annotation 
analysis of the proteins with a FC ≤ 0.80 (n=215). 






Parkinson's disease 13 6.1 6.80E-08 7.8 
Oxidative phosphorylation* 11 5.1 2.70E-06 7 
Huntington's disease 11 5.1 6.80E-05 4.9 
Alzheimer's disease 10 4.7 1.30E-04 5.1 
Non-alcoholic fatty liver disease (NAFLD) 9 4.2 3.40E-04 5.1 
Cardiac muscle contraction 6 2.8 1.70E-03 6.8 
Bile secretion 5 2.3 8.30E-03 6.2 
Dilated cardiomyopathy 5 2.3 1.60E-02 5.1 
Metabolic pathways* 23 10.7 1.90E-02 1.6 
Ribosome 6 2.8 2.10E-02 3.7 
GO TERMS: BIOLOGICAL PROCESSES 
platelet degranulation 10 4.7 2.60E-06 8.5 
mitochondrial respiratory chain complex I assembly*# 7 3.3 7.90E-05 9.7 
mitochondrial electron transport, NADH to ubiquinone*# 6 2.8 2.30E-04 10.7 
actin filament organization 6 2.8 1.40E-03 7.3 
response to oxidative stress 7 3.3 1.60E-03 5.6 
protein lipoylation 3 1.4 2.60E-03 37.5 
negative regulation of endothelial cell proliferation 4 1.9 4.30E-03 12.1 
negative regulation of ATPase activity* 3 1.4 5.50E-03 26.2 
aerobic respiration* 4 1.9 6.10E-03 10.6 
protein targeting to mitochondrion* 4 1.9 6.70E-03 10.3 
muscle contraction 6 2.8 7.50E-03 4.9 
muscle filament sliding 4 1.9 9.10E-03 9.2 
retina homeostasis 4 1.9 1.10E-02 8.7 
rRNA processing 8 3.7 1.10E-02 3.3 
wound healing 5 2.3 1.30E-02 5.5 
Ossification 5 2.3 1.30E-02 5.5 
cellular response to interferon-beta 3 1.4 1.40E-02 16.4 
ribosomal small subunit biogenesis 3 1.4 1.40E-02 16.4 
mitochondrial electron transport, cytochrome c to oxygen* 3 1.4 2.10E-02 13.1 
SRP-dependent cotranslational protein targeting to membrane 5 2.3 2.20E-02 4.7 
Translation 8 3.7 2.60E-02 2.8 
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cellular response to vascular endothelial growth factor stimulus 3 1.4 2.80E-02 11.4 
response to calcium ion 4 1.9 2.80E-02 6 
response to electrical stimulus 3 1.4 3.00E-02 10.9 
positive regulation of osteoblast differentiation 4 1.9 3.10E-02 5.8 
cytoplasmic translation 3 1.4 3.30E-02 10.5 
ribosomal large subunit biogenesis 3 1.4 3.30E-02 10.5 
viral transcription 5 2.3 3.90E-02 3.9 
positive regulation of phagocytosis 3 1.4 4.30E-02 9 
sarcomere organization 3 1.4 4.30E-02 9 
one-carbon metabolic process* 3 1.4 4.50E-02 8.7 
nuclear-transcribed mRNA catabolic process, nonsense-mediated 
decay 5 2.3 4.70E-02 3.7 
vascular endothelial growth factor receptor signaling pathway 4 1.9 4.90E-02 4.9 
GO TERMS: CELLULAR COMPARTMENTS 
mitochondrion* 42 19.6 2.30E-09 2.8 
mitochondrial inner membrane* 20 9.3 5.80E-07 4 
extracellular exosome 55 25.7 3.10E-05 1.7 
prefoldin complex 4 1.9 4.70E-05 50.8 
mitochondrial respiratory chain complex I*# 6 2.8 2.10E-04 10.9 
platelet alpha granule lumen 6 2.8 3.70E-04 9.7 
Cytosol 57 26.6 6.90E-04 1.5 
Cytoskeleton 13 6.1 1.00E-03 3.1 
cell surface 16 7.5 1.20E-03 2.6 
focal adhesion 13 6.1 1.60E-03 3 
mitochondrial proton-transporting ATP synthase complex* 4 1.9 1.60E-03 16.9 
mitochondrial membrane* 6 2.8 4.10E-03 5.7 
actin filament 5 2.3 6.10E-03 6.8 
cytosolic large ribosomal subunit 5 2.3 7.10E-03 6.5 
basement membrane 5 2.3 1.20E-02 5.6 
Costamere 3 1.4 1.90E-02 14 
integral component of mitochondrial inner membrane* 3 1.4 2.10E-02 13.3 
respiratory chain* 3 1.4 2.10E-02 13.3 
stress fiber 4 1.9 2.30E-02 6.6 
Microvillus 4 1.9 2.60E-02 6.2 
M band 3 1.4 2.70E-02 11.6 
blood microparticle 6 2.8 2.80E-02 3.5 
myelin sheath 6 2.8 2.80E-02 3.5 
Cytoplasm 72 33.6 3.20E-02 1.2 
Microspike 2 0.9 3.30E-02 59.3 
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granular component 2 0.9 4.40E-02 44.4 
muscle thin filament tropomyosin 2 0.9 4.40E-02 44.4 
apical plasma membrane 8 3.7 4.60E-02 2.4 
filamentous actin 3 1.4 4.70E-02 8.6 
extracellular matrix 8 3.7 4.90E-02 2.4 
GO TERMS: MOLECULAR FUNCTIONS 
structural constituent of muscle 6 2.8 1.10E-04 12.6 
protein binding 125 58.4 2.00E-04 1.3 
actin filament binding 8 3.7 7.60E-04 5.3 
unfolded protein binding 7 3.3 1.60E-03 5.6 
NADH dehydrogenase (ubiquinone) activity *# 5 2.3 2.10E-03 9.2 
poly(A) RNA binding 25 11.7 2.10E-03 1.9 
structural constituent of ribosome 9 4.2 3.80E-03 3.6 
endopeptidase inhibitor activity 4 1.9 1.00E-02 8.8 
identical protein binding 17 7.9 1.10E-02 2 
structural molecule activity conferring elasticity 2 0.9 2.30E-02 87.9 
structural constituent of cytoskeleton 5 2.3 3.60E-02 4 
ubiquitin conjugating enzyme activity 3 1.4 4.20E-02 9.1 
cytochrome-c oxidase activity * 3 1.4 4.50E-02 8.8 
* References mitochondrion and/or metabolic pathways (n=18) 
# References complex I of the oxidative phosphorylation pathways (n=4) 
1 The number of input proteins involved in the term 
2 The number of input proteins involved in the term divided by the total proteins/genes represented by the term 





Table S2B. Significant KEGG & GO terms determined by functional annotation 
analysis of the proteins with a FC ≥ 1.20 (n=621). 
 
# OF GENES1 %2 P-VALUE3 FOLD ENRICHMENT 
KEGG PATHWAYS 
Chronic myeloid leukemia 9 1.4 2.50E-03 3.8 
Metabolic pathways* 58 9.3 3.10E-03 1.4 
Pancreatic cancer 8 1.3 5.40E-03 3.7 
AMPK signaling pathway 11 1.8 7.50E-03 2.7 
Alzheimer’s disease 13 2.1 9.70E-03 2.3 
Butanoate metabolism* 5 0.8 1.10E-02 5.6 
Carbohydrate digestion and absorption 6 1 1.20E-02 4.3 
Endocytosis 16 2.6 1.40E-02 2 
Insulin signaling pathway 11 1.8 1.60E-02 2.4 
Colorectal cancer 7 1.1 1.60E-02 3.4 
Fatty acid metabolism* 6 1 2.10E-02 3.8 
Notch signaling pathway 6 1 2.10E-02 3.8 
Amino sugar and nucleotide sugar metabolism* 6 1 2.10E-02 3.8 
p53 signaling pathway 7 1.1 2.30E-02 3.1 
Biosynthesis of antibiotics 14 2.3 2.30E-02 2 
Phagosome 11 1.8 2.70E-02 2.2 
Adipocytokine signaling pathway 7 1.1 2.80E-02 3 
Inositol phosphate metabolism* 7 1.1 3.00E-02 3 
Proteoglycans in cancer 13 2.1 3.30E-02 2 
Biosynthesis of unsaturated fatty acids 4 0.6 3.90E-02 5.2 
Viral myocarditis 6 1 4.00E-02 3.2 
Synthesis and degradation of ketone bodies 3 0.5 4.10E-02 9 
Phosphatidylinositol signaling system 8 1.3 4.30E-02 2.5 
Glucagon signaling pathway 8 1.3 4.60E-02 2.4 
Cell adhesion molecules (CAMs) 10 1.6 4.60E-02 2.1 
Fatty acid elongation 4 0.6 4.80E-02 4.8 
Epstein-Barr virus infection 9 1.4 4.90E-02 2.2 
GO TERMS: BIOLOGICAL PROCESSES 
covalent chromatin modification 14 2.3 7.30E-05 3.8 
viral genome replication 5 0.8 8.40E-04 11 
protein targeting to plasma membrane 6 1 1.30E-03 7.1 
antigen processing and presentation of endogenous peptide 
antigen via MHC class I via ER pathway, TAP-independent 3 0.5 3.10E-03 30.9 
positive regulation of apoptotic process* 20 3.2 4.20E-03 2.1 
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carbohydrate phosphorylation 5 0.8 5.90E-03 6.7 
cell cycle arrest 12 1.9 6.10E-03 2.6 
response to oxidative stress* 10 1.6 9.30E-03 2.8 
cell migration 13 2.1 1.00E-02 2.3 
phosphatidylinositol biosynthetic process 7 1.1 1.10E-02 3.7 
long-chain fatty-acyl-CoA biosynthetic process 6 1 1.10E-02 4.4 
macroautophagy* 8 1.3 1.10E-02 3.2 
unsaturated fatty acid biosynthetic process 4 0.6 1.10E-02 8.2 
muscle cell differentiation 4 0.6 1.10E-02 8.2 
IRE1-mediated unfolded protein response 7 1.1 1.20E-02 3.7 
positive regulation of DNA binding 5 0.8 1.20E-02 5.5 
tRNA pseudouridine synthesis 3 0.5 1.40E-02 15.4 
magnesium ion homeostasis 3 0.5 1.40E-02 15.4 
antigen processing and presentation of peptide antigen via MHC 
class I 5 0.8 1.50E-02 5.1 
neuron projection development 9 1.4 1.60E-02 2.8 
positive regulation of substrate adhesion-dependent cell spreading 5 0.8 1.90E-02 4.8 
membrane protein intracellular domain proteolysis 4 0.6 1.90E-02 6.9 
cilium assembly 10 1.6 1.90E-02 2.5 
regulation of apoptotic process* 14 2.3 2.10E-02 2 
inner ear receptor stereocilium organization 4 0.6 2.20E-02 6.5 
regulation of autophagy* 6 1 2.20E-02 3.7 
amyloid precursor protein catabolic process 3 0.5 2.60E-02 11.6 
response to cholesterol 3 0.5 2.60E-02 11.6 
interferon-gamma-mediated signaling pathway 7 1.1 2.70E-02 3 
protein maturation by protein folding 3 0.5 3.20E-02 10.3 
pyrimidine nucleotide metabolic process* 3 0.5 3.20E-02 10.3 
DNA topological change 3 0.5 3.20E-02 10.3 
antigen processing and presentation of exogenous peptide antigen 
via MHC class I, TAP-independent 3 0.5 3.20E-02 10.3 
cilium morphogenesis 10 1.6 3.30E-02 2.3 
cell growth 6 1 3.40E-02 3.3 
viral process 17 2.7 3.40E-02 1.8 
purine nucleotide metabolic process* 3 0.5 4.00E-02 9.3 
regulation of synaptic vesicle exocytosis 3 0.5 4.00E-02 9.3 
cell volume homeostasis 3 0.5 4.00E-02 9.3 
nucleocytoplasmic transport 4 0.6 4.60E-02 4.9 
positive regulation of stress fiber assembly* 5 0.8 4.60E-02 3.7 
UDP-N-acetylglucosamine biosynthetic process 3 0.5 4.70E-02 8.4 
positive regulation of histone deacetylation 3 0.5 4.70E-02 8.4 
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chromatin organization 5 0.8 4.90E-02 3.6 
histone H3 acetylation 5 0.8 4.90E-02 3.6 
glycosaminoglycan catabolic process 4 0.6 5.00E-02 4.7 
GO TERMS: CELLULAR COMPARTMENTS 
extracellular exosome 135 21.7 1.70E-06 1.5 
membrane 110 17.7 3.70E-06 1.5 
endoplasmic reticulum 51 8.2 1.90E-05 1.9 
mitochondrion* 68 11 2.20E-04 1.6 
cytosol 142 22.9 2.80E-04 1.3 
cytoplasm 206 33.2 7.60E-04 1.2 
nucleoplasm 120 19.3 8.10E-04 1.3 
integral component of endoplasmic reticulum membrane 11 1.8 2.00E-03 3.3 
integral component of luminal side of endoplasmic reticulum 
membrane 6 1 2.20E-03 6.4 
phagocytic vesicle membrane 8 1.3 2.90E-03 4.2 
endoplasmic reticulum membrane 44 7.1 3.60E-03 1.6 
intermediate filament 11 1.8 3.80E-03 3 
ruffle membrane 9 1.4 5.10E-03 3.4 
mitochondrial inner membrane* 26 4.2 5.20E-03 1.8 
ER to Golgi transport vesicle membrane 7 1.1 6.60E-03 4.1 
mitochondrial intermembrane space* 8 1.3 1.00E-02 3.3 
myelin sheath 12 1.9 1.10E-02 2.4 
nucleus 202 32.5 1.30E-02 1.1 
melanosome 9 1.4 1.70E-02 2.7 
early endosome 15 2.4 1.80E-02 2 
Golgi membrane 30 4.8 1.80E-02 1.6 
centrosome 23 3.7 2.20E-02 1.7 
costamere 4 0.6 2.20E-02 6.5 
endoplasmic reticulum-Golgi intermediate compartment 7 1.1 2.30E-02 3.2 
endoplasmic reticulum lumen 13 2.1 2.30E-02 2.1 
cilium 11 1.8 2.60E-02 2.2 
autolysosome 3 0.5 2.60E-02 11.5 
ER-mitochondrion membrane contact site* 3 0.5 2.60E-02 11.5 
integral component of mitochondrial outer membrane* 4 0.6 2.90E-02 5.9 
stress fiber* 6 1 3.00E-02 3.4 
F-actin capping protein complex 3 0.5 3.30E-02 10.2 
nuclear heterochromatin 4 0.6 3.30E-02 5.6 
lysosomal membrane 16 2.6 3.50E-02 1.8 
early endosome membrane 9 1.4 3.50E-02 2.4 
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Golgi apparatus 39 6.3 3.60E-02 1.4 
oligosaccharyltransferase complex 3 0.5 4.00E-02 9.2 
dendrite 18 2.9 4.70E-02 1.7 
MHC class I protein complex 3 0.5 4.80E-02 8.4 
GO TERMS: MOLECULAR FUNCTIONS 
protein binding 335 53.9 2.90E-05 1.2 
poly(A) RNA binding 55 8.9 3.10E-03 1.5 
AP-3 adaptor complex binding 3 0.5 3.10E-03 30.5 
TAP binding 3 0.5 3.10E-03 30.5 
nucleosomal DNA binding 7 1.1 3.70E-03 4.6 
cysteine-type endopeptidase activity involved in apoptotic 
process* 4 0.6 7.80E-03 9.4 
chromatin binding 23 3.7 9.80E-03 1.8 
1-phosphatidylinositol-3-phosphate 4-kinase activity 3 0.5 1.00E-02 18.3 
GTPase activity 16 2.6 1.00E-02 2.1 
peptide antigen binding 5 0.8 1.20E-02 5.5 
GTP binding 22 3.5 1.50E-02 1.7 
histone binding 10 1.6 1.90E-02 2.5 
scaffold protein binding 6 1 2.00E-02 3.8 
1-phosphatidylinositol-4-phosphate 5-kinase activity 3 0.5 2.00E-02 13.1 
chromatin DNA binding 6 1 4.10E-02 3.2 
cysteine-type endopeptidase activity 6 1 4.90E-02 3 
* References mitochondrion and/or mitochondrial dynamics (n=20) 
1 The number of input proteins involved in the term 
2 The number of input proteins involved in the term divided by the total proteins/genes represented by the term 






Figure S3. The oxidative phosphorylation (OXPHOS) KEGG pathway is the most 
significant KEGG pathway enriched for proteins with a FC ≤ 0.80 that references 
mitochondria and or OXPHOS. Of the 133 genes in the OXPHOS KEGG pathway 11 
encode proteins with a FC ≤ 0.80 in TAZD45 cells; half (n=5) are subunits of complex I (CI) 

















































Name Module Protein #PSMs* 
Unique 
Peptides FC P-Value 
        
Complex I Subunits 
        
Q9UI09 NDUFA12 N NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 12 
46 8 0.973 0.93 
P28331 NDUFS1 N NADH-ubiquinone oxidoreductase 75 kDa subunit, 
mitochondrial 
173 39 0.864 0.28 
O75380 NDUFS6 N NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, 
mitochondrial 
23 9 0.955 0.49 
P49821 NDUFV1 N NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial 
105 21 0.872 0.21 
P19404 NDUFV2 N NADH dehydrogenase [ubiquinone] flavoprotein 2, 
mitochondrial 
73 15 0.872 0.18 
P56181 NDUFV3 N NADH dehydrogenase [ubiquinone] flavoprotein 3, 
mitochondrial 
5 3 1.037 0.69  
        
        
O43678 NDUFA2 N/Q NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 2 
19 4 0.862 0.15 
O43181 NDUFS4 N/Q NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, 
mitochondrial 
21 7 0.890 0.22 
        
        
Q16718 NDUFA5 Q NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 5 
33 7 0.722 0.24 
P56556 NDUFA6 Q NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 6 
27 7 0.902 0.89 
O95182 NDUFA7 Q NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 7 
33 9 0.834 0.21 
Q16795 NDUFA9 Q NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 9, mitochondrial 
54 18 0.970 0.99 
O75306 NDUFS2 Q NADH dehydrogenase [ubiquinone] iron-sulfur protein 2, 
mitochondrial 
130 22 1.018 0.95 
O75489 NDUFS3 Q NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, 
mitochondrial 
142 18 0.953 0.53 
O75251 NDUFS7 Q NADH dehydrogenase [ubiquinone] iron-sulfur protein 7, 
mitochondrial 
27 6 0.873 0.94 
O00217 NDUFS8 Q NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, 
mitochondrial 
66 9 0.959 0.46 
        
        
P03886 MTND1 PP NADH-ubiquinone oxidoreductase chain 1 4 2 1.236 0.43 
P03891 MTND2 PP NADH-ubiquinone oxidoreductase chain 2 3 2 1.358 0.24 
P03897 MTND3** PP NADH-ubiquinone oxidoreductase chain 3 2 1 0.608 0.01 
P03923 MTND6 PP NADH-ubiquinone oxidoreductase chain 6 2 1 1.391 0.45 
O95299 NDUFA10 PP NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 10, mitochondrial 
56 17 0.957 0.82 
Q86Y39 NDUFA11 PP NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 11 
14 3 0.84 0.20 
Q9P0J0 NDUFA13 PP NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 13 
20 8 0.986 0.90 
O95167 NDUFA3 PP NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 3 
17 4 0.96 0.97 
P51970 NDUFA8 PP NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
subunit 8 
31 7 0.937 0.43 
O95298 NDUFC2 PP NADH dehydrogenase [ubiquinone] 1 subunit C2 19 6 0.808 0.10 
O43920 NDUFS5 PP NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 29 7 0.935 0.22 
        
        
P03905 MTND4 PD NADH-ubiquinone oxidoreductase chain 4 3 2 1.036 0.57 
P03915 MTND5 PD NADH-ubiquinone oxidoreductase chain 5 11 3 0.977 1.00 
O14561 NDUFAB1 PD Acyl carrier protein, mitochondrial 6 2 0.727 0.46 
O75438 NDUFB1 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 1 
3 2 0.995 0.98 
O96000 NDUFB10 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 10 
40 8 0.904 0.47 
Q9NX14 NDUFB11 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 11, mitochondrial 
20 3 0.863 0.10 
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O95178 NDUFB2 PD NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 2 
6 1 0.62 0.12 
O43676 NDUFB3** PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 3 
11 3 0.864 0.05 
O95168 NDUFB4 PD NADH dehydrogenase [ubiquinone] 1 beta 
subcomplex subunit 4 
30 4 0.762 0.22 
O43674 NDUFB5 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 5, mitochondrial 
28 6 0.918 1.00 
O95139 NDUFB6 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 6 
18 7 1.081 0.99 
P17568 NDUFB7 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 7 
11 4 0.814 0.30 
O95169 NDUFB8 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 8, mitochondrial 
13 4 0.911 0.25 
Q9Y6M9 NDUFB9 PD NADH dehydrogenase [ubiquinone] 1 beta subcomplex 
subunit 9 
38 8 0.92 0.17 
        
Complex I Assembly Factors 
      
Q9H845 ACAD9 
 
Acyl-CoA dehydrogenase family member 9, 
mitochondrial 
80 30 1.107 0.15 
Q9GZY4 COA1 
 
Cytochrome c oxidase assembly factor 1 homolog 6 4 1.119 0.78 
Q9BQ95 ECSIT 
 
Evolutionarily conserved signaling intermediate in Toll 
pathway, mitochondrial 
12 9 0.918 0.47 
Q96CU9 FOXRED1 
 
FAD-dependent oxidoreductase domain-containing 
protein 1 
13 6 0.96 0.97 
Q9Y375 NDUFAF1** 
 
Complex I intermediate-associated protein 30, 
mitochondrial 
11 8 0.797 0.004 
Q8N183 NDUFAF2 
 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 2 
49 13 0.855 0.35 
Q9BU61 NDUFAF3 
 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 3 
32 7 0.942 0.88 
Q9P032 NDUFAF4 
 
NADH dehydrogenase [ubiquinone] 1 alpha subcomplex 
assembly factor 4 
30 10 0.952 0.30 
Q5TEU4 NDUFAF5 
 
Arginine-hydroxylase NDUFAF5, mitochondrial 1 1 0.98 0.73 
Q330K2 NDUFAF6 
 
NADH dehydrogenase (ubiquinone) complex I, assembly 
factor 6 
1 1 0.998 0.86 
Q7L592 NDUFAF7 
 
Protein arginine methyltransferase NDUFAF7, 
mitochondrial 
16 10 0.95 0.99 
Q8TB37 NUBPL 
 
Iron-sulfur protein NUBPL 7 5 0.952 1.00 
Q9NPL8 TIMMDC1 
 
Complex I assembly factor TIMMDC1, mitochondrial 23 8 1.118 0.02 
Q8IUX1 TMEM126B 
 
Complex I assembly factor TMEM126B, mitochondrial 1 1 0.984 0.96 
Q9BUB7 TMEM70 
 
Transmembrane protein 70, mitochondrial 5 3 1.063 0.84 
 
* Peptide spectral matches 
Bold Font Subunits or assembly factors with FC ≤ 0.80 (n=6) 




Figure S4. Relative mRNA expression of complex I (CI) subunits; (A) MT-ND3 (B) 
NDUFA5 (C) NDUFB2 (D) NDUFAB1 (E) NDUFB4 (F) NDUFA9 (G) NDUFS3 (H) 
NDUFB6 determined by qRT-PCR and DDCT quantification; WT n=6 (except MT-ND3 
and NDUFS3, n=3), TAZD45 n=6 (except MT-ND3 and NDUFS3, n=3), CTRL n=10 (except 
MT-ND3 n=5), BTHS n=15 (except MT-ND3 n=3). Significant differences are indicated; 














































































































































































































Figure S5. Relative mRNA expression of complex I (CI) subunits varies across 
different LCL lines. Relative mRNA expression of (A) NDUFA5 (B) NDUFB2 (C) 
NDUFAB1 (D) NDUFB4 (E) NDUFAF1 (F) NDUFA9 (G) NDUFS3 (H) NDUFB6 
determined by qRT-PCR and DDCT quantification; WT n=6 (except MT-ND3 and 
NDUFS3, n=3), TAZD45 n=6 (except MT-ND3 and NDUFS3, n=3), CTRL n=10, B1 n=3, 
B2 n=3, B3 n=3, B4 n=3, B5 n=3. Significant differences are indicated; * ≤ 0.05, ** ≤ 
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Figure S6. Immunoblotting of isolated mitochondria for CI and CIII subunits. 
Mitochondria (40 ug) isolated from the indicated lines were immunoblotted for the 
indicated proteins. Band intensities, relative to loading control GRP75, were quantified and 
plotted relative to WT/CTRL abundance; WT n=15, TAZD45 n=15, CTRL n=10, BTHS 






















































































































Figure S7. Difference in complex II (CII) activity between and within cell types. CII 
activity measured in HEK293 WT and TAZD45 or CTRL and BTHS LCLs mitochondria 
(200 ug total protein) on a microplate reader by following the production of ubiquinol by 
CII coupled to the reduction of the dye diclorophenolindophenol (DCPIP, 600nm). (A) 
Analysis of CII activity in LCLs showed that a single BTHS line, BTHS LCL #4, had 
significantly increased CII activity compared to the other BTHS lines; WT n=12, TAZD45 
n=12, CTRL n=10, B1 n=2, B2 n=2, B3 n=2, B4 n=2, B5 n=2, B6 n=2. (B) Activity plotted 
without outlier BTHS LCL #4; WT n=12, TAZD45 n=12, CTRL n=10, BTHS n=10. (C) WT 
n=12, TAZD45 n=12, CTRL n=10, B1 n=2, B2 n=2, B3 n=2, B5 n=2, B6 n=2. Significant 

















































































































Figure S8. Overexpression of CI assembly factor NDUFAF1 does not normalize CI 
activity. (A) HEK293 WT and TAZD45 cells were transiently transfected with tagged 
NDUFAF1 with Lipofectamine 3000 according to manufacturer’s instructions. Whole cell 
extracts (45 ug) of the indicated lines and treatment concentrations were immunoblotted 
for the indicated proteins. (B) CI activity measured in mitochondria (200 ug total protein). 
Activity was measured on a microplate reader (450nm) by following the oxidation of 
NADH to oxidized nicotinamide adenine dinucleotide (NAD+). Activity plotted relative to 
WT abundance; WT n=25, TAZD45 n=26, WT-transfected n=9, TAZD45 n=8. (C) HEK293 
WT and TAZD45 cells were transiently transfected with tagged NDUFAF1 with 
Lipofectamine 3000 according to manufacturer’s instructions. Whole cell extracts and 
isolated mitochondria (45 ug) of the indicated lines and treatment concentrations were 
immunoblotted for the indicated proteins. Significant differences are indicated; * ≤ 0.05, 











































Figure S9. Validation and classification of PARL antibodies. Whole cell lysate (40 ug) 
of the indicated lines were immunoblotted for the indicated proteins. A single band at 
~33kD is present in both WT and TAZD45 cells and absent in the PARL-KO cells, we 































Figure S10. PARL abundance and activity in control and BTHS LCL lines. (A) Whole 
cell lysate (45 ug) of the indicated lines were immunoblotted for the indicated proteins. 
Band intensities, relative to loading control GRP75, were quantified and plotted relative to 
WT/CTRL abundance; CTRL n=26, BTHS n=35. (B) Relative mRNA expression of PARL 
determined by qRT-PCR and DDCT quantification; CTRL n=10, BTHS n=15. (C) Relative 
mRNA expression of PARL varies across different LCL lines; WT n=3, TAZD45 n=3, CTRL 
n=10, B1 n=3, B2 n=3, B3 n=3, B4 n=3, B5 n=3. (D) Whole cell lysate (45 ug) of the 
indicated lines were immunoblotted for the indicated proteins. Band intensities, relative to 
the loading control GRP75, for both full-length and cleaved PGAM5 were individually 
quantified and plotted as the percent of cleaved PGAM5 (cleaved/full+cleaved); CTRL 
n=20, BTHS n=18. Significant differences are indicated; * ≤ 0.05, ** ≤ 0.005, *** ≤ 
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Table S4. Abundance of PARL with CCCP treatment (20uM) at serial time points 
(Figure 3E). 
Cell Line Time Point n# Relative Abundance (/WT 0 mins) 
WT vs. TAZD45 




p= 1.8 x 10-10 




p= 1.3 x 10-3 




p= 2.5 x 10-3 




p= 6.4 x 10-3 




p= 5.7 x 10-5 









Table S5. Percent of PGAM5 cleavage with CCCP treatment (20uM) at serial time 
points (Figure 3D). 
Cell Line Time Point n# 
Percent (%) 
Cleaved PGAM5 
WT vs. TAZD45 
For each time 
point 





p= 1.5 x 10-7 11 









p= 0.001 15 




p= 3.0 x 10-5 16 




p= 2.4 x 10-4 18 




p= 7.5 x 10-5 18 




Table S6. Relative abundance of NDUFAF1 and relevant statistics of HEK293 WT 
and TAZD45 cells treated with BEL and SS-31 (Figure 4A) 
 
  
Line & Treatment n Relative Abundance (/WT) 
WT vs. TAZD45 





WT 27 1 p= 4.9 x 10-10 
ns p= 2.8 x 10-5 
TAZD45 26 0.69 
WT-BEL 9 1 p= 4.5 x 10-3 TAZD45-BEL 9 0.78 
WT-SS-31 9 1 ns TAZD45-SS-31 9 0.92 
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Table S7. Relative mRNA expression and relevant statistics of HEK293 WT and 
TAZD45 cells treated with BEL and SS-31 
 
  
Line & Treatment n 
Average Relative 
Expression 
to WT (2-DDCT) 
p-Value 
WT vs. TAZD45 





NDUFB2 (Figure S11A) 
WT 6 1 p= 0.04 
ns ns 
TAZD45 6 0.85 
WT-BEL 3 1 ns TAZD45-BEL 3 1.03 
WT-SS-31 3 1 ns TAZD45-SS-31 3 0.94 
NDUFAB1 (Figure S11B) 
WT 6 1 p=0.001 
p= 0.02 ns 
TAZD45 6 0.71 
WT-BEL 3 1 ns TAZD45-BEL 3 0.98 
WT-SS-31 3 1 p=0.01 TAZD45-SS-31 3 0.88 
NDUFB4 (Figure S11C) 
WT 4 1 p= 0.02 
ns p= 0.03 
TAZD45 6 0.71 
WT-BEL 3 1 ns TAZD45-BEL 3 0.97 
WT-SS-31 3 1 ns TAZD45-SS-31 3 1.09 
NDUFAF1 (Figure 4B) 
WT 6 1 p= 6.4 x 10-4 
p= 0.05 p= 0.01 
TAZD45 6 0.80 
WT-BEL 3 1 ns TAZD45-BEL 3 0.94 
WT-SS-31 3 1 ns TAZD45-SS-31 3 0.97 
NDUFB6 (Figure S11D) 
WT 6 1 p= 0.01 
p= 0.05 ns 
TAZD45 6 0.75 
WT-BEL 3 1 ns TAZD45-BEL 3 1.04 
WT-SS-31 3 1 p= 0.001 TAZD45-SS-31 3 0.82 
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Figure S11. Relative mRNA expression of (A) NDUFB2 (B) NDUFAB1 (C) NDUFB4 
and (D) NDUFB6 after treatment with BEL and SS-31. Expression determined by qRT-
PCR and DDCT quantification using each respective control; WT n=6, TAZD45 n=3, WT-
BEL n=3, TAZD45-BEL n=3, WT-SS-31 n=3, TAZD45-SS-31 n=3 per gene. Significant 
















































































































Table S8. CI holoenzyme abundance and relevant statistics of HEK293 WT and 
TAZD45 cells treated with BEL and SS-31 
 
  
Line & Treatment n Relative Abundance (/WT) 
WT vs. TAZD45 





CI:CIV (Figure 4C) 
WT 11 1 p= 2.3 x 10-5 
ns ns 
TAZD45 11 0.59 
WT-BEL 8 1 p= 5.2 x 10-3 TAZD45-BEL 8 0.77 
WT-SS-31 3 1 ns TAZD45-SS-31 3 0.80 
CI:CII (Figure 4C) 
WT 10 1 p= 1.6 x 10-4 
p= 6.1 x 10-3 ns 
TAZD45 13 0.66 
WT-BEL 9 1 p= 0.02 TAZD45-BEL 10 0.89 
WT-SS-31 4 1 ns TAZD45-SS-31 6 0.83 
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Table S9. Percentage of cleaved PGAM5 and relevant statistics of HEK293 WT and 
TAZD45 cells treated with BEL and SS-31 (Figure 4D) 
 
  




WT vs. TAZD45 





WT 41 12 
p= 1.5 x 10-7 
p= 0.01 p= 2.6 x 10-4 
TAZD45 41 23 
WT-BEL 16 15 
ns 
TAZD45-BEL 16 18 
WT-SS-31 9 18 
ns 
TAZD45-SS-31 8 13 
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Table S10. Relative abundance of cleaved PARL and relevant statistics of HEK293 
WT and TAZ 45 cells treated with BEL and SS-31 (Figure 4E) 
 
  
Line & Treatment n Relative Abundance of PARL (/WT) 
WT vs. TAZD45 





WT 54 1.00 
p= 1.8 x 10-10 
p= 7.1 x 10-15 p= 9.9 x 10-5 
TAZD45 48 1.51 
WT-BEL 11 0.96 
ns 
TAZD45-BEL 10 0.93 
WT-SS-31 11 1.03 
ns 
TAZD45-SS-31 12 1.11 
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Table S11. Cell lines. 
Line ID in Figures Line ID TAZ Genotype 
C1 E1 WT TAZ 
C2 CD09 WT TAZ 
C3 MF17 WT TAZ 
C4 CL114 WT TAZ 
C5 CL156 WT TAZ 
C6 C1-ND11043 WT TAZ 
C7 C2-ND24284 WT TAZ 
C8 C3-ND0438 WT TAZ 
C9 C5-ND23427 WT TAZ 
B1 JHUHV16_007 c.53_54delCC 
B2 JHUHV16_018 c.207C>G 
B3 JHUHV16_022 c.238G>A 
B4 JHUHV15_033 c.82_84_delGTG 
B5 JHUHV16_104 c.171delA 




Table S12.  Primers used for qRT-PCR. 























































Employing hypothesis-generating untargeted proteomics and metabolomics in cellular 
models of methylmalonic acidemia (MMA), propionic acidemia (PA), Barth syndrome 
(BTHS), we identified and functionally confirmed novel mechanisms of cellular 
pathogenicity. 
Using patient and CRISPR/Cas9-edited cellular modeling of MMA and PA, we 
identified serine metabolism as a novel target of cellular pathogenesis in MMA and PA. 
Glucose labeled flux metabolomics found that both MUT-null and PCCA-null cells have 
increased de novo serine synthesis from extracellular glucose, suggesting that provision of 
glucose is particularly important for the de novo biosynthesis of serine in MMA and PA. 
We also found that MUT-null had an increased abundance of unlabeled serine compared to 
both WT and PCCA-null cells, indicating indicate either increased transport of serine from 
the periphery in the MUT-null cells, or increased serine biosynthesis from other 
intracellular sources. Abnormally low plasma serine has been reported in a number of 
individuals with various primary mitochondrial disorders and has also been reported in an 
individual with MMA after liver/kidney transplant. [1, 2] Therefore, correction of serine 
deficits is potentially highly clinically relevant, and our evidence suggests that serine 
supplementation could represent an avenue for therapy. However, serine supplementation 
may be more beneficial in treating MMA, where transport of extracellular serine (as 
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opposed to de novo synthesis) appears to be the dominant mechanism. As we continue this 
project, we aim to explore the therapeutic potential of manipulating serine metabolism in 
MMA and PA, by investigating the downstream fate of de novo and imported serine, 
alterations in serine synthesis and utilization during cellular and mitochondrial stress, and 
how the manipulation of serine-metabolite-pools and serine products affects overall 
mitochondrial stress. 
Using patient and CRISPR/Cas9-edited cellular modeling of BTHS, we identified 
two areas of mitochondrial dysfunction for further study: mitochondrial respiratory 
complex I (CI), and the PARL-mediated mitochondrial stress response pathway. 
Mitochondrial respiratory chain dysfunction and supercomplex destabilization have been 
shown in several cellular models of BTHS, though a specific decrease of CI has only been 
described in a limited number of studies in patient-derived lymphoblasts. [3–5] We show, 
for the first time, decreased gene and protein expression of specific subunits of CI. Further, 
we show that expression of NDUFAF1, a CI assembly factor, is strikingly abnormal in the 
setting of TAZ-deficiency. We also demonstrated that CI gene expression abnormalities, 
including subunits and assembly factors, are partially rescued with cardiolipin modulation. 
In demonstrating that cardiolipin modulation can rescue CI defects, we propose that CI 
assembly, assembly factor expression (NDUFAF1) and subunit expression (MT-ND3, 
NDUFA5, NDUFAB1, NDUFB2, NDUFB4) are potential cellular markers for treatment 
effect in BTHS. 
PARL, which has roles in the mitochondrial response to stress via regulation of 
apoptosis and mitophagy, and its cleavage of PGAM5, are of particular interest in BTHS, 
where enlarged mitochondria have been observed in BTHS patient and TAZ-deficient 
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mouse cardiac tissue, consistent with impaired mitophagy. [6–9] Similar to CI defects, we 
showed that targeting CL with BEL and SS-31 partially remediates abnormalities in PARL 
abundance and PGAM5 cleavage. The PARL proteolytic and signaling cascade has diverse 
downstream targets in addition to PGAM5, including PINK1, BCL-xL, FUNDC1 and 
others, with numerous effects on mitochondrial and cellular metabolism and survival, and 
thus represents a wide area for future study in TAZ-deficiency. [10, 11] 
As respiratory chain assembly and subunit gene and protein expression are tightly 
linked, it is not possible at this time to know which is the primary vs. secondary in the 
setting of TAZ-deficiency (i.e., whether CL abnormalities affect one or all of these CI-
associated abnormalities), and this warrants further investigation. [12] It is also not clear 
at this time if the abnormalities in PARL expression and CI expression/function are 
interdependent or are each independently initiated by inner mitochondrial membrane 
disturbances caused by CL abnormalities. One way to test this would be to correct the CI 
dysfunction in isolation and examine for remediation of PARL defects. Because 
overexpression of NDUFAF1 in the TAZ-deficient cells was not sufficient to correct CI 
defects and test this hypothesis, other approaches such as downregulating PARL and 
assaying CI function/assembly could be considered. 
Together, CI dysfunction and dysregulation of apoptosis/mitophagy via PARL 
represent attractive areas for study in the tissue-specific aspects of BTHS. Defective 
mitochondrial quality control, particularly as it affects stress responsiveness, is 
increasingly recognized for its role in several forms of cardiac dysfunction [13], and both 
primary and secondary CI defects are well documented in many forms of cardiac 
dysfunction. [14, 15] Furthermore, understanding the diverse and tissue-specific 
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mitochondrial effects caused by TAZ-deficiency have important implications for 
development of therapeutics. For example, CI targeting agents may not be sufficient to 
remediate cardiac or skeletal muscle abnormalities in BTHS, where an underlying defect 
in mitophagy and apoptosis are prominent TAZ-deficient associated abnormalities. 
 
4.1 Future Directions 
Whereas TAZ is ubiquitously expressed, the CL acyl chain composition is tissue specific; 
for example, brain CL is characterized by a diversified array of acyl chains including 
polyunsaturated chains, and in cardiac and skeletal muscle CL is predominantly 
characterized by the tetralinoleoyl form. [16, 17] We hypothesize that due to the tissue-
specific nature of CL composition, dysfunctional TAZ has cell type-specific effects; i.e. 
neurons, with their diversified array of mature CL, are spared from severe bioenergetic and 
cellular effects of TAZ deficiency, whereas cardiomyocytes, with a narrow CL 
composition, will have severe cellular effects as a result of TAZ deficiency. In order to 
investigate the tissue-specific aspects of BTHS we developed a TAZ-deficient induced 
pluripotent stem cell (iPSC) line using CRISPR/Cas9 genome editing. We differentiated 
these cells into cell types clinically affected in BTHS (cardiomyocytes), and cell types 
clinically unaffected (neurons), and plan to evaluate and compare both CI dysfunction and 
dysregulation of apoptosis/mitophagy via PARL. We will further attempt to remediate 
these cellular defects by manipulating the CL composition of the different cell types, and 
evaluate for normalization or exacerbation of CI and PARL abnormalities.  
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We conclude that untargeted studies harnessing the power of -omics has the ability 
to uncover novel pathways of investigation in IEMs beyond primary biochemical defects, 
providing alternative targets for therapeutic interventions. 
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